U.S. patent application number 17/010773 was filed with the patent office on 2020-12-24 for therapeutic agents for reducing parathyroid hormone levels.
The applicant listed for this patent is KAI PHARMACEUTICALS, INC.. Invention is credited to Amos Baruch, Kanad Das, Felix Karim, Derek Maclean, Qun Yin.
Application Number | 20200399309 17/010773 |
Document ID | / |
Family ID | 1000005063200 |
Filed Date | 2020-12-24 |
![](/patent/app/20200399309/US20200399309A1-20201224-C00001.png)
![](/patent/app/20200399309/US20200399309A1-20201224-C00002.png)
![](/patent/app/20200399309/US20200399309A1-20201224-C00003.png)
![](/patent/app/20200399309/US20200399309A1-20201224-C00004.png)
![](/patent/app/20200399309/US20200399309A1-20201224-C00005.png)
![](/patent/app/20200399309/US20200399309A1-20201224-C00006.png)
![](/patent/app/20200399309/US20200399309A1-20201224-C00007.png)
![](/patent/app/20200399309/US20200399309A1-20201224-C00008.png)
![](/patent/app/20200399309/US20200399309A1-20201224-C00009.png)
![](/patent/app/20200399309/US20200399309A1-20201224-C00010.png)
![](/patent/app/20200399309/US20200399309A1-20201224-C00011.png)
View All Diagrams
United States Patent
Application |
20200399309 |
Kind Code |
A1 |
Karim; Felix ; et
al. |
December 24, 2020 |
THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS
Abstract
Compounds having activity for lowering parathyroid hormone
levels are described. In one embodiment, the compounds are
comprised of a contiguous sequence of subunits,
X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7, wherein
the X.sub.1 subunit comprises a thiol-containing moiety and the
distribution of charge on the X.sub.2-X.sub.7 subunits provides the
desired activity. Methods of using the compounds for treating
hyperparathyroidism, bone disease and/or hypercalcemic disorders
are also described, and in particular, methods for lowering plasma
PTH and serum calcium are provided. The compounds can be used to
treat subjects having, for example: primary, secondary or tertiary
hyperparathyroidism; hypercalcemia of malignancy; metastatic bone
disease; or osteoporosis.
Inventors: |
Karim; Felix; (Walnut Creek,
CA) ; Baruch; Amos; (San Francisco, CA) ;
Maclean; Derek; (Los Altos, CA) ; Das; Kanad;
(San Francisco, CA) ; Yin; Qun; (Palo Alto,
CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
KAI PHARMACEUTICALS, INC. |
South San Francisco |
CA |
US |
|
|
Family ID: |
1000005063200 |
Appl. No.: |
17/010773 |
Filed: |
September 2, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16298902 |
Mar 11, 2019 |
|
|
|
17010773 |
|
|
|
|
15629536 |
Jun 21, 2017 |
10280198 |
|
|
16298902 |
|
|
|
|
15018567 |
Feb 8, 2016 |
9701712 |
|
|
15629536 |
|
|
|
|
13769744 |
Feb 18, 2013 |
9278995 |
|
|
15018567 |
|
|
|
|
13365213 |
Feb 2, 2012 |
8377880 |
|
|
13769744 |
|
|
|
|
12846724 |
Jul 29, 2010 |
8999932 |
|
|
13365213 |
|
|
|
|
61313635 |
Mar 12, 2010 |
|
|
|
61255816 |
Oct 28, 2009 |
|
|
|
61229695 |
Jul 29, 2009 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 5/1013 20130101;
C07K 7/06 20130101; A61K 38/00 20130101; A61K 9/0019 20130101; A61K
47/60 20170801; C07K 7/08 20130101; A61K 9/08 20130101 |
International
Class: |
C07K 7/06 20060101
C07K007/06; C07K 5/103 20060101 C07K005/103; A61K 47/60 20060101
A61K047/60; C07K 7/08 20060101 C07K007/08; A61K 9/00 20060101
A61K009/00; A61K 9/08 20060101 A61K009/08 |
Claims
1. A compound comprising the formula:
X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7 wherein
X.sub.1 is an amino acid comprising a thiol-containing group,
D-penicillamine, d-homocysteine or mercaptopropionic acid; X.sub.2,
X.sub.3, X.sub.4, X.sub.5, X.sub.5, and X.sub.7 are each
D-arginine.
2. The compound of claim 1, wherein X.sub.1 is an amino acid
comprising a thiol-containing group is selected from L-cysteine and
D-cysteine.
3. The compound of claim 1 or claim 2, wherein the compound is
chemically modified at the N-terminus, the C-terminus or both.
4. The compound of any one of claims 1-3, wherein the N-terminus of
the compound is acetylated and the C-terminus of the peptide is
amidated.
5. The compound of any one of claims 1-4, wherein the compound is
Ac-crrrrrr-NH.sub.2 (SEQ ID NO: 6).
6. The compound of any one of claims 1-4, wherein the compound is
Ac-beta alanine-rrrrrr-NH.sub.2 (SEQ ID NO: 30).
7. The compound of any one of claims 1-4, wherein the compound is
mercaptopropionic acid-rrrrrr-NH.sub.2 (SEQ ID NO: 31).
8. The compound of any one of claims 1-4, wherein the compound is
Ac-d-homocysteine-rrrrrr-NH.sub.2 (SEQ ID NO: 32).
9. The compound of any one of claims 1-4, wherein the compound is
Ac-D-penicillamin-rrrrrr-NH.sub.2 (SEQ ID NO: 33).
10. A composition comprising the compound of any one of claims 1-9
and a pharmaceutically acceptable excipient.
11. A composition comprising a compound according to any one of
claim 10, for use in the treatment of a subject suffering from
hyperparathyroidism or a hypercalcemic disorder.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 16/298,902, filed Mar. 11, 2019, pending, which is a
continuation of U.S. application Ser. No. 15/629,536, filed Jun.
21, 2017, now U.S. Pat. No. 10,280,198, which is a continuation of
U.S. application Ser. No. 15/018,567, filed Feb. 8, 2016, now U.S.
Pat. No. 9,701,712, which is a continuation of U.S. application
Ser. No. 13/769,744, filed Feb. 18, 2013, now U.S. Pat. No.
9,278,995, which is a continuation of U.S. application Ser. No.
13/365,213, filed Feb. 2, 2012, now U.S. Pat. No. 8,377,880, which
is a continuation-in-part of U.S. application Ser. No. 12/846,724,
filed Jul. 29, 2010, now U.S. Pat. No. 8,999,932 which claims the
benefit of U.S. Provisional Application No. 61/229,695, filed Jul.
29, 2009, and of U.S. Provisional Application No. 61/255,816, filed
Oct. 28, 2009, and of U.S. Provisional Application No. 61/313,635,
filed Mar. 12, 2010. Each of these applications is incorporated
herein by reference in its entirety.
REFERENCE TO SEQUENCE LISTING
[0002] A Sequence Listing is being submitted electronically via EFS
in the form of a text file, created Sep. 1, 2020, and named
"SEQ.txt" (88,084 bytes), the contents of which are incorporated
herein by reference in their entirety.
TECHNICAL FIELD
[0003] The current subject matter relates to compounds with
activity to decrease parathyroid hormone (PTH) levels, to
pharmaceutical compositions comprising the compounds, and to the
use of such compounds and compositions in methods of treatment,
including but not limited to treating hypercalcemia or
hyperparathyroidism or modulating in vivo PTH levels.
BACKGROUND
[0004] Calcium homeostasis is the mechanism by which the body
maintains adequate calcium levels. The process is highly regulated,
and involves a complex interplay between calcium absorption,
transport, storage in bones, deposition in other tissues, and
excretion. PTH is a regulator of circulating calcium levels, and
functions to increase the concentration of calcium in the blood by
enhancing the release of calcium from bone through the process of
bone resorption; increasing reabsorption of calcium from the renal
tubules; and enhancing calcium absorption in the intestine by
increasing the production of 1,25-(OH).sub.2 vitamin D, the active
form of vitamin D. PTH also stimulates phosphorus excretion from
the kidney, and increases release from bone.
[0005] PTH secretion is regulated by the calcium sensing receptor
(CaSR), a G-protein coupled receptor expressed by several cell
types on the surface of parathyroid cells, which detects small
fluctuations in the concentration of extracellular calcium ion
(Ca.sup.2+) and responds by altering the secretion of PTH.
Activation of the CaSR by Ca.sup.2+ inhibits PTH secretion within
seconds to minutes through inhibition of vesicular transport, and
this process may be modulated by protein kinase C (PKC)
phosphorylation of the receptor. The CaSR is also expressed on
osteoblasts and in the kidney, where it regulates renal Ca.sup.2+
excretion.
[0006] In addition, PTH regulates phosphorus homeostasis. PTH
stimulates the parathyroid hormone receptor 1 (PTHR1) on both
apical (brush border membrane) and basolateral membranes of cells
in the GI tract. PTHR1 stimulation leads to an increase in urinary
excretion of phosphate (Pi) as a consequence of reduction by
internalization of the renal Na.sup.+/phosphate (NaPi-IIa)
co-transporter on the brush border membrane.
[0007] PTH is also involved in the regulation of osteoblasts and
osteoclasts in bone. PTH increases circulating Ca.sup.2+ by
increasing bone resorption and renal reabsorption of calcium. PTH
stimulates osteoblasts to produce RANK ligand (RANKL), which binds
to the RANK receptor and activates the osteoclasts, leading to an
increase in bone resorption and an increase in serum Ca.sup.2+.
Osteoprotegerin (OPG) is a decoy receptor for RANKL which blocks
bone resorption. Osteoporosis is caused by an imbalance between the
processes of bone resorption by osteoclasts and bone formation by
osteoblasts.
[0008] The human body contains approximately 1 kg of calcium, 99%
of which resides in bone. Under normal conditions, circulating
calcium ion (Ca.sup.2+) is tightly maintained at a level of about 9
to 10 mg/dL (i.e., 2.25-2.5 mmol/L; .about.600 mg). Approximately 1
g of elemental calcium (Ca.sup.2+) is ingested daily. Of this
amount, approximately 200 mg/day is absorbed, and 800 mg/day is
excreted. In addition, approximately 500 mg/day is released by bone
resorption or is deposited into bone. About 10 g of Ca.sup.2+ is
filtered through the kidney per day, with about 200 mg appearing in
the urine, and the remainder being reabsorbed.
[0009] Hypercalcemia is an elevated calcium level in the blood.
Acute hypercalcemia can result in gastrointestinal (anorexia,
nausea, vomiting); renal (polyuria, polydipsia), neuro-muscular
(depression, confusion, stupor, coma) and cardiac (bradycardia,
first degree atrio-ventricular) symptoms. Chronic hypercalcemia is
also associated with gastrointestinal (dyspepsia, constipation,
pancreatitis); renal (nephrolithiasis, nephrocalcinosis),
neuro-muscular (weakness) and cardiac (hypertension block,
digitalis sensitivity) symptoms. Abnormal heart rhythms can result,
and EKG findings of a short QT interval and a widened T wave
suggest hypercalcemia. Hypercalcemia may be asymptomatic, with
symptoms more commonly occurring at high calcium levels (12.0 mg/dL
or 3 mmol/l). Severe hypercalcemia (above 15-16 mg/dL or 3.75-4
mmol/l) is considered a medical emergency: at these levels, coma
and cardiac arrest can result.
[0010] Hypercalcemia is frequently caused by hyperparathyroidism,
leading to excess bone resorption and elevated levels of serum
calcium. In primary sporadic hyperparathyroidism, PTH is
overproduced by a single parathyroid adenoma; less commonly,
multiple adenomas or diffuse parathyroid gland hyperplasia may be
causative. Increased PTH secretion leads to a net increase in bone
resorption, with release of Ca.sup.2+ and phosphate (Pi). PTH also
enhances renal reabsorption of Ca.sup.2+ and inhibits reabsorption
of phosphate (Pi), resulting in a net increase in serum calcium and
a decrease in phosphate.
[0011] Secondary hyperparathyroidism occurs when a decrease in
circulating levels of Ca.sup.2+ level stimulates PTH secretion. One
cause of secondary hyperparathyroidism is chronic renal
insufficiency (also referred to as chronic kidney disease or CKD),
such as that in renal polycystic disease or chronic pyelonephritis,
or chronic renal failure, such as that in hemodialysis patients
(also referred to as end stage renal disease or ESRD). Excess PTH
may be produced in response to hypocalcemia resulting from low
calcium intake, GI disorders, renal insufficiency, vitamin D
deficiency, and renal hypercalciuria. Tertiary hyperparathyroidism
may occur after a long period of secondary hyperparathyroidism and
hypercalcemia.
[0012] Malignancy is a common cause of non-PTH mediated
hypercalcemia. Hypercalcemia of malignancy, is an uncommon but
severe complication of cancer, affecting between 10% and 20% of
cancer patients, and may occur with both solid tumors and leukemia.
The condition has an abrupt onset and has a very poor prognosis,
with a median survival of only six weeks. Growth factors (GF)
regulate the production of parathyroid hormone-related protein
(PTHrP) in tumor cells. Tumor cells may be stimulated by autocrine
GF to increase production of PTHrP, leading to enhanced bone
resorption. Tumor cells metastatic to bone may also secrete PTHrP,
which can resorb bone and release additional GF which in turn act
in a paracrine manner to further enhance PTHrP production.
[0013] Accordingly, compounds with activity to, for example,
modulate PTH levels and/or calcium levels in vivo are desired.
BRIEF SUMMARY
[0014] In one aspect, a compound, comprising the formula
X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7
is provided, wherein X.sub.1 is a subunit comprising a
thiol-containing group; X.sub.5 is a cationic subunit; X.sub.6 is a
non-cationic subunit; X.sub.7 is a cationic subunit; and at least
one, preferably two, of X.sub.2, X.sub.3 and X.sub.4 is/are
independently a cationic subunit; and wherein the compound has
activity to decrease parathyroid hormone concentration. In one
embodiment, the decrease in parathyroid hormone concentration is a
decrease in blood or plasma parathyroid hormone concentration in a
subject treated with the compound relative to the blood or plasma
parathyroid hormone concentration in the subject prior to
treatment. In another embodiment, the decrease in parathyroid
hormone concentration is achieved in the absence of a histamine
response.
[0015] In another embodiment X.sub.3 and X.sub.4 are non-cationic
while X.sub.1, X.sub.5, X.sub.6 and X.sub.7 are cationic.
[0016] In one embodiment, the X.sub.1 subunit is a thiol-containing
amino acid residue. In another embodiment, the thiol group of the
X.sub.1 subunit is an organic thiol-containing moiety.
[0017] In another embodiment, when the X.sub.1 subunit is a
thiol-containing amino acid residue, it is selected from the group
consisting of L-cysteine, D-cysteine, glutathione, n-acetylated
cysteine, homocysteine and pegylated cysteine.
[0018] In yet another embodiment, the organic thiol-containing
moiety is selected from thiol-alkyl, or thioacyl moieties such as
3-mercaptopropyl or 3-mercaptopropionyl, mercaptopropionic acid,
mercaptoacetic acid, thiobenzyl, or thiopropyl. In still another
embodiment, the organic-thiol-containing moiety is
mercaptopropionic acid.
[0019] In still another embodiment, the X.sub.1 subunit is modified
chemically to comprise an acetyl group, a benzoyl group, a butyl
group, or another amino acid such as acetylated-beta-alanine.
[0020] In yet another embodiment, when the X.sub.1 subunit
comprises a thiol moiety, the X.sub.1 subunit is joined by a
covalent linkage to a second thiol moiety.
[0021] In another embodiment, the formula
X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7 is
comprised of a contiguous sequence of amino acid residues
(designated herein as
(X.sub.aa1)-(X.sub.aa2)-(X.sub.aa3)-(X.sub.aa4)-(X.sub.aa5)-(X.sub.aa6)-(-
X.sub.aa7) SEQ ID NO:1) or a sequence of organic compound subunits
(non-amino acid residues).
[0022] In another embodiment, the contiguous sequence of amino acid
residues is a contiguous sequence of L-amino acid residues, a
contiguous sequence of D-amino acid residues, a contiguous sequence
of a mixture of L-amino acid residues and D-amino acid residues, or
a mixture of amino acid residues and non-natural amino acid
residues.
[0023] In another embodiment, the contiguous sequence of amino acid
residues is linked to a compound to facilitate transport across a
cell membrane. In another embodiment, the contiguous sequence of
amino acid residues is linked to a compound that enhances delivery
of the sequence into or across one or more layers of tissue.
[0024] In another embodiment, the contiguous sequence of amino acid
residues is contained within a sequence of amino acid residues from
8-50 amino acid residues, 8-40 amino acid residues, 8-30 amino acid
residues or 8-20 amino acid residues in length. In yet another
embodiment, the contiguous sequence of amino acid residues is
contained within a sequence of amino acid residues from 8-19 amino
acid residues, 8-18 amino acid residues, 8-17 amino acid residues,
8-16 amino acid residues, 8-15 amino acid residues, 8-14 amino acid
residues, 8-13 amino acid residues, 8-12 amino acid residues, 8-11
amino acid residues, 8-10 amino acid residues, or 8-9 amino acid
residues in length.
[0025] In another embodiment, the X.sub.3 subunit is a cationic
amino acid residue.
[0026] In another embodiment, the X.sub.2 subunit is a non-cationic
amino acid residue, and in another embodiment, the X.sub.4 subunit
is a non-cationic amino acid residue. In one embodiment, the
non-cationic amino acid residue is a D-amino acid.
[0027] In another embodiment, X.sub.3 and X.sub.4 are cationic
D-amino acid residues.
[0028] In another embodiment, the X.sub.5 subunit is a D-amino acid
residue.
[0029] In another aspect, the contiguous sequence in any of the
described compounds is covalently attached via the thiol-containing
group in the X.sub.1 subunit to a second contiguous sequence. For
example, the second contiguous sequence can be identical to the
contiguous sequence (to form a dimer), or can be non-identical, as
would be the case when attached to a moiety that facilitates
transfer of the contiguous sequence across a cell membrane.
[0030] In another aspect, a conjugate comprised of the peptide
carrrar (SEQ ID NO:2) is provided, where the peptide is conjugated
at its N-terminal residue to a Cys residue.
[0031] In one embodiment, the peptide is chemically modified at the
N-terminus, the C-terminus, or both.
[0032] In another embodiment, the N-terminus of the peptide is
chemically modified by acetylation and the C-terminus is chemically
modified by amidation.
[0033] In another embodiment, the conjugate is
Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3).
[0034] In another aspect, a method of treating secondary
hyperparathyroidism (SHPT) in a subject is contemplated, wherein a
compound as described herein is provided to the subject. In various
embodiments, the subject can be suffering from chronic kidney
disease or other condition.
[0035] In another aspect, a method of decreasing parathyroid
hormone in a subject is contemplated, wherein a compound as
described herein is provided to the subject.
[0036] In another aspect, a treatment regimen is provided, the
regimen comprising providing a compound according to any of those
described herein, in combination with a second agent.
[0037] In one embodiment, the second therapeutic agent is vitamin
D, a vitamin D analog or cinacalcet hydrochloride.
[0038] In any of the aspects or embodiments described herein, any
one or more of the sequences is contemplated to be individually
excepted or removed from the scope of the claims. In certain
embodiments, the peptides identified by any one or more of SEQ ID
NOs: 162-182, individually or in any combination, are excluded from
the claimed compounds, compositions and methods.
BRIEF DESCRIPTION OF THE DRAWINGS
[0039] FIG. 1 is a graph of parathyroid hormone level, as percent
of the baseline pre-dose value, as a function of time, in hours, in
rats with acute renal insufficiency (1K1C model), where the rats
were dosed with Ac-crrrr-NH.sub.2 (SEQ ID NO:4, diamonds),
Ac-crrrrr-NH.sub.2 (SEQ ID NO:5, closed squares),
Ac-crrrrrr-NH.sub.2(SEQ ID NO:6, triangles), Ac-crrrrrrr-NH.sub.2
(SEQ ID NO:7, open squares), or saline control (x symbols);
[0040] FIG. 2A is a graph of IP.sub.1 concentration, in nM, as a
function of compound concentration of Ac-carrrar-NH.sub.2 (SEQ ID
NO:26, squares) and Ac-arrrar-NH.sub.2 (SEQ ID NO:29, triangles),
as a measure of the compound's ability to activate the human CaSR
in an in vitro cell assay when the human CaSR is expressed as a
stable transfected HEK-293 cell line;
[0041] FIG. 2B shows the reduction in PTH concentration upon in
vivo administration of peptides identified as SEQ ID NO:26
(Ac-carrrar-NH.sub.2) (squares) and as SEQ ID NO:29
(Ac-arrrar-NH.sub.2) (diamonds), where the peptides were
administered as an IV bolus to normal Sprague Dawley rats at doses
of 9 mg/kg for SEQ ID NO:29 and at 0.5 mg/kg for SEQ ID NO:26. An
intravenous (IV) bolus of saline was used as a control (dashed
line). Plasma PTH levels were assessed prior to dosing and 1, 2, 3
and 4 hours after dosing. Results are presented as group
average.+-.standard deviation (SD), and PTH is shown as percent of
the baseline pre-dose value;
[0042] FIG. 3 is a bar graph that compares the release of histamine
following IV bolus administration of various compounds in normal
Sprague Dawley rats, where the compounds Ac-crrrr-NH.sub.2 (SEQ ID
NO:4), Ac-crrrrr-NH.sub.2 (SEQ ID NO:5), Ac-crrrrrr-NH.sub.2 (SEQ
ID NO:6) and Ac-crrrrrrrr-NH.sub.2 (SEQ ID NO:41) were dosed in an
equimolar IV bolus dose of 2.1 .mu.mol/kg, and plasma histamine was
measured before dosing (pre-dose), 5, 15 and 30 minutes after
dosing;
[0043] FIG. 4 is a bar graph that compares the release of histamine
following IV bolus administration of two compounds in normal
Sprague Dawley rats, where the compounds Ac-c(C)arrrar-NH.sub.2
(SEQ ID NO:3, cross hatched bars) and Ac-crrrrrr-NH.sub.2 (SEQ ID
NO:6, open bars) were dosed at 3 mg/kg, and plasma histamine was
measured before dosing (time zero) and 5, 15 and 30 minutes after
dosing;
[0044] FIG. 5 is a graph of parathyroid hormone level, as percent
of the baseline pre-dose value, as a function of time, in hours, in
normal rats dosed with 0.5 mg/kg by IV bolus of Ac-crrrrrr-NH.sub.2
(SEQ ID NO:6, diamonds), Ac-carrrrr-NH.sub.2 (SEQ ID NO:8,
squares), Ac-crarrrr-NH.sub.2 (SEQ ID NO:9, triangles),
Ac-crrarrr-NH.sub.2 (SEQ ID NO:10, x symbols), Ac-crrrarr-NH.sub.2
(SEQ ID NO:11, * symbols), Ac-crrrrar-NH.sub.2 (SEQ ID NO:12,
circles) or Ac-crrrrra-NH.sub.2 (SEQ ID NO:13, + symbols);
[0045] FIGS. 6A-6B are graphs of parathyroid hormone level, as
percent of the baseline pre-dose value, as a function of time, in
hours, in healthy rats dosed with 0.5 mg/kg by IV bolus of
Ac-carrrar-NH.sub.2 (SEQ ID NO:26, open diamonds),
Ac-crrarar-NH.sub.2 (SEQ ID NO:25, open squares),
Ac-caarrrr-NH.sub.2 (SEQ ID NO:22, triangles), Ac-crraarr-NH.sub.2
(SEQ ID NO:17, closed squares), Ac-c(C)arrrar-NH.sub.2 (SEQ ID
NO:3, diamonds FIG. 6B), Ac-craarrr-NH.sub.2 (SEQ ID NO:24, x
symbols in FIG. 6A); Ac-c(C)rrarar-NH.sub.2 (SEQ ID NO:28, x
symbols, FIG. 6B);
[0046] FIG. 7 shows the decrease in parathyroid hormone levels in
the blood as a function of time, for the compound
Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) administered as an IV bolus to
normal Sprague Dawley rats at doses of 1 mg/kg (diamonds), 0.5
mg/kg (squares), 0.3 mg/kg (triangles), and 0.1 mg/kg (x symbols).
An intravenous (IV) bolus of saline (circles) was used as a
control. Plasma PTH levels were assessed prior to dosing and at 1,
2, 3 and 4 hours after dosing.
[0047] FIG. 8 is a graph of parathyroid hormone level, as percent
of the baseline pre-dose value, as a function of time, in hours, in
rats with acute renal insufficiency (1K1C model), in rats with 1K1C
model of acute renal insufficiency, where the rats were dosed via
IV bolus with the compound Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) at
doses of 3 mg/kg (diamonds), 1 mg/kg (triangles), 0.5 mg/kg
(squares) and 0.3 mg/kg (x symbols), or saline (squares); the
dashed line in FIG. 8 indicating baseline PTH level pre-dosing;
[0048] FIG. 9 is a graph of parathyroid hormone level, as percent
of the baseline pre-dose value, as a function of time, in hours, in
rats dosed intravenously with saline (x symbols) or with the
compounds Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6, open diamonds), and
Ac-carrrar-NH.sub.2 (SEQ ID NO:26, open squares) at 1 mg/kg via a
30-minute IV infusion, where plasma PTH levels were assessed prior
to dosing, 16 hours and 24 hours after dosing;
[0049] FIG. 10 is a graph of parathyroid hormone level, as percent
of the baseline pre-dose value, as a function of time, in hours, in
rats with acute renal insufficiency (1K1C model), where the rats
were dosed via IV bolus with the compounds Ac-c(C)arrrar-NH.sub.2
(SEQ ID NO:3, squares, * symbols) and Ac-c(Ac-C)arrrar-NH.sub.2
(SEQ ID NO:146, triangles, diamonds) at doses of 0.3 mg/kg
(squares, triangles) and 0.5 mg/kg (*, diamonds);
[0050] FIG. 11 is a graph of parathyroid hormone level, as percent
of the baseline pre-dose value, as a function of time, in hours, in
rats treated via micropore-facilitated transdermal delivery of
Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6, two animals, squares and
triangles) or with saline via transdermal delivery (diamonds);
[0051] FIG. 12 is a graph of parathyroid hormone level, as percent
of the baseline pre-dose value, as a function of time, in hours, in
rats treated via micropore-facilitated transdermal delivery of
Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3);
[0052] FIG. 13 is a graph of mean PTH (as percent of baseline)
during and following a 6 hour IV infusion of Ac-c(C)arrrar-NH.sub.2
(SEQ ID NO:3) in normal Sprague-Dawley rats, where the compound was
infused at rates of 1 .mu.g/kg/hr (squares), 3 .mu.g/kg/hr
(circles), and 10 .mu.g/kg/hr (triangles);
[0053] FIG. 14A shows PTH (as a percent of baseline) during and
following a 6 hour IV infusion of Ac-c(C)arrrar-NH.sub.2 (SEQ ID
NO:3) in the 1K1C rat model of acute renal insufficiency, where
rats were intravenously infused at dose rates of 30 .mu.g/kg/hr
(diamonds) and 100 .mu.g/kg/hr (squares);
[0054] FIG. 14B is a bar graph showing serum calcium, in mg/dL, for
the 1K1C model rats treated as in FIG. 14A.
[0055] The present subject matter may be understood more readily by
reference to the following detailed description of the preferred
embodiments and the examples included herein.
DETAILED DESCRIPTION
I. Definitions
[0056] Within this application, unless otherwise stated,
definitions of the terms and illustration of the techniques of this
application may be found in any of several well-known references
such as: Sambrook, J., et al., Molecular Cloning: A Laboratory
Manual, Cold Spring Harbor Laboratory Press (1989); Goeddel, D.,
ed., Gene Expression Technology, Methods in Enzymology, 185,
Academic Press, San Diego, Calif. (1991); "Guide to Protein
Purification" in Deutshcer, M. P., ed., Methods in Enzymology,
Academic Press, San Diego, Calif. (1989); Innis, et al., PCR
Protocols: A Guide to Methods and Applications, Academic Press, San
Diego, Calif. (1990); Freshney, R. I., Culture of Animal Cells: A
Manual of Basic Technique, 2nd Ed., Alan Liss, Inc. New York, N.Y.
(1987); Murray, E. J., ed., Gene Transfer and Expression Protocols,
pp. 109-128, The Humana Press Inc., Clifton, N.J. and Lewin, B.,
Genes VI, Oxford University Press, New York (1997).
[0057] As used herein, the singular form "a", "an", and "the"
include plural references unless indicated otherwise. For example,
"a" modulator peptide includes one of more modulator peptides.
[0058] As used herein a compound has "activity to decrease
parathyroid hormone level" or "PTH-lowering activity" when the
compound, upon administration to a subject, lowers plasma
parathyroid hormone (PTH) relative to the plasma PTH concentration
prior to administration of the compound. In one embodiment, the
decrease in PTH level is at least 20%, 30%, 40%, 50%, 60%, 70%,
80%, 90% or 95% lower one hour after compound administration that
the PTH level prior to administration of the compound.
[0059] As used herein, "absence of a histamine response" or "lack
of a histamine response" intends a dose of a compound that produces
a less than 15-fold, 14-fold, 13-fold, 12-fold, 11-fold, 10-fold,
9-fold, 8-fold, 7-fold, 6-fold, 5-fold, 4-fold, or 3-fold increase
in histamine, measured in vitro in an assay as described herein,
where the fold change is determined based on histamine levels
before incubation with the compound and after 15 minutes incubation
with compound.
[0060] As used herein, "amino acid" refers to natural and
non-natural amino acids. The twenty naturally occurring amino acids
(L-isomers) are designated by the three letter code with the prefix
"L-" (except for glycine which is achiral) or by the one letter
code in upper-case: alanine ("L-Ala" or "A"), arginine ("L-Arg" or
"R"), asparagine ("L-Asn" or "N"), aspartic acid ("L-Asp" or "D"),
cysteine ("L-Cys" or "C"), glutamine ("L-Gln" or "Q"), glutamic
acid ("L-Glu" or "E"), glycine ("Gly" or "G"), histidine ("L-His"
or "H"), isoleucine ("L-Ile" or "I"), leucine ("L-Leu" or "L"),
lysine ("L-Lys" or "K"), methionine ("L-Met" or "M"), phenylalanine
("L-Phe" or "F"), proline ("L-Pro" or "P"), serine ("L-Ser" or
"S"), threonine ("L-Thr" or "T"), tryptophan ("L-Trp" or "W"),
tyrosine ("L-Tyr" or "Y") and valine ("L-Val" or "V"). L-norleucine
and L-norvaline may be represented as (NLeu) and (NVal),
respectively. The nineteen naturally occurring amino acids that are
chiral have a corresponding D-isomer which is designated by the
three letter code with the prefix "D-" or by the lower-case one
letter code: alanine ("D-Ala" or "a"), arginine ("D-Arg" or "r"),
asparagine ("D-Asn" or "a"), aspartic acid ("D-Asp" or "d"),
cysteine ("D-Cys" or "c"), glutamine ("D-Gln" or "q"), glutamic
acid ("D-Glu" or "e"), histidine ("D-His" or "h"), isoleucine
("D-Ile" or "i"), leucine ("D-Leu" or "I"), lysine ("D-Lys" or
"k"), methionine ("D-Met" or "m"), phenylalanine ("D-Phe" or "f"),
proline ("D-Pro" or "p"), serine ("D-Ser" or "5"), threonine
("D-Thr" or "t"), tryptophan ("D-Trp" or "w"), tyrosine ("D-Tyr" or
"y") and valine ("D-Val" or "v"). D-norleucine and D-norvaline may
be represented as (dNLeu) and (dNVal), respectively. Although
"amino acid residue" is often used in reference to a monomeric
subunit of a peptide, polypeptide or protein, and "amino acid" is
often used in reference to a free molecule, usage of these terms in
the art overlaps and varies. The term "amino acid" and "amino acid
residue" are used interchangeably and may refer to a free molecule
or a monomeric subunit of a peptide, polypeptide or protein,
depending on context.
[0061] To determine the percent "homology" or percent "identity" of
two amino acid sequences, the sequences are aligned for optimal
comparison purposes (e.g., gaps can be introduced in the sequence
of one polypeptide for optimal alignment with the other
polypeptide). The amino acid residues at corresponding amino acid
positions are then compared. When a position in one sequence is
occupied by the same amino acid residue as the corresponding
position in the other sequence, then the molecules are identical at
that position. As used herein amino acid or nucleic acid "homology"
is equivalent to amino acid or nucleic acid "identity".
Accordingly, the percent sequence identity between the two
sequences is a function of the number of identical positions shared
by the sequences (i.e., percent sequence identity=numbers of
identical positions/total numbers of positions.times.100). Percent
sequence identity between two polypeptide sequences can be
determined using the Vector NTI software package (Invitrogen
Corporation, 5791 Van Allen Way, Carlsbad, Calif. 92008). A gap
opening penalty of 10 and a gap extension penalty of 0.1 are used
for determining the percent identity of two polypeptides. All other
parameters are set at the default settings.
[0062] A "cationic amino acid" intends an amino acid residue that
has a net positive charge at physiologic pH (7.4), as is the case,
for example, in the amino acid residues where the side chain, or "R
group", contains an amine functional group or other functional
group that can accept a proton to become positively charged at
physiologic pH, such as a guanidine or imidazole moiety. Cationic
amino acid residues include arginine, lysine, histidine,
2,3-diaminopropionic acid (Dap), 2,4-diaminobutyric acid (Dab),
ornithine, and homoarginine.
[0063] A "cationic subunit" intends a subunit that has a net
positive charge at physiologic pH (7.4).
[0064] As used herein, "conservative amino acid substitutions" are
substitutions which do not result in a significant change in the
activity or tertiary structure of a selected polypeptide or
protein. Such substitutions typically involve replacing a selected
amino acid residue with a different amino acid residue having
similar physico-chemical properties. Groupings of amino acids and
amino acid residues by physico-chemical properties are known to
those of skill in the art. For example, among the
naturally-occurring amino acids, families of amino acid residues
having similar side chains have been defined in the art, and
include basic side chains (e.g., lysine, arginine, histidine),
acidic side chains (e.g., aspartic acid, glutamic acid), uncharged
polar side chains (e.g., glycine, asparagine, glutamine, serine,
threonine, tyrosine, cysteine), nonpolar side chains (e.g.,
alanine, valine, leucine, isoleucine, proline, phenylalanine,
methionine, tryptophan), beta-branched side chains (e.g.,
threonine, valine, isoleucine) and aromatic side chains (e.g.,
tyrosine, phenylalanine, tryptophan, histidine).
[0065] As used herein, "chemical cross-linking" refers to covalent
bonding of two or more molecules.
[0066] A peptide or peptide fragment is "derived from" a parent
peptide or polypeptide if it has an amino acid sequence that is
identical or homologous to at least a contiguous sequence of five
amino acid residues, more preferably eight amino acid residues, of
the parent peptide or polypeptide. The compounds described herein
may be in the form of pharmaceutically acceptable salts.
Pharmaceutically acceptable salts include acid addition salts, such
as hydrochloride, hydrobromide, sulfurate, nitrate, phosphorate,
acetate, propionate, glycolate, pyruvate, oxalate, malate,
malonate, succinate, maleate, fumarate, tartarate, citrate,
benzoate, cinnamate, mandelate, methanesulfonate, ethanesulfonate,
p-toluene-sulfonate, salicylate and the like, and base addition
salts, such as sodium, potassium, calcium, magnesium, lithium,
aluminum, zinc, ammonium, ethylenediamine, arginine, piperazine and
the like.
[0067] As used herein, the term "hyperparathyroidism" refers to
primary, secondary and tertiary hyperparathyroidism, unless
otherwise indicated.
[0068] The term "intradermal" intends that in the methods of
treatment described herein a therapeutically effective amount of a
calcimimetic compound is applied to skin to deliver the compound to
layers of skin beneath the stratum corneum, and thus achieve a
desired therapeutic effect.
[0069] As used herein, an "isolated" or "purified" polypeptide or
biologically active portion thereof is free of some of the cellular
material when produced by recombinant DNA techniques, or chemical
precursors or other chemicals when chemically synthesized. The
language "substantially free of cellular material" includes
preparations of polypeptides in which the polypeptide is separated
from some of the cellular components of the cells in which it is
naturally or recombinantly produced. When the polypeptide or
biologically active portion thereof is recombinantly produced, it
is also preferably substantially free of culture medium, i.e.,
culture medium represents less than about 20%, more preferably less
than about 10%, and most preferably less than about 5% of the
volume of the polypeptide preparation. The language "substantially
free of chemical precursors or other chemicals" includes
preparations of polypeptides in which the polypeptide is separated
from chemical precursors or other chemicals that are involved in
the synthesis of the polypeptide. In one embodiment, the language
"substantially free of chemical precursors or other chemicals"
includes preparations of a polypeptide having less than about 30%
(by dry weight) of chemical precursors or other chemicals,
preferably less than about 20% chemical precursors or other
chemicals, more preferably less than about 15% chemical precursors
or other chemicals, still more preferably less than about 10%
chemical precursors or other chemicals, and most preferably less
than about 5% chemical precursors or other chemicals. In preferred
embodiments, isolated polypeptides, or biologically active portions
thereof, lack contaminating polypeptides from the same organism
from which the domain polypeptide is derived.
[0070] As used herein, "macromolecule" refers to a molecule, such
as a peptide, polypeptide, protein or nucleic acid, that typically
has a molecular weight greater than about 900 Daltons.
[0071] A "non-cationic amino acid" intends an amino acid residue
that has no charge or a net negative charge at physiologic pH
(7.4), as is the case, for example, in the amino acid residues
where the side chain, or "R group", is neutral (neutral polar and
neutral non-polar) and acidic. Non-cationic amino acids include
those residues with an R group that is a hydrocarbon alkyl or
aromatic moiety (e.g., valine, alanine, leucine, isoleucine,
phenylalanine); a neutral, polar R group (asparagine, cysteine,
glutamine, serine, threonine, tryptophan, tyrosine); or a neutral,
non-polar R group (glycine, methionine, proline, valine,
isoleucine). Non-cationic amino acids with an acidic R group
include asparatic acid and glutamic acid.
[0072] A "polymer" refers to a linear chain of two or more
identical or non-identical subunits joined by covalent bonds.
[0073] As used herein, "peptide" and "polypeptide" refer to any
polymer made up of a chain of amino acid residues linked by peptide
bonds, regardless of its size. Although "protein" is often used in
reference to relatively large polypeptides, and "peptide" is often
used in reference to small polypeptides, usage of these terms in
the art overlaps and varies. Thus, for simplicity, the term
"peptide" will be used herein, although in some cases the art may
refer to the same polymer as a "polypeptide." Unless otherwise
indicated, the sequence for a peptide is given in the order from
the amino terminus to the carboxyl terminus.
[0074] A "thiol-containing group" or "thiol-containing moiety" as
used herein intends a functional group comprising a sulfur-hydrogen
bond (--SH), and that is capable of reacting with another thiol
under physiologic conditions to form a disulfide bond. A thiol that
is capable of forming a disulfide bond with another thiol is
referred to herein as a "reactive thiol." In a preferred embodiment
the thiol-containing group is less than 6 atoms away from the
backbone of the compound. In a more preferred embodiment, the
thiol-containing group has the structure
(--SH--CH.sub.2--CH.sub.2--C(O)--O--)--.
[0075] As used herein, "small molecule" refers to a molecule other
than a macromolecule, such as an organic molecule, and typically
has a molecular weight of less than 1000 daltons.
[0076] As used herein, "subject" refers to a human subject or an
animal subject.
[0077] A "subunit" intends a monomeric unit that is joined to more
than one other monomeric unit to form a polymeric compound, where a
subunit is the shortest repeating pattern of elements in the
polymeric compound. Exemplary subunits are amino acids, which when
linked form a polymer compound such as those referred to in the art
as a peptide, a polypeptide or a protein.
[0078] As used herein, a "therapeutically effective amount" is an
amount required to produce a desired therapeutic effect. For
example, in methods for reducing serum calcium in hypercalcemic
subjects, a therapeutically effective amount is the amount required
to reduce serum calcium levels by at least 1%, 2%, 3%, 4%, 5%, 6%,
7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%
or 25%. Calcium may be measured as total calcium or as ionized
calcium. By way of another example, in methods for lowering in vivo
PTH, a therapeutically effective amount is the amount required to
reduce PTH levels by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%,
10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20% or 25%.
[0079] As used herein, the term "transdermal" means that in the
methods of treatment described herein a therapeutically effective
amount of a calcimimetic agent is applied to skin to deliver the
compound to systemic circulation and thus achieve a desired
therapeutic effect.
[0080] Unless otherwise specified, all documents referred to herein
are incorporated by reference in their entirety.
II. Compounds
[0081] In one aspect, a compound comprising the sequence of
subunits X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7 is
provided, where X.sub.1 is a subunit comprising a thiol group;
X.sub.5 is a cationic subunit; X.sub.6 is a non-cationic subunit;
X.sub.7 is a cationic a subunit; and at least two of X.sub.2,
X.sub.3 and X.sub.4 are independently a cationic subunit. The
compounds have activity to decrease parathyroid hormone (PTH)
levels and/or decrease calcium levels in a subject's blood. A
decrease in parathyroid hormone levels, as will be illustrated
below, intends a lowering of plasma or blood PTH concentration in a
subject relative to the plasma or blood PTH concentration prior to
treatment with the compound. In one embodiment, the compound
achieves a reduction in plasma PTH concentration by at least 50%
within one hour after dosing, relative to the plasma PTH prior to
dosing. The compounds are exemplified by peptides, although a
skilled artisan will appreciate that non-peptidic compounds that
have the desired activity can be designed based on the
structure-activity relationship studies described herein.
[0082] As used herein parathyroid hormone or PTH is an 84 amino
acid peptide produced by the parathyroid gland and its breakdown
products. Besides full length PTH (which consists of residues 1-84
and is sometimes referred to as "intact" of "bioactive" PTH)
various PTH fragments generated by proteolysis and other routes of
metabolism are present in blood. The amino-terminal 1-34 region of
the intact PTH molecule is biologically active. This region of the
molecule contains the amino acid sequence that enables PTH to bind
to the parathyroid hormone receptors in target tissues. The middle
and carboxy-terminal 35-84 region of the intact PTH molecule is
believed to be biologically inert but possesses immunological
reactivity. PTH 7-84 is thought to exert effects that are opposite
to those of 1-84 PTH. Various assays have been developed to measure
PTH levels including various breakdown products and are reviewed by
Souberbielle et. al., Kidney International, 77:93-100 (2010), which
is incorporated herein by reference. In one embodiment, a compound
having activity to decrease PTH level as defined herein is
ascertained using a validated PTH quantification method that
detects the intact bioactive form of PTH(1-84), and commercially
available kits are known in the art (e.g., see Example 3
herein).
[0083] In a first study, compounds containing 4 to 7 cationic
(e.g., arginine) subunits were generated and tested for their
ability to lower PTH as compared with baseline PTH values and
saline-treated animals. Specifically, a 1K1C model of acute renal
insufficiency was established for use in characterizing the
PTH-lowering activity in a renal dysfunction environment. The 1K1C
model is described in Example 1A, and the compounds synthesized for
testing included (i) Ac-crrrr-NH.sub.2 (SEQ ID NO:4), (ii)
Ac-crrrrr-NH.sub.2 (SEQ ID NO:5), (iii) Ac-crrrrrr-NH.sub.2 (SEQ ID
NO:6), (iv) Ac-crrrrrrr-NH.sub.2 (SEQ ID NO:7) and (v) saline
control.
[0084] As described in Example 1B, the compounds identified as SEQ
ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 were each
administered by a 30-minute IV infusion to 1K1C model animals. FIG.
1 shows the reduction in plasma PTH levels as a percent of the
pre-dosing (baseline) level. All four compounds dosed at 3 mg/kg
produced a significant drop in plasma PTH, but differences in the
potency and duration of PTH reduction suggest a relationship
between the net positive charge and PTH-lowering activity. For
example, the compound Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6; triangles)
with six cationic (arginine) subunits had increased efficacy as
well as the duration of action compared to the compounds
Ac-crrrr-NH.sub.2 (SEQ ID NO:4; diamonds) and Ac-crrrrr-NH.sub.2
(SEQ ID NO:5; squares), containing four and five cationic
(arginine) subunits, respectively. Surprisingly, the compound
Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6; triangles) with six cationic
(arginine) subunits had increased duration of action compared to
the compound Ac-crrrrrrr-NH.sub.2 (SEQ ID NO:7, open squares) with
seven cationic (arginine) residues, suggesting that activity or
potency of the compounds does not correlate merely with increasing
cationic charge of the compound. That is, the compound
Ac-crrrrrrr-NH.sub.2 (SEQ ID NO:7) with seven cationic subunits
(arginine residues) produced a similar initial drop in PTH as the
compounds with fewer cationic residues, but over the 24 hours
following dosing was less efficacious than Ac-crrrrrr-NH.sub.2 (SEQ
ID NO:6) and Ac-crrrrr-NH.sub.2 (SEQ ID NO:5). These latter two
compounds produced a mean PTH reduction of .about.40% and 60% at
the 24 hour time point, respectively. Both the extent of PTH
reduction and duration of PTH are important criteria for obtaining
optimal therapeutic benefit for patients in need of treatment. It
should be noted that the compounds in this study were administered
at the same mg/kg dose but, due to differences in molecular weight,
a different number of moles of each compound was actually dosed.
Therefore, Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) was significantly more
potent than Ac-crrrr-NH.sub.2 (SEQ ID NO:4) and Ac-crrrrr-NH.sub.2
(SEQ ID NO:5) on a per mole basis.
[0085] Further studies were done to explore the structure-activity
relationship of the compounds. The compound Ac-crrrrrr-NH.sub.2
(SEQ ID NO:6) was modified by sequential replacement of an arginine
residue with an alanine residue at each of the subunit positions
X.sub.2-X.sub.7. The compounds were characterized in an in vitro
human calcium-sensing receptor (CaSR) assay, described in Example
2, wherein HEK 293 cells that express the human calcium-sensing
receptor were used to measure activity of exemplary compounds.
Without wishing to be bound by theory, it is thought that the
mechanism by which the described compounds lower PTH in vivo is
through the activation of the CaSR, which is expressed in the
parathyroid gland and controls PTH secretion. Activation of the
CaSR leads to an increase in intracellular calcium and
inositol-3-phosphate (IP3) and the subsequent accumulation of
inositol-phosphate-1 (IP.sub.1). Accordingly, in this in vitro
assay, the half maximal effective concentration of compound to
reduce IP.sub.1 generation by 50% was determined (EC.sub.50). The
same compounds were also tested in vivo to determine their
PTH-lowering activity, as described in Example 3. Results are shown
in Table 1. The numbers in the column titled "% PTH AUC (1-4 hrs)
of saline control" of Table 1 define activity as reduction in Area
Under the Curve (AUC) of PTH over 4 hours as a percent of PTH AUC
derived from saline-treated control rats. For example, an AUC
(compound treated)/AUC (saline control)*100 that is equal to 0
would be indicative of a highly active PTH-lowering compound that
completely suppresses PTH (to an undetectable level) for 4 hours
after a single IV administration of isoflurane (IF)-anesthetized
normal rats. In contrast, a value of AUC (compound treated)/AUC
(saline control)*100 that is equal to or greater than 100 would be
indicative of an inactive compound.
TABLE-US-00001 TABLE 1 In vitro and In vivo activity of Exemplary
Compounds In vivo activity in normal rats** % PTH reduction of 0.5
mg/kg baseline at IV bolus 1 hour post % PTH In IV admin. AUC of
vitro SEQ ID of 0.5 mg/kg saline EC.sub.50 NO. Structure* compound
control (uM) SEQ ID Ac-crrrrrr- 4 0 0.5 NO: 6 NH.sub.2 SEQ ID
Ac-carrrrr- 0 0 1.1 NO: 8 NH.sub.2 SEQ ID Ac-crarrrr- 0 7 1.0 NO: 9
NH.sub.2 SEQ ID Ac-crrarrr- 0 0 1.1 NO: 10 NH.sub.2 SEQ ID
Ac-crrrarr- 9 45 5.9 NO: 11 NH.sub.2 SEQ ID Ac-crrrrar- 3 3 0.45
NO: 12 NH.sub.2 SEQ ID Ac-crrrrra- 4 28 1.1 NO: 13 NH.sub.2 Saline
128 100 ND *Bolded fond indicates D-alanine substitutions of
cationic amino acids (D-arginine in SEQ ID NO: 6. **PTH reduction
following 0.5 mg/kg IV administration in isofluorane-anesthetized
normal rats-PTH was measured at 1, 2, 3 and 4 hours post
administration and cumulative AUC was calculated. PTH data were
calculated according to the following formula: AUC.sub.cmpd
treated/AUC.sub.saline control*100.
[0086] In Table 1, the compounds Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6),
Ac-carrrrr-NH.sub.2 (SEQ ID NO:8) and Ac-crrarrr-NH.sub.2 (SEQ ID
NO:10) were quite potent, as evidenced by the decrease in percent
PTH to below the detection limit or essentially zero as measured in
vivo after a single IV administration in normal rats. Substitution
of the cationic (arginine) residue at positions 2, 3, 4 or 7 of
Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) resulted in an approximately
two-fold loss in in vitro potency. The substitution at position 5
to produce the compound Ac-crrrarr-NH.sub.2 (SEQ ID NO:11) produced
a 5-10 fold reduction in in vitro potency, although the in vivo
percent PTH AUC reduction of 45% could be sufficiently active for
clinical therapy. Surprisingly, the substitution of the cationic
arginine residue at position 6 with the uncharged (alanine) residue
actually improved potency. The data illustrate that cationic and
uncharged residues at different positions are not all equal and
there are changes in activity as a result of change in the compound
structure.
[0087] To further evaluate the effect of change in activity as a
function of change in compound structure, another series of analogs
of Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) was generated containing
double amino acid substitutions, where two cationic (arginine)
residues were replaced by uncharged (alanine) residues, and tested
for potency. Data are shown in Table 2. It is worth noting that
this series of compounds have the same net cationic charge as SEQ
ID NO:4 (four cationic residues) yet surprisingly some are very
active (SEQ ID NO:26) with very low % PTH AUC of saline control
while others are inactive (e.g., SEQ ID NO:14). Unexpectedly, this
suggests that position of charges as well as total cationic charge
can influence potency of the compounds for reduction of PTH. The
data shown in Table 2 is consistent with the data shown in Table 1
suggesting that the cationic residues of SEQ ID NO:6 are essential
at positions 5 and 7 but is not required at position 6, for
PTH-lowering activity.
TABLE-US-00002 TABLE 2 In vivo Activity of Exemplary Compounds In
vivo activity in normal rats** % PTH reduction of baseline at 0.5
mg/kg 1 hour post IV IV bolus administration % PTH AUC SEQ ID
Compound of 0.5 mg/kg of saline NO. Structure* compound control*
Saline Saline 128 100 SEQ ID Ac-crrarra- 86 130 NO: 14 NH.sub.2 SEQ
ID Ac-cararrr- 75 116 NO: 15 NH.sub.2 SEQ ID Ac-carrarr- 118 105
NO: 16 NH.sub.2 SEQ ID Ac-crraarr- 39 102 NO: 17 NH.sub.2 SEQ ID
Ac-crararr- 72 87 NO: 18 NH.sub.2 SEQ ID Ac-carrrra- 29 72 NO: 19
NH.sub.2 SEQ ID Ac-crarrra- 45 69 NO: 20 NH.sub.2 SEQ ID
Ac-crrraar- 36 50 NO: 21 NH.sub.2 SEQ ID Ac-caarrrr- 24 48 NO: 22
NH.sub.2 SEQ ID Ac-crarrar- 0 43 NO: 23 NH.sub.2 SEQ ID Ac-craarrr-
8 9 NO: 24 NH.sub.2 SEQ ID Ac-crrarar- 4 6 NO: 25 NH.sub.2 SEQ ID
Ac-carrrar- 0 1 NO: 26 NH.sub.2 SEQ ID Ac-c(C)arrrar- 2 8 NO: 27
NH.sub.2 SEQ ID Ac-c(C)rrarar- 0 16 NO: 28 NH.sub.2 *Bolded font
indicates respective D-alanine substitutions of cationic amino
acids (D-arginine) in Ac-crrrrrr-NH.sub.2 (SEQ ID NO: 6) **PTH
reduction following 0.5 mg/kg IV administration in
isofluorine-anesthetized normal rats-PTH was measured at 1, 2, 3
and 4 hours post administration and cumulative AUC was calculated.
PTH data were calculated according to the following formula:
AUC.sub.cmpd treated/AUC.sub.saline control*100.
[0088] The data in Table 2 illustrates the structural changes that
influence activity. In one embodiment, the compound is
Ac-caarrrr-NH.sub.2 (SEQ ID NO:22) and in another embodiment, the
compound is Ac-craarrr-NH.sub.2 (SEQ ID NO:24).
[0089] Further structure-activity relationship studies were
conducted using the in vitro cell assay in HEK 293 cells that
express the human calcium-sensing receptor, as described in Example
4. The ability of the peptides Ac-carrrar-NH.sub.2 (SEQ ID NO:26)
and Ac-arrrar-NH.sub.2 (SEQ ID NO:29) to activate the human CaSR
was ascertained by the measuring accumulation of inositol
monophosphate (IP.sub.1), which is reflective of IP.sub.3
production. IP.sub.3 production is an important cell signaling
second messenger and its production is a direct downstream
consequence of CaSR activation. Accumulation of IP.sub.1 following
IP.sub.3 production can be obtained by treating the cells used in
the assay with Lithium Chloride (LiCl.sub.2) which inhibits the
enzyme that converts IP.sub.1 to inositol. In the studies described
in Example 4 accumulation of IP.sub.1 was measured in the presence
of the exemplary compounds Ac-carrrar-NH.sub.2 (SEQ ID NO:26) and
Ac-arrrar-NH.sub.2 (SEQ ID NO:29). Results are shown in FIG.
2A.
[0090] The concentration of IP.sub.1 is reported as nM along the
Y-axis and compound concentrations of SEQ ID NO:26 or SEQ ID NO:29
are reported as M along the X-axis. Absence of the N-terminal
D-cysteine residue from SEQ ID NO:29 dramatically reduced the
ability of the compound to activate the CaSR as compared to SEQ ID
NO:26. That is, elimination of the N-terminal cysteine residue
significantly reduced the potency of the compound, as the peptides
Ac-carrrar-NH (SEQ ID NO:26) and Ac-arrrar-NH.sub.2 (SEQ ID NO:29)
differ only by the presence or absence of the N-terminal
D-cysteine.
[0091] The contribution of the thiol-containing group in the
X.sub.1 subunit of the compound (e.g., in certain embodiments where
the compound is a peptide on the N-terminal residue), was also
investigated in an in vivo study. The PTH-lowering activity of the
peptides identified as SEQ ID NO:26 (Ac-carrrar-NH.sub.2) and as
SEQ ID NO:29 (Ac-arrrar-NH.sub.2) was evaluated in vivo according
to the procedures in Example 4. Plasma PTH levels were assessed
prior to dosing and at 1, 2, 3 and 4 hours after dosing. The
results are shown in FIG. 2B. As seen, a 0.5 mg/kg dose of the
peptide Ac-carrrar-NH.sub.2 (SEQ ID NO:26) (squares) decreased PTH
blood concentration to a non-detectable level for up to 4 hours
after dosing. In contrast, the peptide lacking an N-terminal
residue with a thiol-containing group, Ac-arrrar-NH.sub.2 (SEQ ID
NO:29), diamonds, did not reduce PTH concentration, even at a
substantially higher dose (i.e., 9 mg/kg).
[0092] The structure-activity relationship of the thiol-containing
group in the X.sub.1 subunit of the compound was further analyzed
by preparing compounds with differing X.sub.1 subunits. The
compounds, shown in Table 3, were tested in vivo in normal rats for
activity to reduce PTH.
TABLE-US-00003 TABLE 3 In vivo Activity of Exemplary Compounds In
vivo activity in normal rats* 0.5 mg/kg IV bolus % PTH AUC of
saline SEQ ID NO. Compound Structure control** Saline Saline 100
SEQ ID NO: 6 Ac-crrrrrr-NH.sub.2 3 SEQ ID NO: 30
Ac-bAla-crrrrrr-NH.sub.2 0 SEQ ID NO: 31 Mpa-rrrrrr-NH.sub.2 2 SEQ
ID NO: 32 Ac-dHcy-rrrrrr-NH.sub.2 21 SEQ ID NO: 33
Ac-dPen-rrrrrr-NH.sub.2 9 *Bolded font indicates respective
substitution of thiol-containing residue (D-cysteine) in
Ac-crrrrrr-NH.sub.2 (SEQ ID NO: 6). **PTH reduction following 0.5
mg/kg IV administration in isoflurane-anesthetized normal rats-PTH
was measured at 1, 2, 3 and 4 hours post administration and
cumulative AUC was calculated. PTH data were calculated according
to the following formula: AUC.sub.cmpd treated/AUC.sub.saline
control*100.
[0093] The data in Table 3 illustrates that the thiol-containing
X.sub.1 subunit can be varied. Compounds with the following in the
N-terminal residue were tested--D-cysteine (cys), D-penicillamine
(dPen), d-homocysteine (dHcy) and mercaptopropionic acid (Mpa). In
addition, a natural or non-natural amino acid, such as beta
alanine, can be conjugated to the N-terminal thiol-containing
residue. The data illustrates that cationic compounds such as
Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) containing different
thiol-containing groups in the X.sub.1 subunit effectively reduce
PTH in vivo. Substituting the N-terminal cysteine residue with
methionine, which does not contain a thiol group, resulted in a
compound with very poor in vivo PTH-lowering activity (data not
shown).
[0094] Based on the studies above, compounds of the contiguous
sequence of subunits
X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7, where
X.sub.1 is a subunit comprising a thiol-containing group, have
activity to decrease parathyroid hormone levels. In one embodiment,
the thiol-containing group on the X.sub.1 subunit is selected from
the group consisting of thiol-containing amino acid residues and
organic thiol-containing moieties. In another embodiment, the
thiol-containing group is capable of reacting with another thiol
group under physiologic pH and temperature. In certain embodiments
where the thiol-containing residue is an amino acid residue, the
X.sub.1 subunit can be any one of cysteine, glutathione,
mercapto-propionic acid, n-acetylated cysteine and PEGylated
cysteine. In embodiments where the thiol-containing group is on a
non-amino acid residue subunit, such an organic small molecule with
a thiol-containing group, the X.sub.1 subunit can be a thiol-alkyl,
or thioacyl moieties such as 3-mercaptopropyl or
3-mercaptopropionyl residues. In one embodiment, the thiol is not
homocysteine.
[0095] Accordingly, and in another embodiment, the compounds
described herein have "clinical activity to decrease parathyroid
hormone level", which intends that the compound, upon
administration to a subject, lowers plasma parathyroid hormone as
measured by the cumulative PTH area under the curve (PTH AUC) over
4 hours post administration compared to PTH AUC of a corresponding
vehicle treated control subject. The plasma PTH concentrations are
measured using, for example, a commercially available ELISA kit
that detects bioactive intact PTH 1-84 (see Example 3 for a
specific kit). compound with clinical activity to decrease
parathyroid hormone level reduces the PTH AUC by at least 20%, 30%,
40%, 50%, 60%, 70%, 80%, 90%, 95% compared to the PTH AUC of a
corresponding vehicle treated control subject.
[0096] The studies above, and others described below, illustrate
further embodiments of the compounds described herein, wherein the
X.sub.1 subunit in some embodiments can be modified chemically,
such as by chemical modification to include an acetyl group, a
benzoyl group, a benzyl group, a butyl group, a natural or
unnatural amino acid such as acetylated-beta-alanine or is joined
by a covalent linkage to another thiol moiety. Peptide therapeutics
may be vulnerable to attack by peptidases. Exopeptidases are
typically non-specific enzymes which cleave amino acid residues
from the amino or carboxy termini of a peptide or protein.
Endopeptidases, which cleave within an amino acid sequence, can
also be non-specific; however endopeptidases frequently recognize
particular amino sequences (recognition sites) and cleave the
peptide at or near those sites. Accordingly, modifications to the
compound to protect it from proteolytic degradation are
contemplated.
[0097] One method of protecting a peptide from proteolytic
degradation involves chemically modifying, or "capping," the amino
and/or carboxy termini of the peptides. As used herein, the terms
"chemically modified" or "capped" are used interchangeably to refer
to the introduction of a blocking group to a terminus or to both
termini of the compound via a covalent modification. Suitable
blocking groups serve to cap the termini of the peptides without
decreasing the biological activity of the peptides. Any residue
positioned at the amino or carboxy termini, or both, of the
described compounds, including the thiol-containing subunits can be
chemically modified.
[0098] In a preferred embodiment, the amino terminus of the
compound is chemically modified by acetylation, to provide an
N-acetyl peptide (which may be represented as "Ac-" in a structure
or formula herein). In a preferred embodiment, the carboxy terminus
of the described peptides, is chemically modified by amidation to
provide a primary carboxamide at the C-terminus (which may be
represented as "--NH.sub.2" in a peptide sequence, structure or
formula herein). In a preferred embodiment, both the amino terminus
and carboxy terminus are chemically modified by acetylation and
amidation, respectively. However, other capping groups are
possible. For example, the amino terminus may be capped by
acylation with groups such as an acetyl group, a benzoyl group, or
with natural or unnatural amino acids such as beta-alanine capped
with an acetyl group, or by alkylation with groups such as a benzyl
group or a butyl group, or by sulfonylation to form sulfonamides.
Similarly, the carboxy terminus may be esterified, or converted to
a secondary amide, and acyl sulfonamide, or the like. In some
embodiments, the amino terminus or the carboxy terminus may
comprise a site for attachment of a polyethylene glycol (PEG)
moiety, i.e., the amino or carboxy termini may be chemically
modified by reaction with a suitably functionalized PEG.
[0099] Protecting peptides from endopeptidases typically involves
identification and elimination of an endopeptidase recognition site
from a peptide. Protease recognition sites are well known to those
of ordinary skill in the art. Thus it is possible to identify a
potential endoprotease recognition site and then eliminating that
site by altering the amino acid sequence within the recognition
site. Residues in the recognition sequence can be moved or removed
to destroy the recognition site. Preferably, a conservative
substitution is made with one or more of the amino acids which
comprise an identified protease recognition site.
A. Additional Structure-Activity Relationship Studies
[0100] Additional structure activity studies were conducted, to
further evaluate the effect of properties of each subunit in the
compound on its therapeutic activity. These studies are now to be
described with reference to Example 5.
[0101] A series of compounds having an L-amino acid residue
substituted for a D-amino acid residue were prepared based on the
PTH-lowering scaffold Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3). The
compounds were administered to subjects and plasma PTH levels were
assessed prior to dosing and 1, 2, 3 and 4 hours after dosing, as
described in Example 5 and the AUC was calculated as the sum of the
PTH concentration values at the time points of 1, 2, 3 and 4 hours,
normalized by the AUC for the saline control at the same time
points, multiplied by 100. The results are shown in Table 4.
TABLE-US-00004 TABLE 4 Effect of L-Amino Acid Substitution on
Potency In vivo activity in normal rats 0.5 mg/kg IV bolus % PTH
AUC* of Compound Name Structure saline control SEQ ID NO: 3
Ac-c(C)arrrar-NH.sub.2 8 SEQ ID NO: 34 Ac-C(C)arrrar-NH.sub.2 17
SEQ ID NO: 35 Ac-c(C)Arrrar-NH.sub.2 68 SEQ ID NO: 36
Ac-c(C)aRrrar-NH.sub.2 87 SEQ ID NO: 37 Ac-c(C)arRrar-NH.sub.2 182
SEQ ID NO: 38 Ac-c(C)arrRar-NH.sub.2 130 SEQ ID NO: 39
Ac-c(C)arrrAr-NH.sub.2 129 SEQ ID NO: 40 Ac-c(C)arrraR-NH.sub.2 142
Saline 100 *PTH reduction following 0.5 mg/kg IV administration in
isoflurane-anesthetized normal rats-PTH was measured at 1, 2, 3 and
4 hours post administration and cumulative AUC was calculated. PTH
data were calculated according to the following formula:
AUC.sub.cmpd treated/AUC.sub.saline control*100
[0102] The exemplary compounds shown in Table 4 were chemically
modified at both the N-terminus and the C-terminus, as indicated by
the Ac and NH.sub.2 designations. The sequence of seven subunits
carrrar (SEQ ID NO:3), wherein all subunits were D-amino acid
residues, was modified by replacing one subunit at a time with an
L-amino acid. The X.sub.1 subunit was a D-Cys residue (or L-Cys
residue in SEQ ID NO:34) conjugated via a disulfide linkage to an
L-Cys residue, as indicated by the parenthetical designation (C).
The PTH-lowering in vivo data in Table 4 shows that chirality of
Arg and Ala affect activity of the compounds. In one embodiment, a
compound of the sequence
X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7 is
contemplated, where at least the subunits identified as X.sub.4 and
X.sub.7 are D-amino acid residue subunits. In another embodiment,
the subunits identified as X.sub.4, X.sub.5, X.sub.6 and X.sub.7
are D-amino acid residue subunits. In a preferred embodiment, the
subunits identified as X.sub.3, X.sub.4, X.sub.5, X.sub.6 and
X.sub.7 are D-amino acid residue subunits. In most preferred
embodiments, the subunits identified as X.sub.2, X.sub.3, X.sub.4,
X.sub.5, X.sub.6 and X.sub.7 are D-amino acid residue subunits, and
all of the subunits X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5,
X.sub.6 and X.sub.7 are D-amino acid residue subunits.
[0103] In other studies, it also was found that substitution of a
peptide having all L-amino acids with all D-amino acids did not
reduce the in vitro activity of the peptides tested; in fact,
peptides composed entirely of D-amino acids appeared to enhance the
potency for activation of the CaSR. It was also shown that some of
the cationic (arginine) residues, at specific positions relative to
the cysteine residue, could be substituted with uncharged (alanine)
residues with minimal effect on the activity toward the CaSR.
[0104] To further characterize the relationship between structure
and activity against the CaSR, a variety of cationic peptides with
different numbers (4 to 8) of arginine residues (all of which
contained an N-terminal cysteine) were tested using the HEK-293 in
vitro cell assay. A direct correlation was found between the number
of cationic subunits and the potency of the compound, where potency
is evidenced by ability to activate the CaSR. Reducing the number
of cationic (e.g., arginine) subunits from 5 to 4 resulted in the
largest shift in potency (>10-fold) suggesting that there may be
an activity inflection point between compounds having these net
charges, that a cationic subunit at subunit X.sub.5 is preferred
for activity. Accordingly, the compounds of the structure
X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7 are
contemplated, wherein X.sub.5 is a cationic subunit. In certain
embodiments the X.sub.1 is a subunit comprises a thiol group that
is capable of reacting with another thiol group under physiologic
conditions (a "reactive thiol", intending a thiol that reacts with
another thiol (e.g., cysteine with cysteine) under physiologic
conditions of pH 7.4 and body temperature).
[0105] Unexpectedly, Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) with six
cationic residues, when evaluated in vivo, exhibited greater and
more prolonged activity than Ac-crrrrrrrr-NH.sub.2 (SEQ ID NO:41),
which has eight cationic residues. This is in contrast to the
observation that SEQ ID NO:41 was more potent at activating the
CaSR in this in vitro cell assay. Without wishing to be bound by
theory, it is thought that the superior performance of
Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) in vivo may stem from better
pharmacokinetic properties of Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6),
because Ac-crrrrrrrr-NH.sub.2 (SEQ ID NO:6441 is expected to be
taken up into cells by virtue of its cell-penetrating
characteristic, and thus removed from proximity to the active
portion of the CaSR.
[0106] To further explore the structure-activity relationship of
Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6), some of the cationic (arginine)
residues were replaced with uncharged (alanine) residues. It was
found that replacing the cationic (arginine) residues at subunit
positions X.sub.2 and X.sub.4 resulted in a compound (SEQ ID NO:15)
that had significantly reduced potency in vitro in activating the
CaSR. By contrast, replacing the cationic (arginine) residues at
subunit positions X.sub.2 and X.sub.6 resulted in a compound (SEQ
ID NO:26) that retained much of the potency seen with
Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6). These results suggest that the
position of charged residues in the compound contributes to potency
and, in some embodiments, may outweigh the contribution of total
positive charge of the peptide. It also appears that cationic
(arginine) residues at certain positions, such as subunit position
X.sub.5, contribute disproportionately to potency.
[0107] It was found that the presence of an N-terminal cysteine
markedly enhances the potency of the peptides for activating the
CaSR. The CaSR is a 7-transmembrane G-protein-coupled receptor with
a large extracellular domain that functions as a homodimeric
receptor. There are 18 cysteine residues in the extracellular
domain, some of which have been shown by polymorphism or mutational
analysis to be important for receptor activity. Of particular note
are cysteines 129 and 131 of the Loop 2 region of the extracellular
domain. Cysteines 129 and 131 are thought to form an intermolecular
disulfide bridge between the two monomers of the receptor complex,
which is in a closed or inhibited configuration. Mutation of
cysteine 129 activates the CaSR, as do a number of other mutations
including a full deletion of the Loop2 region. The enhanced potency
provided by the N-terminal cysteine residue in the described
compounds could result from a specific interaction with one or more
of the cysteine residues in the extracellular domain of the
CaSR.
[0108] To further evaluate the effect of chirality of amino acid
substitutions on in vitro CaSR activity, a series of analogs of
Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) were generated containing L-amino
acid or achiral amino acid (glycine) substitutions at various
positions and tested for potency against the CaSR. Tested analogs
included Ac-cGrrrGr-NH.sub.2 (SEQ ID NO:42), (ii)
Ac-cArrrAr-NH.sub.2 (SEQ ID NO:43), and (iii) Ac-CaRrRaR-NH.sub.2
(SEQ ID NO:44). All of the foregoing analogs had significantly
lower potency than Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6), ranging from
a 10-fold difference for SEQ ID NO:44 (the most potent of the three
analogs) and a more than 2000-fold difference for SEQ ID NO:43 (the
least potent of the three analogs). Ac-carrrar-NH.sub.2 (SEQ ID
NO:26), in which cationic D-amino acid residues (D-arginine
residues) at positions 2 and 6 of SEQ ID NO:6 were replaced by
uncharged D-amino acid residues (D-arginine residues), the change
in activity was much less (.about.3 fold difference). Thus,
surprisingly, it was found that interrupting the all D-amino acid
residue of Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) with two or more
L-amino acid residues resulted in a significant reduction in
potency. Also surprising was that potency was decreased more than
80-fold when the interrupting residue was an uncharged achiral
amino acid residue (glycine residue) compared to when it was an
uncharged L-amino acid residue (L-alanine residue).
[0109] Also surprising was that replacing the two uncharged D-amino
acid residues (D-alanine residues) of Ac-carrrar-NH.sub.2 (SEQ ID
NO:26) with their L-counterparts (SEQ ID NO:43), resulted in a
greater than 600-fold decrease in potency, while replacing them
with an uncharged achiral amino acid residue (glycine residue) (SEQ
ID NO:42) resulted in less than an 8-fold reduction in potency; and
that replacing three cationic D-amino acid residues (D-arginine
residues) of Ac-carrrar-NH.sub.2 (SEQ ID NO:26) with their
L-counterparts (SEQ ID NO:44), resulted in less than a 4-fold
difference in potency.
[0110] The activity of a variety of peptides and conjugates was
tested against the human CaSR. These studies were conducted by
measuring IP.sub.1 production in HEK293 cells that express the
human CaSR. The EC.sub.50 values are shown in Table 5. Each peptide
was tested in eight different concentrations, in duplicates, to
establish a dose response curve. Curve fitting was performed using
GraphPad Prism. In Table 5, and throughout the specification,
residues provided in capital letters are L-amino acids, while lower
case letters indicate D-amino acids. "Ac" indicates an acetyl
capping group, "NH.sub.2" indicates an amide capping group,
"Ac-bAla" is an acetylated beta-alanine, "GSH" indicates reduced
glutathione, "GS" indicates oxidized glutathione, "PEG" refers to
polyethylene glycol, "PEG2" and "PEG5" refer to polyethylene glycol
moieties of 2 kDa and 5 kDa, respectively, and "Mpa" refers to
mercaptopropionic acid. A group bracketed by parentheses indicates
that group or moiety is attached to the side-chain of the preceding
subunit or amino acid residue.
TABLE-US-00005 TABLE 5 EC.sub.50 values for cationic peptides in
CaSR in vitro assay Compound Name Structure EC.sub.50 (.mu.M) (SEQ
ID NO: 45) (SEQ ID NO: 47) ##STR00001## 21 (SEQ ID NO: 46) (SEQ ID
NO: 47) ##STR00002## 21 (SEQ ID NO: 47) Ac-CYGRKKRRQRRR-NH.sub.2
4.5 (SEQ ID NO: 48) Ac-YGRKKRRQRRR-NH.sub.2 16 (SEQ ID NO: 41)
Ac-crrrrrrrr-NH.sub.2 0.3 (SEQ ID NO: 6) Ac-crrrrrr-NH.sub.2 0.5
(SEQ ID NO: 15) Ac-cararrr-NH.sub.2 13 (SEQ ID NO: 26)
Ac-carrrar-NH.sub.2 1.6 (SEQ ID NO: 4) Ac-crrrr-NH.sub.2 16 (SEQ ID
NO: 5) Ac-crrrrr-NH.sub.2 2.5 (SEQ ID NO: 7) Ac-crrrrrrr-NH.sub.2
0.6 (SEQ ID NO: 49) Ac-caraarrr-NH.sub.2 1000 (SEQ ID NO: 8)
Ac-carrrrr-NH.sub.2 1.1 (SEQ ID NO: 9) Ac-crarrrr-NH.sub.2 1 (SEQ
ID NO: 10) Ac-crrarrr-NH.sub.2 1.1 (SEQ ID NO: 50)
Ac-cygrkkrrqrrr-NH.sub.2 2 (SEQ ID NO: 51) ##STR00003## 0.44 (SEQ
ID NO: 3) Ac-c(C)arrrar-NH.sub.2 10 (SEQ ID NO: 52) ##STR00004##
0.7 (SEQ ID NO: 30) Ac-bAla-crrrrrr-NH.sub.2 1 (SEQ ID NO: 53)
Ac-c(GS)rrrrrr-NH.sub.2 7.8 (SEQ ID NO: 54) GS-crrrrrr -- (SEQ ID
NO: 55) Ac-c(Ac-C)arrrar-NH.sub.2 21 (SEQ ID NO: 56)
Ac-c(Mpa)arrrar-NH.sub.2 21 (SEQ ID NO: 57)
Ac-c(PEG2-C)arrrar-NH.sub.2 2.3 (SEQ ID NO: 58)
Ac-c(PEG5-C)rrrrrr-NH.sub.2 0.58 (SEQ ID NO: 59)
Ac-c(PEG2-C)rrrrrr-NH.sub.2 0.02 (SEQ ID NO: 34)
Ac-C(C)arrrar-NH.sub.2 2.5 (SEQ ID NO: 60) c(C)arrrar-NH.sub.2 3.1
(SEQ ID NO: 61) Ac-bAla-c(C)arrrar-NH.sub.2 2.6 (SEQ ID NO: 62)
bAla-c(C)arrrar -- (SEQ ID NO: 42) Ac-cGrrrGr-NH.sub.2 12 (SEQ ID
NO: 63) Ac-cGrrrGr -- (SEQ ID NO: 64) Ac-cArrrAr -- (SEQ ID NO: 43)
Ac-cArrrAr-NH.sub.2 >1000 (SEQ ID NO: 44) Ac-CaRrRaR-NH.sub.2
5.6 (SEQ ID NO: 65) Ac-cvrrrvr-NH.sub.2 35 (SEQ ID NO: 66)
Ac-cvrrrvr -- (SEQ ID NO: 67) Ac-Crrrrrr-NH.sub.2 6.2 (SEQ ID NO:
68) Ac-carrrer-NH.sub.2 62 (SEQ ID NO: 69) Ac-cerrrar-NH.sub.2 31
(SEQ ID NO: 72) Ac-cakrrar-NH.sub.2 35 (SEQ ID NO: 73)
Ac-carkrar-NH.sub.2 31 (SEQ ID NO: 74) Ac-carrrar-OH 31 (SEQ ID NO:
11) Ac-crrrarr-NH.sub.2 5.9 (SEQ ID NO: 12) Ac-crrrrar-NH.sub.2
0.45 (SEQ ID NO: 13) Ac-crrrrra-NH.sub.2 1.1 (SEQ ID NO: 75)
Ac-CARRRAR-NH.sub.2 58 (SEQ ID NO: 76) Ac-caarrrrrr-NH.sub.2 4.5
(SEQ ID NO: 77) Ac-caaarrrrrr-NH.sub.2 4.6 (SEQ ID NO: 78)
Ac-carararar-NH.sub.2 5.3 (SEQ ID NO: 29) Ac-arrrar-NH.sub.2
>1000 (SEQ ID NO: 79) Ac-carrrarar-NH.sub.2 13 (SEQ ID NO: 80)
crrrrrr-NH.sub.2 1.1 (SEQ ID NO: 32) Ac-dHcy rrrrrr-NH.sub.2 2 (SEQ
ID NO: 81) Ac-c(Benzoyl)rrrrrr-NH.sub.2 3.6 (SEQ ID NO: 82)
Ac-c(acetyl)rrrrrr-NH.sub.2 4.1
[0111] In another study of the structure activity relationship, the
contribution of non-cationic amino acids to the potency of the
peptides was evaluated by preparing a series of peptides with
various D-amino acid residues or glycine (Table 6) or with
sterically-hindered non-natural amino acids (Table 7), substituted
at various positions in the peptide Ac-carrrar-NH.sub.2 (SEQ ID
NO:26) and in the peptide Ac-crrarar-NH.sub.2 (SEQ ID NO:153). The
peptides were administered as an IV bolus to normal Sprague Dawley
rats at a dose of 0.5 mg/kg. An intravenous (IV) bolus of saline
was used as a control. Plasma PTH levels were assessed prior to
dosing and 1, 2, 3 and 4 hours after dosing. The results are shown
in the tables below, and indicate that: 1) a small amino acid such
as alanine, glycine or serine is preferred at position 6 in the
Ac-carrrar-NH.sub.2 peptide (SEQ ID NO:26), and 2) the alanine in
position 2 in Ac-carrrar-NH.sub.2 (SEQ ID NO:26) is much more
permissive to substitutions and can be substituted with hydrophobic
(e.g. D-Val, D-Leu), aromatic (e.g. D-Phe), or polar (e.g. D-Ser,
D-Gln) natural amino acids as well as non-natural bulky hydrophobic
amino acids (e.g. dNle, dNva) but not acidic ones, and that 3) the
alanine residue in position 4 of the Ac-crrarar-NH.sub.2 (SEQ ID
NO:25) peptide is also very permissive to substitutions and can
accommodate most types of natural amino acids (as well as
non-natural bulky hydrophobic amino acids (e.g. dNle, dNva) but is
not permissive to amino acids that affect secondary conformation,
namely glycine or proline or amino acids with acidic side
chain.
TABLE-US-00006 TABLE 6 Activity of Exemplary Peptide Compounds In
vivo activity in normal rats** 0.5 mg/kg IV bolus Compound % PTH
AUC of SEQ ID NO. Structure* saline control Saline Saline 100 SEQ
ID NO: 83 Ac-carrrfr-NH.sub.2 177 SEQ ID NO: 84 Ac-carrrir-NH.sub.2
161 SEQ ID NO: 85 Ac-carrrlr-NH.sub.2 140 SEQ ID NO: 68
Ac-carrrer-NH.sub.2 81 SEQ ID NO: 87 Ac-carrrvr-NH.sub.2 79 SEQ ID
NO: 88 Ac-carrrpr-NH.sub.2 76 SEQ ID NO: 89 Ac-carrrhr-NH.sub.2 48
SEQ ID NO: 90 Ac-carrrqr-NH.sub.2 41 SEQ ID NO: 91
Ac-carrrtr-NH.sub.2 18 SEQ ID NO: 92 Ac-carrrsr-NH.sub.2 6 SEQ ID
NO: 93 Ac-carrrGr-NH.sub.2 5 SEQ ID NO: 94 Ac-cerrrar-NH.sub.2 103
SEQ ID NO: 95 Ac-cGrrrar-NH.sub.2 45 SEQ ID NO: 96
Ac-cirrrar-NH.sub.2 33 SEQ ID NO: 97 Ac-cprrrar-NH.sub.2 30 SEQ ID
NO: 98 Ac-clrrrar-NH.sub.2 26 SEQ ID NO: 99 Ac-cqrrrar-NH.sub.2 24
SEQ ID NO: 100 Ac-ctrrrar-NH.sub.2 23 SEQ ID NO: 101
Ac-cvrrrar-NH.sub.2 19 SEQ ID NO: 102 Ac-csrrrar-NH.sub.2 13 SEQ ID
NO: 103 Ac-chrrrar-NH.sub.2 1 SEQ ID NO: 104 Ac-cfrrrar-NH.sub.2 0
SEQ ID NO: 105 Ac-crrGrar-NH.sub.2 69 SEQ ID NO: 106
Ac-crrprar-NH.sub.2 68 SEQ ID NO: 107 Ac-crrerar-NH.sub.2 56 SEQ ID
NO: 108 Ac-crrtrar-NH.sub.2 13 SEQ ID NO: 109 Ac-crrhrar-NH.sub.2 9
SEQ ID NO: 110 Ac-crrfrar-NH.sub.2 6 SEQ ID NO: 111
Ac-crrsrar-NH.sub.2 4 SEQ ID NO: 112 Ac-crrqrar-NH.sub.2 4 SEQ ID
NO: 113 Ac-crrvrar-NH.sub.2 3 SEQ ID NO: 114 Ac-crrlrar-NH.sub.2 1
SEQ ID NO: 115 Ac-crrirar-NH.sub.2 0 *Bolded font indicates
respective substitution of alanine residues in Ac-carrrar-NH.sub.2
(SEQ ID NO: 6) or Ac-crrarar-NH.sub.2 (SEQ ID NO: 25). **PTH
reduction following 0.5 mg/kg IV administration in
isoflurane-anesthetized normal rats-PTH was measured at 1, 2, 3 and
4 hours post administration and cumulative AUC was calculated. PTH
data were calculated according to the following formula:
AUC.sub.cmpd treated/AUC.sub.saline control*100.
TABLE-US-00007 TABLE 7 Activity of Exemplary Peptide Compounds In
vivo activity in normal rats* 0.5 mg/kg IV bolus % PTH AUC of
saline SEQ ID NO. Compound Structure* control** Saline Saline 100
SEQ ID NO: 116 Ac-crr-Sar-rar-NH.sub.2 141 SEQ ID NO: 117
Ac-carrr-Sar-r-NH.sub.2 111 SEQ ID NO: 118
Ac-c-Nma-rrr-Nma-r-NH.sub.2 105 SEQ ID NO: 119
Ac-crrar-Nma-r-NH.sub.2 101 SEQ ID NO: 120
Ac-c-Aib-rrr-Aib-r-NH.sub.2 94 SEQ ID NO: 121
Ac-crr-Nma-rar-NH.sub.2 86 SEQ ID NO: 122 Ac-carrr-Nma-r-NH.sub.2
74 SEQ ID NO: 123 Ac-c-Aib-rrrar-NH.sub.2 70 SEQ ID NO: 124
Ac-carrr-Aib-r-NH.sub.2 68 SEQ ID NO: 125
Ac-c-Sar-rrr-Sar-r-NH.sub.2 65 SEQ ID NO: 126
Ac-crrar-Sar-r-NH.sub.2 62 SEQ ID NO: 127 Ac-c-Nma-rrrar-NH.sub.2
56 SEQ ID NO: 128 Ac-c-Sar-rrrar-NH.sub.2 50 SEQ ID NO: 129
Ac-carrr-Nle-r-NH.sub.2 64 SEQ ID NO: 130
Ac-c-dNle-rrr-dNle-r-NH.sub.2 54 SEQ ID NO: 131
Ac-carrr-dNva-r-NH.sub.2 54 SEQ ID NO: 132
Ac-c-dNva-rrr-dNva-r-NH.sub.2 27 SEQ ID NO: 133
Ac-crrar-dNle-r-NH.sub.2 26 SEQ ID NO: 134 Ac-c-dNle-rrrar-NH.sub.2
10 SEQ ID NO: 135 Ac-crrar-dNva-r-NH.sub.2 8 SEQ ID NO: 136
Ac-c-dNva-rrrar-NH.sub.2 7 SEQ ID NO: 137 Ac-crr-dNva-rar-NH.sub.2
3 SEQ ID NO: 138 Ac-crr-dNle-rar-NH.sub.2 3 *Bolded font indicates
respective substitution of alanine residues in Ac-carrrar-NH.sub.2
(SEQ ID NO: 26) or Ac-crrarar-NH.sub.2 (SEQ ID NO: 25). Sar = the
non-natural amino acid Sarcosine; Nma = N-methyl alanine; AiB =
amino isobutyric acid; dNva = D-Norvaline; dNle = D-Norleucine
**PTH reduction following 0.5 mg/kg IV administration in
isoflurane-anesthetized normal rats-PTH was measured at 1, 2, 3 and
4 hours post administration and cumulative AUC was calculated. PTH
data were calculated according to the following formula:
AUC.sub.cmpd treated/AUC.sub.saline control*100.
TABLE-US-00008 TABLE 8 Activity of Exemplary Peptide Compounds In
vivo activity in normal rats** 0.5 mg/kg IV bolus % PTH AUC SEQ ID
NO. Compound Structure* of saline control Saline Saline 100 SEQ ID
NO: 97 Ac-c(C)arrrar-NH.sub.2 8 SEQ ID NO: 101
Ac-c(GS)rrrrrr-NH.sub.2 12 SEQ ID NO: 139 Ac-c(dHcy)arrrar-NH.sub.2
32 SEQ ID NO: 140 Ac-c(Mpa)arrrar-NH.sub.2 25 SEQ ID NO: 141
Ac-c(Ac--C)arrrar-NH.sub.2 38 SEQ ID NO: 142 Ac-c(c)arrrar-NH.sub.2
0 SEQ ID NO: 143*** Ac-c(C-PEG20)rrrrrr-NH.sub.2 25 SEQ ID NO:
144**** Ac-c(C-PEG40)rrrrrr-NH.sub.2 15 SEQ ID NO: 145 ##STR00005##
40 SEQ ID NO: 145 SEQ ID NO: 26 ##STR00006## 42 SEQ ID NO: 25 SEQ
ID NO: 25 ##STR00007## 2 SEQ ID NO: 26 SEQ ID NO: 26 ##STR00008## 1
*Bolded font showing in parenthesis indicates respective
thiol-containing conjugating groups. GS = oxidized glutathione;
dHcy = D-homocysteine; Mpa = Mercaptopropionic acid; PEG =
polyethylene glycol. **PTH reduction following 0.5 mg/kg IV
administration in isoflurane-anesthetized normal rats - PTH was
measured at 1, 2, 3 and 4 hours post administration and cumulative
AUC was calculated. PTH data were calculated according to the
following formula: AUC.sub.cmpd treated/AUC.sub.saline control*100.
***Compound was dosed at 10 mg/kg (~ equivalent molarity to a 0.5
mg/kg non-PEGylated peptide) ****Compound was dosed at 20 mg/kg (~
equivalent molarity to a 0.5 mg/kg non-PEGylated peptide)
B. Histamine Response and Structure-Activity Relationship
Studies
[0112] Poly-cationic compounds have been reported in the literature
to trigger the release of the active biogenic amine histamine. See
Church et al., J. Immunol., 128(5):2116-2121 (1982); Lagunoff et
al., Ann. Rev. Pharmacol. Toxicol., 23:331-51 (1983). It is thought
that histamine release is a result of mast cell and basophil
activation occurring in a Gai dependent manner. See Aridor et al.,
J. Cell Biol., 111(3):909-17 (1990). Reducing or eliminating this
physiological reaction is desirable, inter alia, for improving the
therapeutic margin of cationic peptide calcimimetics for the
treatment of SHPT.
[0113] Studies were conducted to evaluate the histamine release
induced upon in vivo administration of the compounds described
herein. In a first study, described in Example 6, dosing by IV
bolus or infusion into normal Sprague Dawley rats was used to
evaluate histamine release associated with various compounds. To
evaluate the effect of net positive charge on the histamine release
associated with a compound, peptides containing 4 to 7 cationic
(arginine) residues were generated and tested for their ability to
trigger histamine release in vivo, according to the procedure
described in Example 6. The tested peptides included (i)
Ac-crrrr-NH.sub.2 (SEQ ID NO:4), (ii) Ac-crrrrr-NH.sub.2 (SEQ ID
NO:5), (iii) Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) and (iv)
Ac-crrrrrrrr-NH.sub.2 (SEQ ID NO:41).
[0114] As shown in FIG. 3, when an equivalent number of moles of
each peptide was administered by IV bolus to normal rats, SEQ ID
NO:41 (8 arginine residues) displayed the largest induction of
histamine. Other compounds with fewer Arg residues, including SEQ
ID NO:6 (6 arginine residues), SEQ ID NO:5 (5 arginine residues),
and SEQ ID NO:4 (4 arginine residues), also produced a spike in
histamine level, but to a lesser extent compared to SEQ ID NO:41.
SEQ ID NO:6, SEQ ID NO:5 and SEQ ID NO:4 generated milder responses
in their histamine release activity (.about.2-3 fold above
baseline). SEQ ID NO:5 and SEQ ID NO:4 were, however, less potent
than SEQ ID NO:6 with respect to lowering plasma PTH.
[0115] Because the PTH-reducing activity of Ac-crrrrrr-NH.sub.2
(SEQ ID NO:6) was accompanied by lack of a histamine response,
additional evaluations were conducted based on Ac-crrrrrr-NH.sub.2
(SEQ ID NO:6) in order to evaluate whether it was possible to still
further decrease histamine response without sacrificing
PTH-lowering activity. As will be shown in the data below,
substitution of cationic (arginine) residues in Ac-crrrrrr-NH.sub.2
(SEQ ID NO:6) with non-cationic (alanine) residues was performed to
produce a series of analogs with an overall reduced net charge and
reduced charge density. Of these analogs, both Ac-cararrr-NH.sub.2
(SEQ ID NO:15) and Ac-carrrar-NH.sub.2 (SEQ ID NO:26) were
associated with lack of a histamine response when administered to
rats by IV bolus. Importantly, these two peptides retained their
potent calcimimetic properties and were able to reduced PTH
secretion in both normal rats and rats with renal dysfunction.
[0116] The compound Ac-crrrrrr-NH.sub.2 identified as SEQ ID NO:6
(2.1 .mu.mole/kg=2.3 mg/kg) triggered an observable histamine
response of about 2-3 fold over baseline compared to 6-9 fold with
SEQ ID NO:41 when dosed by IV bolus (given over less than 1 minute)
in normal rats. The histamine release triggered by
Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) peaked at 5 minutes after dosing
and returned to baseline levels 15 minutes later (FIG. 3). Further
reduction in the number of charged subunits to 5 and 4 arginine
residues per peptide (SEQ ID NO:5 and SEQ ID NO:4, respectively)
further reduced the histamine response as compared with the longer
oligo-arginine peptides; however, a 2-3 fold increase in histamine
over baseline was still observed 5 minutes after IV bolus dosing
(FIG. 3). These results suggest a relationship between the net
charge of the peptide and the associated release of histamine. It
is also noted that arginine-rich peptides with fewer than 7
arginines are quite limited in their ability to enter cells,
suggesting that cell penetration is not required to trigger
histamine release.
[0117] The histamine release associated with the PTH-lowering
compounds Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) and
Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) was evaluated in vivo. The
compound Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) has the following
structure:
##STR00009##
[0118] This conjugate structure is denoted herein as
Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:273 where the L-Cys residue
linked to the thiol-containing residue in the X.sub.1 subunit of
the compound (here, a D-Cys residue) via a Cys-Cys disulfide bond,
is placed in parenthesis in the formula. This notation is used
throughout to designate that the parenthetical moiety is linked to
a second thiol-containing group. Relative to Ac-crrrrrr-NH.sub.2
(SEQ ID NO:6) the compound Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO: 3)
has two cationic (arginine) residues substituted with uncharged
(alanine) residues at subunit positions X.sub.2 and X.sub.6. In
addition, the D-Cys residue in the X.sub.1 position is conjugated
to an L-Cys residue.
[0119] These two compounds were administered to
isoflurane-anesthetized rats (Sprague Dawley) at 3 mg/kg by
intravenous (IV) bolus (given over less than 1 minute). Blood was
drawn prior to dosing and a 5, 15 and 30 minutes after dosing.
Histamine concentration was measured, and the fold change in blood
histamine concentration relative to the pre-dose blood histamine
concentration is shown in FIG. 4. The compound Ac-crrrrrr-NH.sub.2
(SEQ ID NO:6, open bars) induced a histamine response, observed at
the data point 5 minutes post-dosing where a 7-fold increase in
histamine level was observed. The compound Ac-c(C)arrrar-NH.sub.2
(SEQ ID NO:3, cross hatched bars) induced no apparent histamine
response, as seen by the data points at 5, 10 and 15 minutes post
dosing where the histamine level was not increased relative to the
pre-dose (time zero) histamine level.
[0120] To further evaluate the relationship between compound
structure and histamine release, a series of compounds was prepared
and assessed for their ability to trigger induction of histamine in
an in vitro assay using rat peritoneal mast cells. In this assay,
compounds are incubated at 10 .mu.M for 15 minutes at 37.degree. C.
with cells isolated from peritoneal lavage of SD rats. Following
incubation, cell medium is collected and histamine is determined.
The data is shown in Table 9.
TABLE-US-00009 TABLE 9 In vitro Histamine Induction in Rat
Peritoneal Mast Cells of Exemplary Peptide Compounds *Histamine in
vitro Fold change of non-treated SEQ ID NO. Compound Sequence at 10
uM* Saline Saline 1.0 SEQ ID NO: 6 Ac-crrrrrr-NH.sub.2 11.5 SEQ ID
NO: 8 Ac-carrrrr-NH.sub.2 6.6 SEQ ID NO: 9 Ac-crarrrr-NH.sub.2 6.8
SEQ ID NO: 10 Ac-crrarrr-NH.sub.2 5.3 SEQ ID NO: 11
Ac-crrrarr-NH.sub.2 5.0 SEQ ID NO: 12 Ac-crrrrar-NH.sub.2 5.0 SEQ
ID NO: 13 Ac-crrrrra-NH.sub.2 4.1 SEQ ID NO: 15 Ac-cararrr-NH.sub.2
2.5 SEQ ID NO: 22 Ac-caarrrr-NH.sub.2 1.2 SEQ ID NO: 17
Ac-crraarr-NH.sub.2 1.3 SEQ ID NO: 146 Ac-crrrraa-NH.sub.2 1.9 SEQ
ID NO: 26 Ac-carrrar-NH.sub.2 1.4 SEQ ID NO: 3
Ac-c(C)arrrar-NH.sub.2 0.6 SEQ ID NO: 16 Ac-carrarr-NH.sub.2 1.4
SEQ ID NO: 19 Ac-carrrra-NH.sub.2 1.3 SEQ ID NO: 23
Ac-crarrar-NH.sub.2 1.5 SEQ ID NO: 18 Ac-crararr-NH.sub.2 1.4 SEQ
ID NO: 20 Ac-crarrra-NH.sub.2 1.1 SEQ ID NO: 25 Ac-crrarar-NH.sub.2
1.2 SEQ ID NO: 14 Ac-crrarra-NH.sub.2 1.6 SEQ ID NO: 130
Ac-c-dNle-rrr-dNle-r-NH.sub.2 9.2 SEQ ID NO: 132
Ac-c-dNva-rrr-dNva-r-NH.sub.2 4.1 SEQ ID NO: 28
Ac-c(C)rrarar-NH.sub.2 0.7 SEQ ID NO: 24 Ac-craarrr-NH.sub.2 1.0
SEQ ID NO: 21 Ac-crrraar-NH.sub.2 1.0 SEQ ID NO: 134
Ac-c-dNle-rrrar-NH.sub.2 2.2 SEQ ID NO: 129
Ac-carrr-dNle-r-NH.sub.2 2.6 SEQ ID NO: 136
Ac-c-dNva-rrrar-NH.sub.2 2.1 SEQ ID NO: 131
Ac-carrr-dNva-r-NH.sub.2 1.8 SEQ ID NO: 133
Ac-crrar-dNle-r-NH.sub.2 4.3 SEQ ID NO: 135
Ac-crrar-dNva-r-NH.sub.2 1.1 SEQ ID NO: 95 Ac-cGrrrar-NH.sub.2 1.5
SEQ ID NO: 99 Ac-cqrrrar-NH.sub.2 1.9 SEQ ID NO: 103
Ac-chrrrar-NH.sub.2 1.6 SEQ ID NO: 96 Ac-cirrrar-NH.sub.2 3.0 SEQ
ID NO: 98 Ac-clrrrar-NH.sub.2 2.2 SEQ ID NO: 97 Ac-cprrrar-NH.sub.2
0.8 SEQ ID NO: 102 Ac-csrrrar-NH.sub.2 0.9 SEQ ID NO: 100
Ac-ctrrrar-NH.sub.2 1.1 SEQ ID NO: 101 Ac-cvrrrar-NH.sub.2 1.5 SEQ
ID NO: 93 Ac-carrrGr-NH.sub.2 0.9 SEQ ID NO: 90 Ac-carrrqr-NH.sub.2
0.9 SEQ ID NO: 89 Ac-carrrhr-NH.sub.2 2.0 SEQ ID NO: 84
Ac-carrrir-NH.sub.2 1.8 SEQ ID NO: 85 Ac-carrrlr-NH.sub.2 2.5 SEQ
ID NO: 88 Ac-carrrpr-NH.sub.2 1.0 SEQ ID NO: 92 Ac-carrrsr-NH.sub.2
1.2 SEQ ID NO: 91 Ac-carrrtr-NH.sub.2 1.7 SEQ ID NO: 87
Ac-carrrvr-NH.sub.2 1.2 SEQ ID NO: 147 Ac-cakkkak-NH.sub.2 1.1 SEQ
ID NO: 72 Ac-cakrrar-NH.sub.2 1.1 SEQ ID NO: 73 Ac-carkrar-NH.sub.2
1.4 SEQ ID NO: 105 Ac-crrGrar-NH.sub.2 1.8 SEQ ID NO: 112
Ac-crrqrar-NH.sub.2 1.2 SEQ ID NO: 109 Ac-crrhrar-NH.sub.2 2.3 SEQ
ID NO: 115 Ac-crrirar-NH.sub.2 3.4 SEQ ID NO: 114
Ac-crrlrar-NH.sub.2 4.5 SEQ ID NO: 106 Ac-crrprar-NH.sub.2 1.1 SEQ
ID NO: 111 Ac-crrsrar-NH.sub.2 2.0 SEQ ID NO: 108
Ac-crrtrar-NH.sub.2 1.2 SEQ ID NO: 113 Ac-crrvrar-NH.sub.2 1.9 SEQ
ID NO: 104 Ac-cfrrrar-NH.sub.2 6.8 SEQ ID NO: 83
Ac-carrrfr-NH.sub.2 4.0 SEQ ID NO: 68 Ac-carrrer-NH.sub.2 1.3 SEQ
ID NO: 110 Ac-crrfrar-NH.sub.2 6.2 SEQ ID NO: 107
Ac-crrerar-NH.sub.2 0.6 SEQ ID NO: 86 Ac-carrkar-NH.sub.2 1.0 SEQ
ID NO: 70 Ac-carrrak-NH.sub.2 0.9 SEQ ID NO: 148
Ac-cararar-NH.sub.2 0.6 SEQ ID NO: 25 ##STR00010## 9.3 SEQ ID NO:
149 Ac-crrarGr-NH.sub.2 1.6 SEQ ID NO: 150 Ac-crrarqr-NH.sub.2 1.6
SEQ ID NO: 151 Ac-crrarhr-NH.sub.2 2.5 SEQ ID NO: 152
Ac-crrarir-NH.sub.2 4.1 SEQ ID NO: 153 Ac-ca(DAP)rrar-NH.sub.2 1.6
SEQ ID NO: 154 Ac-ca(dHar)(dHar)(dHar)ar-NH.sub.2 2.7 *Method set
forth in Example 7 Abbreviations: See Example 7
[0121] To further evaluate the relationship between compound
structure and histamine release, a series of compounds was prepared
assessed for their ability to trigger induction of histamine in an
in vivo assays. The data is shown in Table 10.
TABLE-US-00010 TABLE 10 In vivo Histamine Induction of Exemplary
Peptide Compounds * Histamine response in vivo Fold change from
pre-dose levels Compound 5' post injection SEQ ID NO. Structure 2
mg/kg IV bolus Saline Saline 1.0 SEQ ID NO: 6 Ac-crrrrrr-NH.sub.2
2.7 SEQ ID NO: 26 Ac-carrrar-NH.sub.2 1.0 SEQ ID NO: 25
Ac-crrarar-NH.sub.2 0.9 SEQ ID NO: 15 Ac-cararrr-NH.sub.2 1.0 SEQ
ID NO: 18 Ac-crararr-NH.sub.2 1.1 SEQ ID NO: 20 Ac-crarrra-NH.sub.2
1.0 SEQ ID NO: 19 Ac-carrrra-NH.sub.2 0.9 SEQ ID NO: 23
Ac-crarrar-NH.sub.2 0.8 SEQ ID NO: 18 Ac-crararr-NH.sub.2 1.0 SEQ
ID NO: 27 Ac-c(C)arrrar-NH.sub.2 0.9 SEQ ID NO: 28
Ac-c(C)rrarar-NH.sub.2 0.9 *Method set forth in Example 7.
[0122] Accordingly, and as can be appreciated in view of the PTH
data and the histamine data described hereinabove, in one
embodiment, a compound that has activity to decrease PTH level in a
subject in the absence of a histamine response is contemplated. In
certain embodiments, absence of a histamine response intends a dose
of the compound that produces a less than 10-fold, more preferably
8-fold, still more preferably 5-fold, and even still more
preferably 3-fold, increase in histamine, measured in vitro in an
assay as described herein, where the fold change is determined
based on histamine levels before incubation with the compound and
after 15 minutes incubation with compound. In a specific
embodiment, the histamine response is determined in an in vitro
assay using rat peritoneal mast cells isolated from peritoneal
lavage of normal Sprague Dawley rats, and where the fold change is
determined based on histamine levels before incubation with the
compound and after 15 minutes incubation with compound. In the
studies conducted herein, the in vitro evaluation of histamine
release was performed using isolated rat peritoneal mast cells
isolated by peritoneal lavage using cold HBSS+25 mM HEPES pH 7.4
containing heparin (5 u/mL). Cells were washed twice in stimulation
buffer (HBSS+25 mM HEPES pH 7.4) and incubated with 10 .mu.M of
compound in stimulation buffer (HBSS+25 mM HEPES pH 7.4) for 15
minutes in a 96-well plate (106/well) at 37.degree. C. Cell
supernatant was analyzed for histamine using histamine EIA kit
(Cayman #589651).
[0123] In another embodiment, a compound that has activity to
decrease PTH level in a subject in the absence of an clinical
histamine response is contemplated. As used herein, absence of a
"clinical histamine response" intends is that a therapeutically
effective amount of a compound as described herein is administered
to the subject without producing a clinically adverse increase in
plasma or blood histamine as measured 5-10 minutes after completion
of dosing or over the course of treatment. For example, when a
compound required to produce a desired therapeutic effect is
administered to a subject by bolus (as used herein "bolus" means
administered over one minute or less) produced an increase in
plasma or blood histamine 5-10 minutes after completion of dosing
that is less than 15-fold, 10-fold, 9-fold, 8-fold, 7-fold, 6-fold,
5-fold, 4-fold, 3-fold, 2-fold above pre-dose levels.
[0124] As can be appreciated from the studies described above, in
one embodiment, the compound comprises a sequence of 3 to 35 amino
acid residues, wherein a plurality of positively charged amino acid
residue subunits is present in the sequence. In some embodiments,
the described compounds comprise 5 to 25 subunits, and in a
preferred embodiment each subunit is an amino acid residue. In
other embodiments, the described compounds comprise 6 to 12
subunits. In still other embodiments, the described compounds
comprise 3 to 9 amino acid subunits. In alternative embodiments the
described compounds comprise 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
31, 32, 33, 34, or 35 subunits.
[0125] The subunits of the described compounds are, in one
embodiment, independently selected from natural or unnatural amino
acids, or their analogs, and may have either the L- or
D-configuration (except for glycine which is achiral). Glycine, the
aliphatic residues alanine, valine, leucine, or isoleucine,
proline, the hydroxyl residues serine and threonine, the acidic
residues aspartic acid and glutamic acid, the amide residues
asparagine, and glutamine, the basic residues lysine and arginine,
histidine, the aromatic residues phenylalanine, tyrosine, and
tryptophan, and the sulfur-containing residues methionine and
cysteine are all contemplated for use in the described compounds.
The number of positively charged subunits, and their density can
affect the potency of the compound for reducing PTH. In some
embodiments, positively charged subunits are separated by one or
more other subunits ("separating subunits"). In one embodiment, the
separating subunits are alanine residues. In some embodiments, the
chirality of the separating subunit affects the potency of the
compound.
[0126] Positively charged amino acid residues of the described
compounds may be a specific natural or unnatural residue, or analog
thereof, having either the L- or D-configuration (e.g., L-arginine)
that is repeated in the sequence, or may be a variety of natural or
unnatural residues, or analogs thereof, having either the L- or
D-configuration. In some embodiments, the compound is a peptide
comprised of from 3 to 20 positively charged amino acid residues, 6
to 12 positively charged amino acid residues, 3 to 9 positively
charged amino acid residues. In some embodiments, the peptides
comprise 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, or 20 positively charged amino acid residues.
[0127] In some embodiments, the positively charged amino acid
residues are independently selected from natural amino acids. In
some embodiments, the positively charged amino acid residues are
independently selected from natural and/or unnatural amino acids.
In some embodiments, the positively charged amino acid residues are
independently selected from the group consisting of arginine,
lysine, histidine, 2,3-diaminopropionic acid (Dap),
2,4-diaminobutyric acid (Dab), ornithine, and homoarginine. In a
preferred embodiment, the positively charged amino acid residues
are arginine residues.
[0128] In some embodiments, the compound is a peptide and is a
single continuous peptide chain or strand. In other embodiments,
the compound is a peptide that is branched. In still other
embodiments, the peptide is conjugated to one or more
thiol-containing moieties (each, a "thiol-containing conjugating
group" or a "conjugating group"). In a preferred embodiment, and as
merely illustrative, the peptide compound is conjugated to a Cys
conjugating group, via a (--S--S--) disulfide bond (for example
-Cys-Cys-). As used herein, the term "compound" is intended to
encompass both such peptides and such conjugates.
[0129] The compounds typically comprise one or more thiol moieties,
preferably one or more reactive thiol moieties. Subunits that have
a thiol group include non-amino acid compounds having a thiol group
and amino acids with a thiol group. The thiol group of the
thiol-containing subunit may be in a conjugated form (e.g., via a
disulfide bond to a conjugating group) or in an unconjugated form
(i.e., as a reduced thiol). In a preferred embodiment, when the
thiol group is in either an unconjugated form or a conjugated form,
it is capable of forming a disulfide bond with a thiol-containing
group. The thiol-containing residue may be located at any position
along the peptide chain, including the amino terminus, the carboxy
terminus, or some other position. In a preferred embodiment, the
thiol-containing residue or subunit may be located at the amino
terminus. In other embodiments, the thiol-containing residue or
subunit may be located at the carboxy terminus or within the
peptide sequence.
[0130] Some representative examples of thiol-containing residues
include, without limitation, cysteine, mercaptopropionic acid,
homo-cysteine, and penicillamine. When the thiol-containing residue
contains a chiral center, it may be present in the L- or
D-configuration. In a preferred embodiment, the thiol-containing
residue is cysteine.
[0131] In some embodiments, the cross-linkage between the thiol
containing subunit at the X.sub.1 position in the compound and the
thiol-containing conjugating group may be cleavable and/or
exchangeable with other thiol-containing conjugating groups such as
cysteine (e.g., by reduction of the disulfide linkage) in vivo to
yield a biologically active form of the compound. In this way, the
conjugate may function as a pro-drug of the compound. A conjugating
group also may be used to modify the physicochemical,
pharmacokinetic and/or pharmacodynamic properties of the described
compounds (e.g., conjugation via a disulfide linkage to a large
PEGylated moiety to enhance the pharmacokinetics).
[0132] In some embodiments, the compound is a peptide comprised of
the amino acid sequence
(X.sub.aa1)-(X.sub.aa2)-(X.sub.aa3)-(X.sub.aa4)-(X.sub.aa5)-(X.sub.aa6)-(-
X.sub.aa7) (SEQ ID NO:155), wherein (X.sub.aa1) is a
thiol-containing amino acid residue, (X.sub.aa2) is a non-cationic
amino acid residue, (X.sub.aa3) is any amino acid residue,
(X.sub.aa4) is any amino acid residue, (X.sub.aa5) is a cationic
amino acid residue, (X.sub.aa6) is a non-cationic residue, and
(X.sub.aa7) is any amino acid residue. The peptide may be modified
at the N-terminus, the C-terminus, or both. In a preferred
embodiment, the peptide is modified at both the N-terminus and
C-terminus by acetylation and amidation, respectively.
[0133] In some embodiments, a peptide comprises the amino acid
sequence
(D-Cys)-(X.sub.aa2)-(X.sub.aa3)-(X.sub.aa4)-(X.sub.aa5)-(X.sub.aa6)-(X.su-
b.aa7) (SEQ ID NO:156), wherein (X.sub.aa2) is a non-cationic amino
acid residue, (X.sub.aa3) is any amino acid residue, (X.sub.aa4) is
any amino acid residue, (X.sub.aa5) is selected from the group
consisting of D-Arg, L-Arg, D-Lys and L-Lys, (X.sub.aa6) is a
non-cationic residue, and (X.sub.aa7) is any amino acid residue.
The peptide may have an N-terminal cap, a C-terminal cap, or both.
In a preferred embodiment, the peptide has both an N-terminal cap
and a C-terminal cap.
[0134] In some embodiments, a peptide comprises the amino acid
sequence
(D-Cys)-(X.sub.aa2)-(X.sub.aa3)-(X.sub.aa4)-(X.sub.aa5)-(X.sub.aa6)-(X.su-
b.aa7) (SEQ ID NO:157), wherein (X.sub.aa2), (X.sub.aa3) and
(X.sub.aa4) are, independently, any amino acid residue (but in a
preferred embodiment are, independently, selected from the group
consisting of D-Ala, D-Val, D-Leu, D-NorVal, and D-NorLeu),
(X.sub.aa5) and (X.sub.aa7) are, independently, any cationic amino
acid residue (but in a preferred embodiment are, independently,
selected from the group consisting of D-Arg, L-Arg, D-Lys and
L-Lys), (X.sub.aa6) is a non-cationic amino acid residue (in a
preferred embodiment, selected from the group consisting of D-Ala,
D-Val, D-Leu, D-NorVal and D-NorLeu). The peptide may have an
N-terminal cap, a C-terminal cap, or both. In a preferred
embodiment, the peptide has both an N-terminal cap and a C-terminal
cap.
[0135] In some embodiments, a peptide comprises the amino acid
sequence
(D-Cys)-(X.sub.aa2)-(X.sub.aa3)-(X.sub.aa4)-(X.sub.aa5)-(X.sub.aa6)-(X.su-
b.aa7) (SEQ ID NO:158), wherein (X.sub.aa2) is a non-cationic amino
acid residue, (X.sub.aa3) is any amino acid residue, (X.sub.aa4) is
any amino acid residue, (X.sub.aa5) is selected from the group
consisting of D-Arg, L-Arg, D-Lys and L-Lys, (X.sub.aa6) is a
non-cationic residue, and (X.sub.aa7) is any amino acid residue.
The peptide may have an N-terminal cap, a C-terminal cap, or both.
In a preferred embodiment, the peptide has both an N-terminal cap
and a C-terminal cap.
[0136] In some embodiments, a peptide comprises the amino acid
sequence
(D-Cys)-(D-Ala)-(X.sub.aa3)-(X.sub.aa4)-(D-Arg)-(D-Ala)-(X.sub.aa7)
(SEQ ID NO:159), wherein (X.sub.aa3) is any cationic amino acid
residue, (X.sub.aa4) is any cationic amino acid residue, and
(X.sub.aa7) is any cationic amino acid residue. The peptide may
have an N-terminal cap, a C-terminal cap, or both. In a preferred
embodiment, the peptide has both an N-terminal cap and a C-terminal
cap.
[0137] In some embodiments, a peptide comprises the amino acid
sequence
(D-Cys)-(X.sub.aa2)-(X.sub.aa3)-(D-Ala)-(D-Arg)-(D-Ala)-(X.sub.aa7)
(SEQ ID NO:160), wherein (X.sub.aa2), (X.sub.aa3) and (X.sub.aa7)
are, independently, any cationic amino acid residue. The peptide
may have an N-terminal cap, a C-terminal cap, or both. In a
preferred embodiment, the peptide has both an N-terminal cap and a
C-terminal cap.
[0138] Another embodiment is a calcimimetic peptide, comprising a
sequence of amino acids linked by peptide bonds, wherein the
sequence comprises 5 to 10 amino acid residues, and wherein the
sequence comprises an amino terminus, a carboxy terminus, at least
one thiol-containing residue, and from 3 to 9 positively charged
residues. In one embodiment, the at least one thiol-containing
residue is a cysteine residue. In another aspect, the cysteine
residue is positioned at the amino terminus of the peptide. In
certain embodiment, the cysteine residue is an L-Cys residue, a
D-Cys residue, or an L- or D-homoCys residue. In other embodiments,
the amino acid residues of the peptide are D-amino acids or L-amino
acids.
[0139] Also encompassed within the scope of the claimed compounds
are peptidomimetic molecules that comprise approximately seven
subunits, wherein at least one subunit contains a thiol moiety,
preferably a reactive thiol moiety, and other subunits are a
plurality of non-cationic subunits, and from 1 to 4 positively
charged subunits. Such peptidomimetic molecules may comprise
non-peptide bonds between two or more of the subunits. The various
features of the compounds discussed above apply generally to the
peptidomimetic molecule. For example, as discussed above, the
subunits used to construct the molecules can be naturally-occurring
amino acids, or residues with non-natural side chains, the termini
of the modules can be capped or non-capped in the manner discussed
above. Similarly, the amino acid residues of the molecule can be L-
or D-amino acid residues. Also as discussed above, the
thiol-containing residues can be in a reduced or oxidized form with
any of the thiol-containing moieties discussed above.
[0140] Many peptidomimetic frameworks and methods for their
synthesis have been developed (Babine, R. E.; Bender, S. L., Chem.
Rev., 97:1359, 1997; Hanessian, S.; et al., Tetrahedron, 53:12789,
1997; Fletcher, M. D.; Cambell, M. C., Chem. Rev., 98:763, 1998);
Peptidomimetics Protocols; Kazmierski W. M., Ed.; Methods in
Molecular Medicine Series, Vol. 23; Humana Press, Inc.; Totowa,
N.J. (1999).
Conjugates
[0141] In some embodiments, the compound is chemically cross-linked
to a thiol-containing conjugating group via a disulfide bond
between the thiol of the compound and a thiol from the conjugating
group. The thiol-containing conjugating group can be a small
molecule, such as cysteine, or a macromolecule, such as a
polypeptide containing a cysteine residue. Examples of suitable
thiol-containing conjugating groups include cysteine, glutathione,
thioalkyl, moieties such as thiobenzyl, mercaptopropionic acid,
N-acetylated cysteine, cysteamide, N-acetylcysteamide,
homocysteine, penicillamine and poly (ethylene glycol) (PEG)
modified (referred to as "PEGylated") thiols such as PEGylated
cysteine or a duplication of the compound (i.e., to form a
homodimer linked by a disulfide linkage). In a preferred
embodiment, the thiol-containing conjugating group is cysteine.
Other cysteine homologs are also contemplated for use as
thiol-containing conjugating groups, either alone or comprised in a
larger conjugating group. Similarly, stereoisomers of cysteine,
homocysteine, and cysteamide are suitable for use as
thiol-containing moieties. Conjugating groups can be used to
improve chemical stability and therefore shelf-life of a
pharmaceutical product. In certain embodiments the thiol-containing
conjugating group and the peptide are the same (i.e., the conjugate
is a dimer), which unexpectedly showed very good chemical stability
compared to heterologous conjugating group such as cysteine.
Without being bound by theory, presumably when the thiol-containing
conjugating group and the peptide are the same, then any
disproportionation (e.g., scrambling of the conjugating group) will
reconstitute the original dimer compound. In contrast,
disproportionation of a compound with a heterologous conjugating
group such as cysteine can lead to formation of homo-dimers of the
peptide plus cystine (cysteine-cysteine homodimer) plus residual
parent compound. A homo-dimer of the peptide (i.e., conjugating
group and the peptide are the same) would be converted to a
cysteine conjugated form of the peptide in vivo due to the high
concentration of reduced cysteine in systemic circulation.
[0142] In some embodiments, the teachings include a disulfide
conjugate of a thiol-containing conjugating group and a peptide
comprising the amino acid sequence
(X.sub.aa1)-(X.sub.aa2)-(X.sub.aa3)-(X.sub.aa4)-(X.sub.aa5)-(X.sub.aa6)-(-
X.sub.aa7) (SEQ ID NO:155), wherein (X.sub.aa1) is an amino acid
residue with a thiol-containing moiety, (X.sub.aa2) is a
non-cationic amino acid residue, (X.sub.aa3) is any amino acid
residue, (X.sub.aa4) is any amino acid residue, (X.sub.aa5) is a
cationic amino acid residue, (X.sub.aa6) is a non-cationic residue,
and (X.sub.aa7) is any amino acid residue. The peptide may have an
N-terminal cap, a C-terminal cap, or both. In a preferred
embodiment, the peptide has both an N-terminal cap and a C-terminal
cap. In a preferred embodiment, the thiol-containing conjugating
group is selected from the group consisting of D-Cys, L-Cys, a
peptide containing D-Cys, and a peptide containing L-Cys. When the
thiol-containing conjugate group is an amino acid or a peptide, it
may have an N-terminal cap, a C-terminal cap, or both. In a
preferred embodiment, the thiol-containing conjugate group has both
an N-terminal cap and a C-terminal cap. In some embodiments, the
thiol-containing conjugating group is itself a peptide comprising
the amino acid sequence of SEQ ID NO:155. In some embodiments, the
thiol-containing conjugating group and the peptide are the same
(i.e., the conjugate is a dimer).
[0143] In some embodiments, the teachings include a conjugate of a
thiol-containing conjugating group and a peptide comprising the
amino acid sequence
(D-Cys)-(X.sub.aa2)-(X.sub.aa3)-(X.sub.aa4)-(X.sub.aa5)-(X.sub.aa6)-(X.su-
b.aa7) (SEQ ID NO:156), wherein (X.sub.aa2) is a non-cationic amino
acid residue, (X.sub.aa3) is any amino acid residue, (X.sub.aa4) is
any amino acid residue, (X.sub.aa5) is selected from the group
consisting of D-Arg, L-Arg, D-Lys and L-Lys, (X.sub.aa6) is a
non-cationic residue, and (X.sub.aa7) is any amino acid residue.
The peptide may have an N-terminal cap, a C-terminal cap, or both.
In a preferred embodiment, the peptide has both an N-terminal cap
and a C-terminal cap. In a preferred embodiment, the
thiol-containing conjugating group is selected from the group
consisting of D-Cys, L-Cys, a peptide containing D-Cys, and a
peptide containing L-Cys. When the thiol-containing conjugate group
is an amino acid or a peptide, it may have an N-terminal cap, a
C-terminal cap, or both. In a preferred embodiment, the
thiol-containing conjugate group has both an N-terminal cap and a
C-terminal cap. In some embodiments, the thiol-containing
conjugating group is itself a peptide comprising the amino acid
sequence of SEQ ID NO:156. In some embodiments, the
thiol-containing conjugating group and the peptide are the same
(i.e., the conjugate is a dimer).
[0144] In some embodiments, the teachings include a conjugate of a
thiol-containing conjugating group and a peptide comprising the
amino acid sequence
(L-Cys)-(X.sub.aa2)-(X.sub.aa3)-(X.sub.aa4)-(X.sub.aa5)-(X.sub.aa6)-(X.su-
b.aa7) (SEQ ID NO:183), wherein (X.sub.aa2) is a non-cationic amino
acid residue, (X.sub.aa3) is any amino acid residue, (X.sub.aa4) is
any amino acid residue, (X.sub.aa5) is selected from the group
consisting of D-Arg, L-Arg, D-Lys and L-Lys, (X.sub.aa6) is a
non-cationic residue, and (X.sub.aa7) is any amino acid residue.
The peptide may have an N-terminal cap, a C-terminal cap, or both.
In a preferred embodiment, the peptide has both an N-terminal cap
and a C-terminal cap. In a preferred embodiment, the
thiol-containing conjugating group is selected from the group
consisting of D-Cys, L-Cys, a peptide containing D-Cys, and a
peptide containing L-Cys. When the thiol-containing conjugate group
is an amino acid or a peptide, it may have an N-terminal cap, a
C-terminal cap, or both. In a preferred embodiment, the
thiol-containing conjugate group has both an N-terminal cap and a
C-terminal cap. In some embodiments, the thiol-containing
conjugating group is itself a peptide comprising the amino acid
sequence of SEQ ID NO:183. In some embodiments, the
thiol-containing conjugating group and the peptide are the same
(i.e., the conjugate is a dimer).
[0145] In some embodiments, the teachings include a conjugate of a
thiol-containing conjugating group and a peptide comprising the
amino acid sequence
(D-Cys)-(D-Ala)-(X.sub.aa3)-(X.sub.aa4)-(D-Arg)-(D-Ala)-(X.sub.aa7)
(SEQ ID NO:161), wherein (X.sub.aa3) is any amino acid residue,
(X.sub.aa4) is any amino acid residue, and (X.sub.aa7) is any amino
acid residue. The peptide may have an N-terminal cap, a C-terminal
cap, or both. In a preferred embodiment, the peptide has both an
N-terminal cap and a C-terminal cap. In a preferred embodiment, the
thiol-containing conjugating group is selected from the group
consisting of D-Cys, L-Cys, a peptide containing D-Cys, and a
peptide containing L-Cys. When the thiol-containing conjugate group
is an amino acid or a peptide, it may have an N-terminal cap, a
C-terminal cap, or both. In a preferred embodiment, the
thiol-containing conjugate group has both an N-terminal cap and a
C-terminal cap. In some embodiments, the thiol-containing
conjugating group is itself a peptide comprising the amino acid
sequence of SEQ ID NO:161. In some embodiments, the
thiol-containing conjugating group and the peptide are the same
(i.e., the conjugate is a dimer).
III. Methods of Use
[0146] In one aspect, methods to prevent, treat or ameliorate
hyperparathyroidism, bone disease and/or other hypercalcemic
disorders by administering the compounds described herein are
contemplated. As illustrated above, the compounds have activity to
decrease PTH and/or calcium levels in a target tissue or tissues,
or in a subject. In certain embodiments, the described compounds
are capable of decreasing PTH and/or calcium levels when a
therapeutically effective amount of the compound is administered to
a subject in need of such treatment. The methods of use will now be
described with reference to Examples 3 and 8-11.
[0147] With reference again to Example 3, and as discussed above
with respect to Table 1, the series of compounds where a cationic
(arginine) residue was sequentially replaced with a non-cationic
residue (alanine) were administered to rats. FIG. 5 shows the time
profile of each compound's ability to reduce blood PTH and the
duration of action of the varying compounds. In FIG. 5, the
compounds Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6, diamonds),
Ac-carrrrr-NH.sub.2 (SEQ ID NO:8, squares) and Ac-crrarrr-NH.sub.2
(SEQ ID NO:10, x symbols) and Ac-crrrrar-NH.sub.2 (SEQ ID NO:12,
circles) were potent in vivo, as evidenced by the decrease in
percent PTH of predose baseline to essentially zero and provided a
duration of potency, where the PTH blood concentration remained
decreased for at least four hours. The compounds
Ac-crarrrr-NH.sub.2 (SEQ ID NO:9, triangles), Ac-crrrarr-NH.sub.2
(SEQ ID NO:11, * symbols) and Ac-crrrrra-NH.sub.2 (SEQ ID NO:13, +
symbols) decreased percent PTH of baseline for about 2-3 hours, and
thereafter the blood concentration of PTH began to increase.
Substitution of the cationic (arginine) residue at subunit
positions 5 or 7 of Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) impacted the
duration of PTH lowering activity.
[0148] The profile of PTH reduction for a series of compounds
containing double amino acid substitutions was also evaluated.
Selected compounds set forth in Table 2, above, were administered
to normal rats by IV bolus at a dose of 0.5 mg/kg and the reduction
in PTH relative to predose PTH blood level was evaluated. Data are
shown in FIGS. 6A-6B, where the compound are identified as follows:
Ac-carrrar-NH.sub.2 (SEQ ID NO:26, open diamonds),
Ac-crrarar-NH.sub.2 (SEQ ID NO:25, open squares),
Ac-caarrrr-NH.sub.2 (SEQ ID NO:22, triangles), Ac-crraarr-NH.sub.2
(SEQ ID NO:17, circles), Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3,
diamonds FIG. 6B), Ac-c(C)rrarar-NH.sub.2 (SEQ ID NO:28, x symbols,
FIG. 6B).
[0149] Another study was done to further evaluate the potency of
the compound Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO: 3). The compound
was intravenously administered to normal rats, as detailed in
Example 2, at doses of 1 mg/kg, 0.5 mg/kg, 0.3 mg/kg, and 0.1
mg/kg. Plasma PTH levels were assessed prior to dosing and for 4
hours thereafter. FIG. 7 shows the results, where the PTH blood
concentration is shown as percent of the baseline pre-dose value. A
dose-related PTH reduction was observed following a single IV bolus
administration with the highest dose of 1 mg/kg (diamonds) had the
largest reduction in PTH, followed by the 0.5 mg/kg (squares), 0.3
mg/kg (triangles), and 0.1 mg/kg (x symbols). The saline control is
shown by the circles symbols. As seen, the peptide when
administered at a therapeutically effective dose achieves a
reduction in PTH of greater than 50% relative to the concentration
of PTH before dosing ("baseline"). Specifically, the peptide when
administered at doses of greater than 0.1 mg/kg reduced PTH
concentration to less than 90% of the baseline PTH concentration 1
hour after IV administration. These doses of the peptide identified
as SEQ ID NO:3 also achieved an area under the curve (AUC) of less
than 50%, the AUC calculated as the sum of the PTH concentration
values at the time points of 1, 2, 3 and 4 hours, normalized by the
AUC for the saline control at the same time points, multiplied by
100.
[0150] The same compound was also tested in subjects (rats) with
renal insufficiency. In this study, the 1K1C model of acute renal
insufficiency was used to evaluate a the compound
Ac-c(C)arrrar-NH.sub.2(SEQ ID NO: 3) to characterize its
PTH-lowering activity in a renal dysfunction environment. The model
is described in Example 1A. The compound was intravenously
administered as a bolus to renally compromised animals (rats) at
doses of 3 mg/kg (n=2), 1 mg/kg (n=5), 0.5 mg/kg (n=6) and 0.3
mg/kg (n=5). A control group of animals was dosed with saline.
Plasma PTH levels were assessed prior to dosing and for several
hours thereafter. FIG. 8 shows the results, where the saline
treated animals (squares) had an increased PTH concentration
relative to the starting PTH level. At various doses of SEQ ID
NO:3, a dose-dependent effect was observed on the duration and
extent of PTH reduction. Animals treated with the lowest dose of
0.3 mg/kg (x symbols) exhibiting reduced PTH at the earliest time
point and an increase in PTH between hours 1-24 after dosing. The
dose levels of 3 mg/kg (diamonds), 1 mg/kg (triangles) and 0.5
mg/kg (squares) provided a reduced PTH blood concentration for more
than 15 hours, and for the highest dose, for more than 24
hours.
[0151] In another study to evaluate the effect of substituting
cationic subunits with uncharged subunits, as exemplified by
alanine amino acid residues, in the context of a subject with renal
insufficiency, an analog of Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) was
generated and tested for its ability to lower PTH in 1K1C model
animals following a 1 mg/kg single intravenous administration. In
the tested analog Ac-carrrar-NH.sub.2 (SEQ ID NO:26), the cationic
subunits at positions X.sub.2 and X.sub.6 of Ac-crrrrrr-NH.sub.2
(SEQ ID NO:6) were substituted with uncharged amino acids.
[0152] As shown in FIG. 9, Ac-carrrar-NH.sub.2 (SEQ ID NO:26, open
squares) shows activity that is equivalent to Ac-crrrrrr-NH.sub.2
(SEQ ID NO:6, open diamonds) at the dose tested (1 mg/kg) with
similar extended duration of action over 24 hours. The analog of
Ac-crrrrrr-NH.sub.2(SEQ ID NO:6) with uncharged subunit
substitutions was found to retain activity and may, in fact, have
in vivo potency and duration of action superior to that of the
compound identified as SEQ ID NO:6. In the compound,
Ac-carrrar-NH.sub.2 (SEQ ID NO:26), D-Arg residues at positions
X.sub.2 and X.sub.6 were substituted with D-Ala residues relative
to the compound identified as SEQ ID NO:6.
[0153] Significantly, as discussed above, administration of the
compound Ac-carrrar-NH.sub.2 (SEQ ID NO:26) was not accompanied
with histamine release, an undesirable side-effect that is seen
with Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) and other similar compounds
when administered at higher doses (>1 mg/kg) by IV bolus. The
marked attenuation of the histamine release with the compound
identified SEQ ID NO:26 increases the therapeutic margin between
the desired PTH-lowering activity and the undesired
histamine-inducing activity following administration by IV bolus.
Accordingly, in a preferred embodiment, compounds having activity
to reduce PTH concentration in vivo in the absence of a histamine
response are provided. Accordingly, in one embodiment, a compound
is provided that has activity to decrease PTH where the compound
when administered and a subject, human or otherwise, decreases PTH
level to below 50% of the pre-dose level within one hour after
dosing. In a specific embodiment, a compound that has significant
activity to decrease PTH intends a compound that when administered
to a normal rate decreases PTH level to below 50% of the pre-dose
level within one hour after dosing by IV bolus.
[0154] In another study, detailed in Example 8, compounds in the
form of a conjugate, where the thiol-containing subunit in position
X.sub.1 was linked through a disulfide linkage to an L-Cys residue.
These compounds have the following structures:
##STR00011##
[0155] In the notation used herein, the compound that is linked to
the thiol-containing moiety in the X.sub.1 subunit is identified
parenthetically, where in these exemplary conjugates the compound
L-Cys is indicated (C) is linked to the thiol-containing moiety in
the X.sub.1 subunit: Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) and
Ac-c(Ac-C)arrrar-NH.sub.2 (SEQ ID NO:141). These compounds were
administered via IV bolus to animals with acute renal insufficiency
(1K1C model) at doses of 0.3 and 0.5 mg/kg, and the results are
shown in FIG. 10. The compound Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3)
is represented by squares (0.3 mg/kg, n=5) and * symbols (0.5
mg/kg, n=6) and the compound Ac-c(Ac-C)arrrar-NH.sub.2 (SEQ ID
NO:141) by triangles (0.3 mg/kg, n=8) and diamonds (0.5 mg/kg,
n=7). This in vivo dose response with SEQ ID NO:3 displays a
dose-dependent reduction in PTH very similar to Ac-crrrrrr-NH.sub.2
(SEQ ID NO:6).
[0156] In some of the in vivo studies described herein, the
compounds, including compounds in conjugate form where the thiol in
the X.sub.1 subunit is cross-linked via a disulfide bond to another
subunit, were administered as a 30-minute IV infusion. However, it
should be noted that shorter infusions (e.g., <5 minutes) or
delivery by IV bolus typically produce comparable pharmacodynamic
reduction of PTH as a longer 30-minute infusion. Subcutaneous bolus
administration also proved to be an efficacious route of delivery
that generated a smaller initial drop in PTH but displayed a
sustained reduction in PTH similar to the profile seen by the IV
route. As shown in FIG. 11, the compound Ac-crrrrrr-NH.sub.2 (SEQ
ID NO:6), was also administered by micropore-facilitated (e.g.,
microporation of the stratum corneum) transdermal delivery, and
demonstrated a reduction in plasma PTH for the several hours it was
monitored. The compound Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6), was also
administered by the transdermal route after microporation resulting
in a reduction in plasma PTH for several hours. Transdermal
delivery of Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) provides an addition
option for clinical delivery of the described compounds.
[0157] To evaluate the effect of administration route on the
activity of Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) in the context of a
subject with renal insufficiency, rats in the 1K1C model were given
1 mg/kg of the peptide as either a subcutaneous (SC) bolus or a
30-minute IV infusion. Both routes of administration effectively
reduced plasma PTH levels for over 24 hours. When
Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) was delivered by IV infusion, PTH
levels fell rapidly by 80-90% from baseline. By 16 hours after
dosing, PTH levels had started to rise although they were still
reduced by .about.80% from baseline. When Ac-crrrrrr-NH.sub.2 (SEQ
ID NO:6) was delivered by SC bolus, PTH levels exhibited a more
moderate initial drop to .about.40% of baseline, but exhibited a
similar duration of reduction as when the peptide was delivered by
the IV route. Twenty-four hours after dosing, PTH levels in animals
dosed by either route had partially rebounded although both still
displayed reduced PTH levels that were .about.40-60% from baseline.
The results showed that this route of administration provides a
similar profile with respect to efficacy and duration of PTH
reduction as IV administration, thus providing an alternative path
for clinical dosing (data not shown).
[0158] Accordingly, in a preferred embodiment, a subject having
secondary hyperparathyroidism (SHPT) is treated using the described
compounds to reduce plasma PTH levels and/or calcium. Untreated
SHPT patients with moderately severe hyperparathyroidism often have
baseline circulating intact PTH levels >300 .mu.g/ml, and levels
that can exceed 600 .mu.g/mL. In a preferred embodiment, the
decrease in PTH levels is measured as a decrease in intact PTH
below pretreatment baseline levels. In another embodiment the
desired decrease in PTH is to bring the plasma PTH levels into
generally recognized guidelines established by the National Kidney
Foundation or other experts in the treatment of kidney disorders
and renal insufficiency.
[0159] In another aspect, methods for treating hyperparathyroidism,
hypercalcemia and/or bone disease are provided, comprising
administering a therapeutically effective amount of a described
compound. In another embodiment, the subject can be treated with a
described compound in combination with one or more other
therapeutically effective agents.
[0160] In another aspect, the described compound is administered in
an amount effective to reduce PTH or PTH effect. In some
embodiments, the reduction in plasma PTH is at least 1%, 2%, 3%,
4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%,
18%, 19%, 20%, 25% or 30% below pretreatment baseline levels for at
least 10 hours post administration of the described compound. In
specific embodiments, the reduction in plasma PTH is at least 20%
at 10 hours post administration. In preferred embodiments, the
reduction in plasma PTH is 15 to 40%, preferably 20 to 50%, more
preferably 30 to 70% below pretreatment baseline levels for at
least 48 hours post administration of the described compound.
[0161] In another aspect, the described compound is administered in
an amount effective to decrease serum calcium or calcium effect. In
some embodiments, the reduction in serum calcium is at least 1%,
2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%,
17%, 18%, 19%, 20% or 25% below pretreatment levels for at least 10
hours post administration of the polycationic peptide. In some
preferred embodiments, the reduction in serum calcium is at least
5% at 10 hours post administration. In some preferred embodiments,
the reduction is serum calcium is 5 to 10%, preferably 5 to 20%
below pretreatment levels for at least 48 hours post administration
of the described compound.
[0162] In another aspect, a method for treating hyperparathyroidism
and/or hypercalcemia in a subject in need thereof is provided,
comprising: administering a therapeutically effective amount of a
described compound, whereby PTH and/or calcium is reduced.
[0163] Based on the relationship between serum calcium, bone
metabolism and PTH, it is thought that the described compounds are
beneficial for the treatment of various forms of bone disease
and/or hypercalcemia in addition to hyperparathyroidism. The
described compounds may have advantages compared to current
therapeutic agents, because they may be administered parenterally
and may not be associated with gastrointestinal adverse effects,
are not metabolized by cytochrome P450 and may result in more
effective reductions in plasma PTH and calcium.
[0164] As discussed above, the described methods may be used alone
or in combination with one or more other therapeutically effective
agents. Such other therapeutically effective agents include, but
are not limited to, treatment with antiresorptive bisphosphonate
agents, such as alendronate and risedronate; integrin blockers,
such as .alpha..sub.v.beta..sub.3 antagonists; conjugated estrogens
used in hormone replacement therapy, such as PREMPRO.TM.,
PREMARIN.TM. and ENDOMETRION.TM.; selective estrogen receptor
modulators (SERMs), such as raloxifene, droloxifene, CP-336,156
(Pfizer) and lasofoxifene; cathespin K inhibitors; vitamin D
therapy; vitamin D analogs, such as ZEMPLAR.TM. (paricalcitol);
CALCIJEX.RTM. (calcitriol), HECTOROL.RTM. (doxercalciferol),
ONE-ALPHA.RTM. (alfacalcidol) and the analogs in development from
Cytochroma known as CTA-018, CTAP201 and CTAP101, other
calcimimetics such as Sensipar.RTM. (cinacalcet); inhibitors of
type II sodium-dependent phosphate transporter family, SLC34
(including the two renal isoforms NaPi-IIa and NaPi-IIc, and the
intestinal NaPi-IIb transporter); phosphatonins (including FGF-23,
sFRP4, MEPE or FGF-7); low dose PTH treatment (with or without
estrogen); calcitonin; inhibitors of RANK ligand; antibodies
against RANK ligand, osteoprotegrin; adensosine antagonists; and
ATP proton pump inhibitors.
[0165] In one embodiment, a described compound is administered at a
dose sufficient to decrease both PTH and serum calcium levels. In
another embodiment, a described compound is administered at a dose
sufficient to decrease PTH without significantly affecting serum
calcium levels. In a further embodiment, a described compound is
administered at a dose sufficient to increase PTH without
significantly affecting serum calcium levels.
Formulations
[0166] A pharmaceutical composition comprising a described compound
and at least one pharmaceutically acceptable excipient or carrier
is provided. Methods of preparing such pharmaceutical compositions
typically comprise the step of bringing into association a
described compound with a carrier and, optionally, one or more
accessory ingredients. The described compounds and/or
pharmaceutical compositions comprising same may be formulated into
pharmaceutically-acceptable dosage forms by conventional methods
known to those of skill in the art. Typically, formulations are
prepared by uniformly and intimately bringing into association a
described compound with liquid carriers, or finely divided solid
carriers, or both, and then, if necessary, shaping the product.
[0167] Pharmaceutical compositions of the present invention
suitable for parenteral administration comprise one or more
described compounds in combination with one or more
pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous
solutions, dispersions, suspensions or emulsions, or sterile
powders which may be reconstituted into sterile injectable
solutions or dispersions just prior to use, which may contain
sugars, alcohols, amino acids, antioxidants, buffers,
bacteriostats, solutes which render the formulation isotonic with
the blood of the intended recipient or suspending or thickening
agents.
[0168] Examples of suitable aqueous and nonaqueous carriers which
may be employed in the pharmaceutical compositions of the invention
include water, ethanol, polyols (such as glycerol, propylene
glycol, polyethylene glycol, and the like), and suitable mixtures
thereof, vegetable oils, such as olive oil, and injectable organic
esters, such as ethyl oleate. Proper fluidity can be maintained,
for example, by the use of coating materials, such as lecithin, by
the maintenance of the required particle size in the case of
dispersions, and by the use of surfactants.
[0169] These pharmaceutical compositions may also contain adjuvants
such as preservatives, wetting agents, emulsifying agents and
dispersing agents. Prevention of the action of microorganisms upon
the described compounds may be ensured by the inclusion of various
antibacterial and antifungal agents, for example, paraben,
chlorobutanol, phenol sorbic acid, and the like. It may also be
desirable to include agents to control tonicity, such as sugars,
sodium chloride, and the like into the compositions. In addition,
prolonged absorption of the injectable pharmaceutical form may be
brought about by the inclusion of agents which delay absorption
such as aluminum monostearate and gelatin.
[0170] In some cases, in order to prolong the effect of a drug, it
is desirable to slow the absorption of the drug from subcutaneous
or intramuscular injection. This may be accomplished by the use of
a liquid suspension of crystalline or amorphous material having
poor water solubility. The rate of absorption of the drug then
depends upon its rate of dissolution which, in turn, may depend
upon crystal size and crystalline form. Alternatively, delayed
absorption of a parenterally-administered drug form is accomplished
by dissolving or suspending the drug in an oil vehicle.
[0171] For example, a described compound may be delivered to a
human in a form of solution that is made by reconstituting a solid
form of the drug with liquid. This solution may be further diluted
with infusion fluid such as water for injection, 0.9% sodium
chloride injection, 5% dextrose injection and lactated ringer's
injection. It is preferred that the reconstituted and diluted
solutions be used within 4-6 hours for delivery of maximum potency.
Alternatively, a described compound may be delivered to a human in
a form of tablet or capsule.
[0172] Injectable depot forms are made by forming microencapsulated
matrices of the described compounds in biodegradable polymers such
as polylactide-polyglycolide. Depending on the ratio of drug to
polymer, and the nature of the particular polymer employed, the
rate of drug release can be controlled. Examples of other
biodegradable polymers include poly(orthoesters) and
poly(anhydrides). Depot injectable formulations are also prepared
by entrapping the drug in liposomes or microemulsions which are
compatible with body tissue.
[0173] When the described compounds are administered as
pharmaceuticals, to humans and animals, they can be given alone or
as a pharmaceutical composition containing, for example, 0.1 to 99%
(more preferably, 10 to 30%) of active ingredient in combination
with a pharmaceutically acceptable carrier. In other embodiments,
the pharmaceutical composition may contain 0.2-25%, preferably
0.5-5% or 0.5-2%, of active ingredient. These compounds may be
administered to humans and other animals for therapy by any
suitable route of administration, including, e.g., subcutaneous
injection, subcutaneous depot, intravenous injection, intravenous
or subcutaneous infusion. These compounds may be administered
rapidly (within <1 minute) as a bolus or more slowly over an
extended period of time (over several minutes, hours or days).
These compounds may be delivered daily or over multiple days,
continuously or intermittently. In one embodiment, the compounds
may be administered transdermally (e.g., using a patch,
microneedles, micropores, ointment, microjet or nanojet).
[0174] Regardless of the route of administration selected, the
described compounds, which may be used in a suitable hydrated form,
and/or the pharmaceutical compositions, are formulated into
pharmaceutically-acceptable dosage forms by conventional methods
known to those of skill in the art.
[0175] Actual dosage levels of the active ingredients in the
pharmaceutical compositions may be varied so as to obtain an amount
of the active ingredient which is effective to achieve the desired
therapeutic response for a particular patient, composition, and
mode of administration, without being toxic to the patient.
[0176] The selected dosage level will depend upon a variety of
factors including the activity of the particular described compound
employed, or the ester, salt or amide thereof, the route of
administration, the time of administration, the rate of excretion
or metabolism of the particular compound being employed, the rate
and extent of absorption, the duration of the treatment, other
drugs, compounds and/or materials used in combination with the
particular compound employed, the age, sex, weight, condition,
general health and prior medical history of the patient being
treated, and like factors well known in the medical arts.
[0177] A physician or veterinarian having ordinary skill in the art
can readily determine and prescribe the effective amount of the
pharmaceutical composition required. For example, the physician or
veterinarian could start doses of the described compounds employed
in the pharmaceutical composition at levels lower than that
required in order to achieve the desired therapeutic effect and
gradually increase the dosage until the desired effect is
achieved.
[0178] In general, a suitable daily dose of a described compound
will be that amount of the compound which is the lowest dose
effective to produce a therapeutic effect. Such an effective dose
will generally depend upon the factors described above. Generally,
intravenous, intramuscular, transdermal, intracerebroventricular
and subcutaneous doses of the described compounds for a patient,
when used for the indicated effects, will range from about 1 .mu.g
to about 5 mg per kilogram of body weight per hour. In other
embodiments, the dose will range from about 5 .mu.g to about 2.5 mg
per kilogram of body weight per hour. In further embodiments, the
dose will range from about 5 .mu.g to about 1 mg per kilogram of
body weight per hour.
[0179] If desired, the effective daily dose of a described compound
may be administered as two, three, four, five, six or more
sub-doses administered separately at appropriate intervals
throughout the day, optionally, in unit dosage forms. In one
embodiment, the described compound is administered as one dose per
day. In further embodiments, the compound is administered
continuously, as through intravenous or other routes. In other
embodiments, the compound is administered less frequently than
daily, such as every 2-3 days, in conjunction with dialysis
treatment, weekly or less frequently.
[0180] The subject receiving this treatment is any animal in need,
including primates, in particular humans, and other mammals such as
equines, cattle, swine and sheep; and poultry and pets in
general.
[0181] The described compounds may be administered as such or in
admixtures with pharmaceutically acceptable carriers and can also
be administered in conjunction with antimicrobial agents such as
penicillins, cephalosporins, aminoglycosides and glycopeptides.
Conjunctive therapy thus includes sequential, simultaneous and
separate administration of the active compound in a way that the
therapeutical effects of the first administered one is not entirely
disappeared when the subsequent is administered.
Routes of Administration for Disclosed Compounds
[0182] These compounds may be administered to humans and other
animals for therapy by any suitable route of administration. As
used herein, the term "route" of administration is intended to
include, but is not limited to subcutaneous injection, subcutaneous
depot, intravenous injection, intravenous or subcutaneous infusion,
intraocular injection, intradermal injection, intramuscular
injection, intraperitoneal injection, intratracheal administration,
intraadiposal administration, intraarticular administration,
intrathecal administration, epidural administration, inhalation,
intranasal administration, sublingual administration, buccal
administration, rectal administration, vaginal administration,
intracisternal administration and topical administration,
transdermal administration, or administration via local delivery
(for example by catheter or stent).
[0183] Transdermal drug delivery to the body is a desirable and
convenient method for systemic delivery of biologically active
substances to a subject, and in particular for delivery of
substances that have poor oral bioavailability, such as proteins
and peptides. The transdermal route of delivery has been
particularly successful with small (e.g., less than about 1,000
Daltons) lipophilic compounds, such as scopolamine and nicotine,
that can penetrate the stratum corneum outer layer of the skin,
which serves as an effective barrier to entry of substances into
the body. Below the stratum corneum is the viable epidermis, which
contains no blood vessels, but has some nerves. Deeper still is the
dermis, which contains blood vessels, lymphatics and nerves. Drugs
that cross the stratum corneum barrier can generally diffuse to the
capillaries in the dermis for absorption and systemic
distribution.
[0184] Technological advances in transdermal delivery have focused
on addressing the need in the art to deliver hydrophilic, high
molecular weight compounds, such as proteins and peptides, across
the skin. One approach involves disruption of the stratum corneum
using chemical or physical methods to reduce the barrier posed by
the stratum corneum. Skin microporation technology, which involves
the creation of micron dimension transport pathways (micropores) in
the skin (in particular, the micropores in the stratum corneum)
using a minimally invasive technique, is a more recent approach.
Techniques to create micropores in the skin (stratum corneum)
include thermal microporation or ablation, microneedle arrays,
phonophoresis, laser ablation and radiofrequency ablation
(Prausnitz and Langer (2008) Nat. Biotechnology 11:1261-68; Arora
et al., Int. J. Pharmaceutics, 364:227 (2008); Nanda et al.,
Current Drug Delivery, 3:233 (2006); Meidan et al. American J.
Therapeutics, 11:312 (2004)).
[0185] As noted above, PTH secretion is regulated by the CaSR which
is expressed on the cell surface of parathyroid cells. Thus, in
order to activate the CaSR, the agent or compound must be delivered
to the parathyroid cell. Transdermal delivery of calcimimetic
agents must achieve delivery across the stratum corneum and provide
systemic exposure to reach the parathyroid cell. To date, the art
has not demonstrated whether a calcimimetic compound can be
delivered transdermally in an amount sufficient for therapeutic
benefit and in particular in an amount sufficient for decreasing
PTH and/or the treatment, attenuation, lessening and/or relief
hypercalcemia.
[0186] In addition to calcimimetics, 1,25-(OH).sub.2 vitamin
D.sub.3 analogs are the most commonly used treatments for patients
with hyperparathyroidism associated with chronic kidney disease and
end stage renal disease. Vitamin D analogs act by facilitating
intestinal absorption of dietary calcium, and reduce PTH levels by
inhibiting PTH synthesis and secretion. While intravenous and oral
delivery of vitamin D has been used therapeutically, to date, the
art has not demonstrated whether vitamin D analogs, such as
ZEMPLAR.TM. (paricalcitol), CALCIJEX.RTM. (calcitriol),
ONE-ALPHA.RTM. (alfacalcidol) and HECTOROL.RTM. (doxercalciferol)
can be delivered transdermally in an amount sufficient for
therapeutic benefit and in particular in an amount sufficient for
decreasing parathyroid hormone (PTH). In addition, the art has not
demonstrated whether the co-administration by transdermal delivery
of a calcimimetic agent in combination with a vitamin D analog
(either as separate formulations or as a co-formulation) in amounts
sufficient for therapeutic benefit, and in particular in amounts
sufficient for decreasing PTH and provide effective treatment for
patients suffering from hyperparathyroidism.
[0187] The calcimimetic agents may be administered across the
stratum corneum, and/or other layers of the epidermis, for local or
systemic delivery, for decreasing parathyroid hormone (PTH) and/or
treating hypercalcemia. In one embodiment, the calcimimetic agent
is delivered via microporation. Any one of a number of techniques
for microporation is contemplated, and several are briefly
described.
[0188] Microporation can be achieved by mechanical means and/or
external driving forces, to breach the stratum corneum to deliver
the calcimimetic agents described herein through the surface of the
skin and into the underlying skin layers and/or the
bloodstream.
[0189] In a first embodiment, the microporation technique is
ablation of the stratum corneum in a specific region of the skin
using a pulsed laser light of wavelength, pulse length, pulse
energy, pulse number, and pulse repetition rate sufficient to
ablate the stratum corneum without significantly damaging the
underlying epidermis. The calcimimetic agent is then applied to the
region of ablation. Another laser ablation microporation technique,
referred to as laser-induced stress waves (LISW), involves
broadband, unipolar and compressible waves generated by high-power
pulsed lasers. The LISWs interact with tissues to disrupt the
lipids in the stratum corneum, creating intercellular channels
transiently within the stratum corneum. These channel, or
micropores, in the stratum corneum permit entry of the calcimimetic
agent.
[0190] Sonophoresis or phonophoresis is another microporation
technique that uses ultrasound energy. Ultrasound is a sound wave
possessing frequencies above 20 KHz. Ultrasound can be applied
either continuously or pulsed, and applied at various frequency and
intensity ranges (Nanda et al., Current Drug Delivery, 3:233
(2006)).
[0191] Another microporation technique involves the use of a
microneedle array. The array of microneedles when applied to a skin
region on a subject pierce the stratum corneum and do not penetrate
to a depth that significantly stimulates nerves or punctures
capillaries. The patient, thus, feels no or minimal discomfort or
pain upon application of the microneedle array for generation of
micropores through which the calcimimetic agent is delivered.
[0192] Microneedle arrays comprised of hollow or solid microneedles
are contemplated, where the calcimimetic agent can be coated on the
external surface of the needles or dispensed from the interior of
hollow needles. Examples of microneedle arrays are described, for
example, in Nanda et al., Current Drug Delivery, 3:233 (2006) and
Meidan et al. American J. Therapeutics, 11:312 (2004). First
generation microneedle arrays were comprised of solid, silicon
microneedles that were externally coated with a therapeutic agent.
When the microarray of needles was pressed against the skin and
removed after about 10 seconds, the permeation of the agent on the
needles into the body was readily achieved. Second generation
microneedle arrays were comprised of microneedles of solid or
hollow silicon, polycarbonate, titanium or other suitable polymer
and coated or filled with a solution of the therapeutic compound.
Newer generations of microneedle arrays are prepared from
biodegradable polymers, where the tips of the needles coated with a
therapeutic agent remain in the stratum corneum and slowly
dissolve.
[0193] The microneedles can be constructed from a variety of
materials, including metals, ceramics, semiconductors, organics,
polymers, and composites. Exemplary materials of construction
include pharmaceutical grade stainless steel, gold, titanium,
nickel, iron, tin, chromium, copper, palladium, platinum, alloys of
these or other metals, silicon, silicon dioxide, and polymers.
Representative biodegradable polymers include polymers of hydroxy
acids such as lactic acid and glycolic acid polylactide,
polyglycolide, polylactide-co-glycolide, and copolymers with
poly(ethylene glycol), polyanhydrides, poly(ortho)esters,
polyurethanes, poly(butyric acid), poly(valeric acid), and
poly(lactide-co-caprolactone). Representative non-biodegradable
polymers include polycarbonate, polyester, and polyacrylamides.
[0194] The microneedles can have straight or tapered shafts. In one
embodiment, the diameter of the microneedle is greatest at the base
end of the microneedle and tapers to a point at the end distal the
base. The microneedle can also be fabricated to have a shaft that
includes both a straight (untapered) portion and a tapered portion.
The needles may also not have a tapered end at all, i.e. they may
simply be cylinders with blunt or flat tips. A hollow microneedle
that has a substantially uniform diameter, but which does not taper
to a point, is referred to herein as a "microtube." As used herein,
the term "microneedle" includes both microtubes and tapered needles
unless otherwise indicated.
[0195] Electroporation is another technique for creating micropores
in the skin. This approach uses the application of microsecond or
millisecond long high-voltage electrical pulses to created
transient, permeable pores within the stratum corneum.
[0196] Other microporation techniques include use of radio waves to
create microchannels in the skin. Thermal ablation is yet another
approach to achieve delivery of larger molecular weight compounds
transdermally.
[0197] Applicants have discovered that low doses of calcimimetic
agents may be therapeutically administered over an extended period
of time to treat SHPT. This markedly differs from current dose
requirements of other calcimimetics (e.g., cinacalcet
hydrochloride).
[0198] Transdermal delivery of the compounds described herein was
demonstrated in the studies described in Examples 9-10. In a first
study, the compound Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) was
administered transdermally to rats in which a small area of the
skin was microporated by 5 passes of a 1.0 mm derma roller under
moderate pressure. A solution of either Ac-crrrrrr-NH.sub.2 (SEQ ID
NO: 6) or saline was placed on the microporated area of skin. Blood
draws were taken over a 4 hour period and plasma was analyzed for
PTH levels by ELISA. The results are shown in FIG. 11, where the
plasma PTH is shown as a percent of pre-dose baseline for the
saline treated animal (diamonds) and the two animals treated with
the test compound (squares, triangles). These data indicate that
the compound Ac-crrrrrr-NH.sub.2 (SEQ ID NO: 6) can be delivered
systemically in sufficient quantities by transdermal route (in this
case, micropore-facilitated transdermal delivery) using a derma
roller to effectively and significantly reduce PTH levels from
baseline for the .about.4 hours that were studies. It should be
noted that Ac-crrrrrr-NH.sub.2 (SEQ ID NO: 6) has been shown to
effectively reduce PTH levels from baseline in the 1K1C rat model
of acute renal insufficiency when administered by short IV infusion
as well as in normal rats (data not shown).
[0199] In another study, described in Example 10, the compound
Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) was administered
micropore-facilitated transdermal delivery to normal rats using a
transdermal patch. A transdermal patch system containing 10%
solution (by weight) of Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) in
saline was placed over the microporated area and left in place for
.about.30 hours. Blood draws were taken from the rats periodically
over the 30 hours and plasma samples were analyzed for PTH levels
by ELISA. The results are shown in FIG. 12. Surprisingly, these
data demonstrate that micropore-facilitated transdermal delivery
can achieve sufficient sustained delivery of Ac-c(C)arrrar-NH.sub.2
(SEQ ID NO:3) to produce a significant and extended reduction in
PTH for >30 hours in rats with normal renal function. These data
demonstrate that microporation facilitated transdermal delivery of
the conjugate Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) using a patch
can achieve sufficient blood exposure of the peptide over the
course of treatment to produce a significant and sustained
reduction in PTH from baseline for >30 hrs. These data
demonstrate that transdermal patch delivery on a daily basis or
longer would enable treatment of both dialysis and non-hemodialysis
patients in need of treatment. For example, CKD (stage 4), primary
hyperparathyroidism and secondary hyperparathyroidism (SHPT) in
renal transplant patients who are not typically treated with IV
drugs, but could be readily treated by a daily transdermal patch
via microporation facilitated transdermal delivery.
[0200] Another study was conducted to further evaluate the route of
administration of the compounds. As described in Example 11, the
compound Ac-c(C)arrrar-NH.sub.2(SEQ ID NO:3) was administered by
very low dose IV infusion to normal rats and to rats with renal
insufficiency to identify the lowest dose needed to be administered
by infusion, transdermal patch system or other sustained delivery
means to achieve significant PTH reduction. Healthy rats were
intravenously infused for six hours with very low doses (1
.mu.g/kg/hr, 3 .mu.g/kg/hr, and 10 .mu.g/kg/hr) of
Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3). Blood samples were taken
prior to dosing (pre) and at 2 hours, 4 hours, 6 hours (just prior
to the end of infusion; EOI) and 8 hours (2 hrs post EOI) after the
start of infusion and plasma was analyzed for PTH levels by ELISA.
Surprisingly, the data shown in FIG. 13 demonstrate that infusion
of very low doses of Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) (1
.mu.g/kg/hr (squares), 3 .mu.g/kg/hr (circles), and 10 .mu.g/kg/hr
(triangles)) for 6 hours are effective to produce significant
reduction in PTH from baseline over the course of infusion. These
data indicate that low doses delivered continuously could be as
effective as (or even more effective than) much larger doses
delivery as a single bolus.
[0201] The PTH lowering effect was further evaluated in the rat
1K1C model of acute renal insufficiency. 1K1C model rats were
intravenously infused with low doses of Ac-c(C)arrrar-NH.sub.2 (SEQ
ID NO:3) (30 .mu.g/kg/hr and 100 .mu.g/kg/hr) for 6 hours. Blood
samples were taken prior to dosing (Pre), and at 2 hours, 4 hours,
6 hours (just prior to the end of infusion; EOI), 8 hours (2 hrs
post EOI) and 24 hours after the start of infusion and plasma was
analyzed for PTH levels by ELISA. The data shown in FIG. 14A
demonstrate that IV infusion of low doses of Ac-c(C)arrrar-NH.sub.2
(SEQ ID NO:3) significantly reduce PTH from baseline levels in the
1K1C model, a model of renal insufficiency where baseline PTH
levels can be seen to be from 400 to >1100 .mu.g/mL.
Surprisingly, 6 hours of low dose IV infusion (diamonds, 30
.mu.g/kg/hr and squares, 100 .mu.g/kg/hr) of Ac-c(C)arrrar-NH.sub.2
(SEQ ID NO:3) were able to reduce PTH from baseline for .about.24
hours. Consistent with this dramatic PTH reduction in the 1K1C rat
model, FIG. 14B shows a bar graph plotting serum calcium data in
this acute renal insufficiency, and show a corresponding reduction
in serum calcium following low dose IV infusion of
Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3). These data demonstrate that
Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) is a very potent calcimimetic
compound that is able to reduce PTH and calcium following infusion
or delivery of low doses (for example by transdermal delivery) over
the course of .about.24 hours. These data further support the
conclusion that low dose sustained delivery of a calcimimetic agent
by IV infusion or by micropore-facilitated transdermal delivery
could be an effective treatment for patients on a daily or less
frequent basis.
Combination Therapy
[0202] As described above, the methods of use may be used alone or
in combination with other approaches for the treatment of
hypercalcemia and/or bone disease. Such other approaches include,
but are not limited to, treatment with agents such as
bisphosphonate agents, integrin blockers, hormone replacement
therapy, selective estrogen receptor modulators, cathepsin K
inhibitors, vitamin D therapy, vitamin D analogs, such as
ZEMPLAR.TM. (paricalcitol), CALCIJEX.RTM. (calcitriol),
ONE-ALPHA.RTM. (alfacalcidol) and HECTOROL.RTM. (doxercalciferol),
anti-inflammatory agents, low dose PTH therapy (with or without
estrogen), calcimimetics, phosphate binders, calcitonin, inhibitors
of RANK ligand, antibodies against RANK ligand, osteoprotegrin,
adensosine antagonists and ATP proton pump inhibitors.
[0203] In one embodiment, a combination therapy uses vitamin D or a
vitamin D analog in combination with a calcimimetic agent. Vitamin
D aids in the absorption of calcium and functions to maintain
normal blood levels of calcium and phosphorous. PTH works to
enhance calcium absorption in the intestine by increasing the
production of 1,25-(OH).sub.2 vitamin D, the active form of vitamin
D. PTH also stimulates phosphorus excretion from the kidney, and
increases release from bone.
[0204] As discussed above, secondary hyperparathyroidism is
characterized by an elevation in parathyroid hormone (PTH)
associated with inadequate levels of active vitamin D hormone.
Vitamin D or a vitamin D analog may be used to reduce elevated PTH
levels in treatment of secondary hyperparathryoidism. In one
embodiment, the invention includes a pharmaceutical composition
comprising a calcimimetic agent and a vitamin D analog.
[0205] In one embodiment, the invention includes a pharmaceutical
composition comprising a calcimimetic agent and ZEMPLAR.TM.
(paricalcitol). Paricalcitol is a synthetic analog of calcitriol,
the metabolically active form of vitamin D. The recommended initial
dose of Zemplar is based on baseline intact parathyroid hormone
(iPTH) levels. If the baseline iPTH level is less than or equal to
500 .mu.g/mL, the daily dose is 1 .mu.g and the "three times a
week" dose (to be administered not more than every other day) is 2
.mu.g. If the baseline iPTH is greater than 500 .mu.g/mL, the daily
dose is 2 .mu.g, and the "three times a week" does (to be
administered not more than every other day) is 4 .mu.g. Thereafter,
dosing must be individualized and based on serum plasma iPTH
levels, with monitoring of serum calcium and serum phosphorus.
Paricalcitol is described in U.S. Pat. Nos. 5,246,925 and
5,587,497.
[0206] In another embodiment, the invention includes a
pharmaceutical composition comprising a calcimimetic agent and
CALCIJEX.RTM. (calcitriol). Calcitriol is the metabolically active
form of vitamin D. The recommended initial dosage for CALCIJEX.RTM.
(oral) is 0.25 .mu./day. This amount may be increased by 0.25
.mu.g/day at 4- to 8-wk intervals. Normal or only slightly reduced
calcium levels may respond to dosages of 0.25 .mu.g every other
day. For patients on dialysis, the recommended initial dose for
CALCIJEX.RTM. (IV) is 0.02 .mu.g/kg (1 to 2 .mu.g) 3 times/week,
every other day. This amount may be increased by 0.5 to 1 .mu.g,
every 2 to 4 wk. Calcitriol is described in U.S. Pat. Nos.
6,051,567 and 6,265,392 and 6,274,169.
[0207] In one embodiment, a pharmaceutical composition comprising a
calcimimetic agent and HECTOROL.RTM. (doxercalciferol) is provided.
Doxercalciferol is a synthetic analog of vitamin D that undergoes
metabolic activation in vivo to form 1.alpha.,25-dihydroxyvitamin
D.sub.2, a naturally occurring, biologically active form of vitamin
D. The recommended initial dose of HECTOROL.RTM. is 10 .mu.g
administered three times weekly at dialysis (approximately every
other day). The initial dose should be adjusted, as needed, in
order to lower blood iPTH into the range of 150 to 300 .mu.g/mL.
The dose may be increased at 8-week intervals by 2.5 .mu.g if iPTH
is not lowered by 50% and fails to reach target range. The maximum
recommended dose of HECTOROL is 20 .mu.g administered three times a
week at dialysis for a total of 60 .mu.g per week. Doxercalciferol
is described in U.S. Pat. Nos. 5,602,116 and 5,861,386 and
5,869,473 and 6,903,083.
[0208] The particular combination of therapies (therapeutics or
procedures) to employ in a combination regimen will take into
account compatibility of the desired therapeutics and/or procedures
and the desired therapeutic effect to be achieved. It will also be
appreciated that the therapies employed may achieve a desired
effect for the same disorder (for example, an inventive compound
may be administered concurrently with another agent used to treat
the same disorder), or they may achieve different effects (e.g.,
control of any adverse effects). As used herein, additional
therapeutic agents that are normally administered to treat or
prevent a particular disease, or condition, are known as
"appropriate for the disease, or condition, being treated".
[0209] A combination treatment of the present invention as defined
herein may be achieved by way of the simultaneous, sequential or
separate administration of the individual components of said
treatment.
[0210] The compounds or pharmaceutically acceptable compositions
thereof may also be incorporated into compositions for coating
implantable medical devices, bio-erodible polymers, implantable
pump, and suppositories. Accordingly, in another aspect, a
composition for coating an implantable device comprising a
described compound as described generally above is contemplated,
and a carrier suitable for coating the implantable device. In still
another aspect, included is an implantable device coated with a
composition comprising a compound as described generally above, and
a carrier suitable for coating said implantable device.
[0211] Suitable coatings and the general preparation of coated
implantable devices are described in U.S. Pat. Nos. 6,099,562;
5,886,026; and 5,304,121. The coatings are typically biocompatible
polymeric materials such as a hydrogel polymer,
polymethyldisiloxane, polycaprolactone, polyethylene glycol,
polylactic acid, ethylene vinyl acetate, and mixtures thereof. The
coatings may optionally be further covered by a suitable topcoat of
fluorosilicone, polysaccarides, polyethylene glycol, phospholipids
or combinations thereof to impart controlled release
characteristics in the composition.
Potential Clinical Markers for Determining Treatment Efficacy
[0212] Determination of the effectiveness of a described method of
treatment may be determined by a variety of methods.
[0213] Normal levels of serum calcium are in the range of 8.8 mg/dL
to 10.4 mg/dL (2.2 mmol/L to 2.6 mmol/L). In certain cases, the
efficacy of treatment may be determined by measurement of serum and
urinary markers related to calcium, including but not limited to,
total and ionized serum calcium, albumin, plasma PTH, PTHrP,
phosphate, vitamin D, and magnesium.
[0214] In other cases, efficacy may be determined by measurement of
bone mineral density (BMD), or by measurement of biochemical
markers for bone formation and/or bone resorption in serum or
urine. Potential bone formation markers include, but are not
limited to, total alkaline phosphatase, bone alkaline phosphatase,
osteocalcin, under-carboxylated osteocalcin, C-terminal procollagen
type I propeptide, and N-terminal procollagen type I propeptide.
Potential bone resorption markers include, but are not limited,
hydroxyproline, hydroxylysine, glycosyl-galactosyl hydroxylysine,
galactosyl hydroxylysine, pyridinoline, deoxypyridinoline,
N-terminal crosslinking telopeptide of type I collagen, C-terminal
crosslinking telopeptide of type I collagen, C-terminal
crosslinking telopeptide of type I collagen generated by MMPs, bone
sialoprotein, acid phosphatase and tartrate-resistant acid
phosphatase.
[0215] In other cases, efficacy may be determined by the percent
reduction in PTH relative to a pre-dosing (baseline) level and/or
by achieving a desirable PTH level as generally accepted as being
beneficial to patients (for example, guidelines established by the
National Kidney Foundation). Still in other cases, efficacy may be
determined by measurement of the reduction in parathyroid gland
hyperplasia associated with a hyperparathyroidism disease.
[0216] It is expected that when a described method of treatment is
administered to a subject in need thereof, the method of treatment
will produce an effect, as measured by, for example, one or more
of: total serum calcium, ionized serum calcium, total blood
calcium, ionized blood calcium, albumin, plasma PTH, blood PTH,
PTHrP, phosphate, vitamin D, magnesium, bone mineral density (BMD),
total alkaline phosphatase, bone alkaline phosphatase, osteocalcin,
under carboxylated osteocalcin, C-terminal procollagen type I
propeptide, N-terminal procollagen type I propeptide,
hydroxyproline, hydroxylysine, glycosyl-galactosyl hydroxylysine,
galactosyl hydroxylysine, pyridinoline, deoxypyridinoline,
N-terminal crosslinking telopeptide of type I collagen, C-terminal
crosslinking telopeptide of type I collagen, C-terminal
crosslinking telopeptide of type I collagen generated by MMPs, bone
sialoprotein, acid phosphatase and tartrate-resistant acid
phosphatase. Effects include prophylactic treatment as well as
treatment of existing disease.
[0217] A biologically effective molecule may be operably linked to
a described peptide with a covalent bond or a non-covalent
interaction. In specific embodiments, the operably linked
biologically effective molecules can alter the pharmacokinetics of
the described compounds by virtue of conferring properties to the
compound as part of a linked molecule. Some of the properties that
the biologically effective molecules can confer on the described
compounds include, but are not limited to: delivery of a compound
to a discrete location within the body; concentrating the activity
of a compound at a desired location in the body and reducing its
effects elsewhere; reducing side effects of treatment with a
compound; changing the permeability of a compound; changing the
bioavailability or the rate of delivery to the body of a compound;
changing the length of the effect of treatment with a compound;
altering the in vitro chemical stability of the compound; altering
the in vivo stability of the compound, half-life, clearance,
absorption, distribution and/or excretion; altering the rate of the
onset and the decay of the effects of a compound; providing a
permissive action by allowing a compound to have an effect.
[0218] In a further aspect, the described compound may be
conjugated to polyethylene glycol (PEG). The selected PEG may be of
any convenient molecular weight, and may be linear or branched, and
may be optionally conjugated through a linker. The average
molecular weight of PEG will preferably range from about 2
kiloDalton (kDa) to about 100 kDa, more preferably from about 5 kDa
to about 40 kDa. Alternatively, the PEG moiety used can be 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20
kDa.
[0219] The described compounds may be conjugated to PEG through a
suitable amino acid residue located at any position on the
compounds. The described compounds may optionally contain an
additional amino acid residue to which PEG is conjugated, including
for example, an additional amine-containing residue, such as
lysine.
[0220] PEGylated peptides are known in the art to increase serum
half-life of conjugated peptide. A variety of methods are known in
the art for the formation of PEGylated peptides. For example, the
PEG moiety can be linked to the amino terminus, the carboxy
terminus or through a side chain of the claimed peptide, optionally
through the presence of a linking group. In other embodiments, the
PEG moiety may be linked to the sulfur of a thiol-containing amino
acid, such as cysteine, or may be coupled to the sidechain of an
amine-containing amino acid, such as lysine.
[0221] The PEG groups will generally be attached to the described
compound by acylation or alkylation through a reactive group on the
PEG moiety (e.g., an aldehyde, amine, oxime, hydrazine thiol,
ester, or carboxylic acid group) to a reactive group on the
described compound (e.g., an aldehyde, amine, oxime, hydrazine,
ester, acid or thiol group), which may be located at the amino
terminus, carboxy terminus, or a sidechain position of the
described compound. One approach for preparation of PEGylation of
synthetic peptides consists of combining through a conjugate
linkage in solution, a peptide and a PEG moiety, each bearing a
functional group that is mutually reactive towards the other.
Peptides can be easily prepared using conventional solution or
solid phase synthesis techniques. Conjugation of the peptide and
PEG is typically done in aqueous phase and may be monitored by
reverse phase HPLC. The PEGylated peptides can be readily purified
and characterized, using standard techniques known to one of skill
in the art.
[0222] One or more individual subunits of the described compounds
may also be modified with various derivatizing agents known to
react with specific side chains or terminal residues. For example,
lysinyl residues and amino terminal residues may be reacted with
succinic anhydride or other similar carboxylic acid anhydrides
which reverses the charge on the lysinyl or amino residue. Other
suitable reagents include, e.g., imidoesters such as methyl
picolinimidate; pyridoxal; pyridoxal phosphate; chloroborohydride;
trinitrobenzenesulfonic acid; O-methylisourea, 2,4,-pentanedione;
and transaminase-catalyzed reaction with glyoxalate. Arginyl
residues may be modified by reaction with conventional agents such
as phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and
ninhydrin.
[0223] In addition, the described compounds may be modified to
include non-cationic residues that provide immunogenic residues
useful for the development of antibodies for bioanalytical ELISA
measurements, as well as to evaluate immunogenicity. For example,
the described compounds may be modified by incorporation of
tyrosine and/or glycine residues. Specific modifications of tyrosyl
residues are of particular interest for introducing spectral labels
into tyrosyl residues. Non-limiting examples include reaction with
aromatic diazonium compounds or tetranitromethane. Most commonly,
N-acetylimidazole and tetranitromethane are used to form O-acetyl
tyrosyl and 3-nitro derivatives, respectively.
Kits Comprising the Disclosed Compounds
[0224] The invention also provides kits for carrying out the
therapeutic regimens of the invention. Such kits comprise
therapeutically effective amounts of the described compounds having
activity as a CaSR modulator, in pharmaceutically acceptable form,
alone or in combination with other agents, in pharmaceutically
acceptable form. Preferred pharmaceutical forms include the
described compounds in combination with sterile saline, dextrose
solution, buffered solution, sterile water, or other
pharmaceutically acceptable sterile fluid. Alternatively the
composition may include an antimicrobial or bacteriostatic agent.
Alternatively, the composition may be lyophilized or desiccated. In
this instance, the kit may further comprise a pharmaceutically
acceptable solution, preferably sterile, to form a solution for
injection purposes. In another embodiment, the kit may further
comprise a needle or syringe, preferably packaged in sterile form,
for injecting the composition. In other embodiments, the kit
further comprises an instruction means for administering the
composition to a subject. The instruction means can be a written
insert, an audiotape, an audiovisual tape, or any other means of
instructing the administration of the composition to a subject.
[0225] In one embodiment, the kit comprises (i) a first container
containing a described compound having activity as a CaSR
modulator; and (ii) instruction means for use. In another
embodiment the kit comprises (i) a first container containing a
compound as described herein, and (ii) a second container
containing a pharmaceutically acceptable vehicle for dilution or
reconstitution.
[0226] In another embodiment, the kit comprises (i) a first
container containing a described compound having activity as a CaSR
modulator; (ii) a second container containing an anticalcemic
agent; and (iii) instruction means for use.
[0227] In one embodiment, the anticalcemic agent is and agent
selected from the group consisting of bisphosphonate agents,
hormone replacement therapeutic agents, vitamin D therapy, vitamin
D analogs, such as ZEMPLAR.TM. (paricalcitol); CALCIJEX.RTM.
(calcitriol), ONE-ALPHA.RTM. (alfacalcidol) and HECTOROL.RTM.
(doxercalciferol), low dose PTH (with or without estrogen), and
calcitonin.
[0228] In related aspects, the invention provides articles of
manufacture that comprise the contents of the kits described above.
For instance, the invention provides an article of manufacture
comprising an effective amount of a described peptide, alone or in
combination with other agents, and instruction means indicating use
for treating diseases described herein.
EXAMPLES
[0229] The following examples are offered to illustrate but not to
limit the compounds and methods described herein. Various
modifications may be made by the skilled person without departing
from the true spirit and scope of the subject matter described
herein.
Example 1
Cationic Compounds with PTH Lowering Activity
A. Model of Renal Insufficiency
[0230] A rat model of acute renal insufficiency (also referred to
as the 1K1C model) was developed to simulate the pathology of SHPT
associated with end stage renal disease. The model exhibits
pathological characteristics of hyper parathyroidsm associated with
a lack of renal function, specifically the significant elevation of
plasma PTH and reduction in serum calcium. The development of this
model allowed for the further characterization of described
compounds in the context of a subject with renal dysfunction and
elevated PTH. Typical baseline PTH levels in this model averaged
.about.450 .mu.g/mL.
[0231] The 1K1C model of acute renal insufficiency involves the
removal of one kidney followed by exposure of the remaining kidney
to 45 minutes of ischemia and 48 hours of reperfusion. The ensuing
ischemia/reperfusion (I/R) damage to the remaining kidney results
in significant necrosis and renal failure. Serum creatinine levels
were elevated for over 24-48 hours following I/R insult (data not
shown). Also due to the resulting renal dysfunction, total PTH
levels are dramatically increased from the pre-I/R injury levels of
.about.100 .mu.g/mL. By 48 hours post-I/R, plasma PTH levels were
elevated to .about.450 .mu.g/mL (.about.5 fold increase) and in
some instances reach as high as .about.1200 .mu.g/mL. This
reproducible increase in serum creatinine and PTH provided a robust
model that mimics the physiology seen ESRD patients.
[0232] Cinacalcet hydrochloride (SENSIPAR.RTM.), an approved
calcimimetic agent that is used to lower PTH for the treatment of
SHPT, was tested in the 1K1C model of acute renal insufficiency.
Oral administration of cinacalcet at 30 mg/kg significantly lowered
PTH by approximately 50% for up to 6 hours. This result is
consistent with the published preclinical data for cinacalcet
(Nemeth et al., J. Pharmacol. Exp. Ther., 308(2):627-35 (2004)) and
validates that the 1K1C model of acute renal insufficiency is an
appropriate model for evaluating the activity of calcimimetics for
this indication.
[0233] The protocol used in this study is as follows. Male Sprague
Dawley rats were purchased from Charles River Laboratories
(Hollister, Calif.; requested purchase weight 250-275 g). For
studies with test articles, animals were pre-cannulated in the
femoral and jugular veins for drug administration and blood draws,
respectively. Animals were maintained in a temperature-controlled
environment with a constant 12 hours light/12 hours dark cycle and
free access to food and water at all times. All experimental
procedures with animals were performed according to IACUC
guidelines.
[0234] General anesthesia was induced and maintained by
intraperitoneal (IP) injection of sodium pentobarbital (5.2%, 0.4
mL/rat). For animals that received 45 minutes of renal ischemia an
additional IP injection of sodium pentobarbital (5.2%, 0.1 mL/rat)
was given to maintain the anesthetic plane. Blood sampling for PTH
measurements following administration of compounds in normal rats
was done under continuous isoflurane anesthesia.
[0235] A clean, aseptic technique was used for the entire
procedure. After rats were anesthetized, the abdomen was shaved
with electric clippers prior to the operation and the skin cleaned
with 70% alcohol solution.
[0236] For model development studies, the left femoral vein was
cannulated with a PE-10 tube for blood drawing. Both kidneys were
exposed via a laparotomy. A right nephrectomy was performed after
the right renal pedicle and ureter were ligated with double 2-0
silk sutures. After confirmation of non-bleeding in the right
pedicle, the left renal artery was carefully dissected and clamped
with a micro vascular clip to induce left renal global ischemia.
Renal ischemia was confirmed by observation of a global white-grey
color change (blanching). The abdominal incision was temporarily
covered with gauze to help maintain the temperature of the
abdominal organs. After 45 minutes, the designated period of
ischemia, the clip was removed and left renal artery flow was
considered restored upon observation of a global restoration of red
color. The abdominal incision was closed in layers with 2-0 silk
sutures. The animal was then recovered from anesthesia.
Physiological parameters including body temperature
(36-37.5.degree. C.) and body weight were measured throughout the
procedure. Body temperature was monitored and maintained using a
heat pad rectal probe feedback system.
[0237] Approximately 48 hours after the 1K1C surgery (I/R injury),
animals were dosed with various compounds to measure effects on
plasma PTH and calcium. In most cases, test articles were
administered by IV infusion (infusion time 5, 10 or 30 minutes)
although in some studies compounds were administered by IV bolus or
subcutaneous (SC) bolus injection. For drug administration and
blood draws, animals were anesthetized with isoflurane.
[0238] Blood samples were collected periodically throughout the
course of the study. Serum samples were analyzed for of calcium
levels and plasma samples were analyzed for PTH. Due to the range
of baseline PTH values for individual rats, all data are normalized
to pre-dosing (baseline) levels. Serum creatinine was measured
using a commercially available kit from BioAssay Systems (Hayward,
Ca), catalog #DICT-500. Analyses were performed according to the
manufacturer's instructions.
B. Testing Compounds in Renal Insufficiency Model
[0239] Compounds with the following sequences were prepared for
testing in the renal insufficiency model: Ac-crrrr-NH.sub.2 (SEQ ID
NO:4), n=4, Ac-crrrrr-NH.sub.2 (SEQ ID NO:5), n=4,
Ac-crrrrrr-NH.sub.2(SEQ ID NO:6), n=7, Ac-crrrrrrr-NH.sub.2 (SEQ ID
NO:7), n=4, and saline control, n=2. The peptides were administered
to animals at a dose of 3 mg/kg by a 30-minute IV infusion. Prior
to dosing a blood sample was drawn to determine baseline,
pre-dosing PTH plasma concentration. Results are shown in FIG. 1 as
follows: Ac-crrrr-NH.sub.2 (SEQ ID NO:4, diamonds),
Ac-crrrrr-NH.sub.2 (SEQ ID NO:5, squares), Ac-crrrrrr-NH.sub.2(SEQ
ID NO:6, triangles), and Ac-crrrrrrr-NH.sub.2 (SEQ ID NO:7, open
squares).
Example 2
In Vitro Cell Assay in HEK-293 Expressing the Human Calcium-Sensing
Receptor
[0240] Human embryonic kidney (HEK) 293T cells were seeded into a
T25 flask at 2 million cells per flask and allowed to incubate at
37.degree. C. in 5% CO.sub.2 overnight. The day after, these cells
were transfected with human CaSR receptor using lipofectamine 2000
transfection reagent 24 hrs post transfection, cells were seeded in
384 well plates at 8,000 cells/well. Assays were carried out 48
hours after the transfection. In some cases, EC.sub.50 values were
determined by measuring inositol monophosphate production in the
HEK293 cells, stably transfected with the human calcium-sensing
receptor (see Table 1).
[0241] The cell culture medium was aspirated from the wells and
replaced with 28 .mu.L of 1.times. stimulation buffer (Hepes 10 mM,
CaCl.sub.2) 1 mM, MgCl2 0.5 mM, KCl 4.2 mM, NaCl 146 mM, glucose
5.5 mM, LiCl 50 mM pH 7.4). Cells were incubated with compounds at
various concentrations (1 mM or 300 .mu.M as the highest and
further 1/2 log serial dilutions) at 37.degree. C. for 1.5 hrs
before reaction termination. IP.sub.1 production was determined in
cells using the Cisbio IP-One Tb kit (621PAPEC) and according to
manufacturer instructions. In brief, incubation with the compound
was terminated by sequentially adding D2 labeled-IP.sub.1 and
cryptate-labeled anti-IP.sub.1 in lysis buffer and further
incubating at room temperature for 60 minutes. Plates were read at
620 nm and 668 nm with 314 nm excitation. Non-transfected 293 cells
were used as negative control.
[0242] The ratio of fluorescence at 668 nm and 620 nm was
determined. IP.sub.1 concentrations were calculated from standard
curves (generated with Graph Pad Prism ver. 4) using known
concentrations of IP.sub.1 standards. EC.sub.50s were calculated
based on the values of the fluorescent ratio OD(668 nm)/(OD620 nm)
using non-linear regression curve fitting in Prism software.
[0243] Peptides and conjugates were prepared by solid-phase
chemistry at 0.25 mmol scale on an ABI automated synthesizer.
Sequential coupling of Fmoc-amino acids (4 eq, Anaspec) to
Rink-amide resin (NovaBiochem) was accomplished using HBTU/DIEA
activation. The assembled peptide was cleaved with a TFA cocktail
(phenol (5%), triisopropylsilane (2.5%) and water (2.5%); 10 mL per
gram of resin) and isolated by precipitation with diethyl ether.
After purification by C.sub.18 HPLC the final product was isolated
in the TFA salt form by lyophilization of appropriate fractions,
and characterized by HPLC (>95% purity) and LC-MS (confirmed
MVV).
Example 3
In Vivo Administration of Compounds with Cationic Subunits
[0244] The peptides were administered intravenously at a dose of
0.5 mg/kg into isoflurane-anesthetized normal Sprague Dawley rats.
A control group of rats was treated with saline. Blood was drawn
prior to dosing and every hour for 4 hours. Rats were maintained
under isoflurane anesthesia for the entire study. The concentration
of PTH in the plasma was measured by ELISA, detecting the bioactive
intact PTH 1-84 (Immutopics International catalog number 60-2700),
and the cumulative area under the curve for AUC was calculated for
the data points inclusive of 1-4 hours. Percent PTH reduction was
calculated according to the following formula: AUC.sub.cmpd
treated/AUC.sub.saline control*100.
Example 4
Structure-Activity Relationship Studies: In Vivo Activity
[0245] The peptides tested identified herein as SEQ ID NO: 26
(Ac-carrrar-NH.sub.2) and as SEQ ID NO:29 (Ac-arrrar-NH.sub.2) were
tested in vitro using the HEK293 CaSR transfected cells, according
to the procedure in Example 2. The peptides were also tested in
vivo, by administering as an IV bolus to normal Sprague Dawley rats
at doses of 9 mg/kg for SEQ ID NO:29 and at 0.5 mg/kg for SEQ ID
NO: 26. An intravenous (IV) bolus of saline was used as a control.
Plasma (K.sub.2EDTA) PTH levels were assessed prior to dosing and
1, 2, 3 and 4 hours after dosing. Rats were maintained under
isoflurane anesthesia for the entire study. The results are shown
in FIGS. 2A-2B, presented as group average.+-.standard deviation
(SD). In FIG. 2B, PTH is shown as percent of the baseline pre-dose
value.
Example 5
Structure-Activity Relationship Studies: D- and L-Amino Acid
Subunits
[0246] A series of compounds having an L-amino acid residue
substituted for a D-amino acid residue were prepared. The compounds
were administered as an IV bolus to normal Sprague Dawley rats at a
dose of 0.5 mg/kg. An intravenous (IV) bolus of saline was used as
a control. Plasma (K.sub.2EDTA) PTH levels were assessed prior to
dosing and 1, 2, 3 and 4 hours after dosing, and the AUC was
calculated as described above. Rats were maintained under
isoflurane anesthesia for the entire study. The results are shown
in Table 4 above.
Example 6
Structure-Activity Relationship Studies: Histamine Release
[0247] To evaluate the effect of net positive charge on the
histamine release associated with a compound, peptides containing 4
to 7 cationic (arginine) residues were generated and tested for
their ability to trigger histamine release in vivo. The tested
peptides included (i) Ac-crrrr-NH.sub.2 (SEQ ID NO:4), (ii)
Ac-crrrrr-NH.sub.2 (SEQ ID NO:5), (iii) Ac-crrrrrr-NH.sub.2 (SEQ ID
NO:6) and (iv) Ac-crrrrrrrr-NH.sub.2; SEQ ID NO:41).
[0248] Male Sprague-Dawley rats were obtained (Charles River)
pre-cannulated in the femoral and jugular veins for drug infusion
and blood draws, respectively. All IV drug treatments were
conducted under anesthetic (isoflurane). Animals were dosed by a
1-minute IV push in a total volume of 0.5 mL. Blood samples were
taken at 5, 15 and 30 minutes following IV bolus to generate plasma
(K.sub.2EDTA) samples for histamine analysis. For 30 minute IV
infusion studies, sample was taken at the end of infusion. In some
case rats in the 1K1C model of acute renal ischemia were used.
[0249] An equal volume of saline was injected following each blood
draw to replace lost volume. Approximately 0.2 mL of blood was
withdrawn at each time point using pre-coated EDTA syringes to
facilitate serum collection.
[0250] Histamine ELISAs were performed on diluted plasma using the
Histamine Enzyme Immunoassay (EIA) kit (Cat #A05890, SPI-BIO,
Montigny le Bretonneux, France). The Histamine EIA kit is a
derivitization-amplified competitive enzyme immunoassay which
detects histamine within the range of 40 .mu.g/mL to 5,500
.mu.g/mL. The samples were analyzed in duplicate according to the
manufacturer's protocol.
[0251] Lyophilized peptides (TFA salts) were weighed and the
recorded mass was adjusted for peptide content. Solutions were
prepared by dissolving the material in normal saline to generate
the desired peptide concentration. In some cases the molarity of
peptide was adjusted to allow for inter-peptide comparison. The
peptides were administered by IV bolus at an equivalent dose on a
per mole basis as SEQ ID NO:41 (i.e., 0.7 .mu.mole/rat) by a
1-minute IV bolus and plasma histamine was measured before dosing
(pre-dose), 5, 15 and 30 minutes after dosing. Data are presented
as group averages (n=2).+-.SD. Histamine release is shown as fold
change from pre-dose (baseline) levels. Results are shown in FIG.
3. Data are presented as group averages (n=2).+-.SD.
Example 7
Structure-Activity Relationship Studies: Histamine Release
[0252] For in vitro evaluation of histamine release, isolated rat
peritoneal mast cells were isolated by performing peritoneal lavage
using cold HBSS+25 mM HEPES pH 7.4 containing heparin (5 u/mL).
Cells were washed twice in stimulation buffer (HBSS+25 mM HEPES pH
7.4) and incubated with 10 .mu.M of compound in stimulation buffer
(HBSS+25 mM HEPES pH 7.4) for 15 minutes in a 96-well plate
(10.sup.6/well) at 37.degree. C. Cell supernatant was analyzed for
histamine using histamine EIA kit (Cayman #589651). Data is shown
in Table 10.
[0253] For the in vivo evaluation of histamine release, compounds
were dosed in isoflurane-anesthetized normal rats at 2 mg/kg by IV
bolus (administered over less than one minute). Plasma histamine
was measured 5 minutes after compound administration (Cayman
histamine EIA #589651). Data is shown in Table 11.
[0254] The abbreviations used herein, and in particular in Tables
10-11 are summarized here.
TABLE-US-00011 Ahx 6-aminohexanoic acid Aib 2-aminoisobutyric acid
bAla beta-alanine (3-aminopropionic acid) dHcy D-homocysteine dNle
D-norleucine dNva D-norvaline dPen D-penicillamine EG ethylene
glycol spacer, H2N--(CH2CH2--O)4--CH2--CO2H Hcy homocysteine Mpa
3-mercaptopropionic acid or mercaptopropionic acid Nma
N-methylalanine PEG poly (ethylene glycol) Sar Sarcosine
(N-methylglycine) dHar D-homoarginine GS Glutatione (conjugated)
DAP 1,3-diaminopropionic acid
Example 8
Structure-Activity Relationship Studies: In Vivo Activity
[0255] The compound Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) was
prepared for comparison with the compound Ac-carrrar-NH.sub.2 (SEQ
ID NO:26). In the compound Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) the
thiol-containing subunit in position X.sub.1 is conjugated via a
disulfide linkage to an L-Cys residue. The two compounds were
administered via IV bolus to animals with the 1K1C model of acute
renal insufficiency at doses of 0.3 and 0.5 mg/kg. Plasma PTH
levels were assessed prior to dosing and periodically for 24 hours
after dosing. Results are shown in FIG. 10, where data shown are
group averages.+-.SEM, where as a function of time, in hours, in
rats with 1K1C model of acute renal insufficiency, the compound
Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) is represented by squares (0.3
mg/kg, n=5) and * symbols (0.5 mg/kg, n=6) and the compound
Ac-c(Ac-C)arrrar-NH.sub.2 (SEQ ID NO:141) by triangles (0.3 mg/kg,
n=8) and diamonds (0.5 mg/kg, n=7).
Example 9
Micropore Facilitated Transdermal Delivery of Calcimimetic
Agents
[0256] To evaluate systemic delivery of a calicimimetic agent,
Ac-crrrrrr-NH.sub.2 (SEQ ID NO:6) was administered to CD hairless
rats transdermally using a reservoir. Ac-crrrrrr-NH.sub.2 (SEQ ID
NO:6) was applied as a 10% solution in saline to an approximately 1
cm.sup.2 area on the back of CD.RTM. hairless rats that were
microporated by 5 passes of a 1.0 mm Derma Roller under moderate
pressure. A polystyrene chamber (I.D. 9.5 mm) was glued over the
microporated area of skin to create a drug reservoir in which the
solution of either Ac-crrrrrr-NH.sub.2 (SEQ ID NO: 6) or a saline
solution were applied. A 10% solution of Ac-crrrrrr-NH.sub.2 (SEQ
ID NO: 6) was administered in the reservoir chamber on two rats, a
saline solution alone was administered in the reservoir chamber on
one rat. The reservoirs were covered with tape to prevent
evaporation. Blood draws were taken over a 4 hour period and plasma
was analyzed for PTH levels by ELISA. The results are shown in FIG.
11.
Example 10
Sustained Delivery of Calcimimetic Agents by Micropore Facilitated
Transdermal Patch
[0257] To further evaluate systemic delivery of a calcimimetic
agent, Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) was administered
transdermally to normal rats using a transdermal patch. Normal rats
were treated with microneedle array and transdermal patch system. A
small area of fur on the back of Sprague Dawley rats (.about.350 g)
was sheared using clippers and an area of skin was microporated
using a 14.times.14 array (.about.1 cm.sup.2) of microneedles
(.about.0.5 mm). A transdermal patch system containing 10% solution
(by weight) of Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) in saline was
placed over the microporated area and left in place for .about.30
hours. Blood draws were taken from the rats periodically over the
30 hours and plasma samples was analyzed for PTH levels by ELISA.
The results are shown in FIG. 12.
Example 11
Infusion of Calcimimetic Agents
[0258] To further evaluate the PTH lowering effect of the
calcimimetic compound Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO:3) was
administered by very low dose IV infusion to normal rats and rats
with renal insufficiency to identify the lowest dose needed to be
administered by infusion, transdermal patch system or other
sustained delivery means to achieve significant PTH reduction.
Normal Sprague-Dawley male rats (250-300 g) were intravenously
infused for 6 hours with Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO: 3) at
dose rates of 1 .mu.g/kg/hr, 3 .mu.g/kg/hr, and 10 .mu.g/kg/hr.
Blood samples were taken prior to dosing, at 2 hours, 4 hours, 6
hours (just prior to the end of infusion; EOI) and 8 hours (2 hrs
post EOI) and plasma was analyzed for PTH levels by ELISA. The data
are shown in FIG. 13, where rats treated with 1 .mu.g/kg/hr
(squares), 3 .mu.g/kg/hr (diamonds), and 10 .mu.g/kg/hr (triangles)
for 6 hours were effective to produce significant reduction in PTH
from baseline over the course of infusion.
[0259] A similar study was conducted in rats with the 1K1C model of
acute renal insufficiency. 1K1C model rats were intravenously
infused with Ac-c(C)arrrar-NH.sub.2 (SEQ ID NO: 273 at dose rates
of 30 .mu.g/kg/hr and 100 .mu.g/kg/hr for 6 hours. Blood samples
were taken prior to dosing (Pre), at 2 hours, 4 hours, 6 hours
(just prior to the end of infusion; EOI), 8 hours (2 hrs post EOI)
and 24 hours and plasma was analyzed for PTH levels by ELISA. The
data are shown in FIG. 14A (30 .mu.g/kg/hr, diamonds, and 100
.mu.g/kg/hr, squares) and the serum calcium for the animals is
shown in FIG. 14B.
Sequence CWU 1
1
18317PRTArtificial SequenceSynthetic peptideVARIANT(1)...(7)Xaa =
any amino acid as defined in the specification filed herewith 1Xaa
Xaa Xaa Xaa Xaa Xaa Xaa1 527PRTArtificial SequenceSynthetic
peptideVARIANT(1)..(1)Xaa = D-CysVARIANT(2), (6)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-Arg 2Xaa Xaa Xaa Xaa Xaa Xaa
Xaa1 537PRTArtificial SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
disulfide bond to CysVARIANT(2), (6)Xaa = D-AlaVARIANT(3), (4),
(5), (7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 3Xaa Xaa Xaa Xaa
Xaa Xaa Xaa1 545PRTArtificial SequenceSynthetic
peptideVARIANT(1)..(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)...(5)Xaa = D-ArgMOD_RES(5)C-terminal
amidation 4Xaa Xaa Xaa Xaa Xaa1 556PRTArtificial SequenceSynthetic
peptideVARIANT(1)..(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)..(6)Xaa = D-ArgMOD_RES(6)C-terminal amidation
5Xaa Xaa Xaa Xaa Xaa Xaa1 567PRTArtificial SequenceSynthetic
peptideVARIANT(1)..(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)..(7)Xaa = D-ArgMOD_RES(7)C-terminal amidation
6Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 578PRTArtificial SequenceSynthetic
peptideVARIANT(1)..(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)..(8)Xaa = D-ArgMOD_RES(8)C-terminal amidation
7Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 587PRTArtificial
SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)..(2)Xaa =
D-AlaVARIANT(3)...(7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 8Xaa
Xaa Xaa Xaa Xaa Xaa Xaa1 597PRTArtificial SequenceSynthetic
peptideVARIANT(1)..(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)..(2)Xaa = D-ArgVARIANT(3)..(3)Xaa =
D-AlaVARIANT(4)...(7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 9Xaa
Xaa Xaa Xaa Xaa Xaa Xaa1 5107PRTArtificial SequenceSynthetic
peptideVARIANT(1)..(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2), (3), (5)...(7)Xaa = D-ArgVARIANT(4)..(4)Xaa
= D-AlaMOD_RES(7)C-terminal amidation 10Xaa Xaa Xaa Xaa Xaa Xaa
Xaa1 5117PRTArtificial SequenceSynthetic peptideVARIANT(1)..(1)Xaa
= D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)...(4),
(6)...(7)Xaa = D-ArgVARIANT(5)..(5)Xaa = D-AlaMOD_RES(7)C-terminal
amidation 11Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5127PRTArtificial
SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)...(5), (7)Xaa
= D-ArgVARIANT(6)..(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation
12Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5137PRTArtificial SequenceSynthetic
peptideVARIANT(1)..(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)...(6)Xaa = D-ArgVARIANT(7)..(7)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 13Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5147PRTArtificial SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(6)Xaa = D-ArgVARIANT(4), (7)Xaa = D-AlaMOD_RES(7)C-terminal
amidation 14Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5157PRTArtificial
SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (4)Xaa =
D-AlaVARIANT(3), (5) (6), (7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 15Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5167PRTArtificial
SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (5)Xaa =
D-AlaVARIANT(3), (4), (6), (7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 16Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5177PRTArtificial
SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (6),
(7)Xaa = D-ArgVARIANT(4), (5)Xaa = D-AlaMOD_RES(7)C-terminal
amidation 17Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5187PRTArtificial
SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (4), (6),
(7)Xaa = D-ArgVARIANT(3), (5)Xaa = D-AlaMOD_RES(7)C-terminal
amidation 18Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5197PRTArtificial
SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (7)Xaa =
D-AlaVARIANT(3)...(6)Xaa = D-ArgMOD_RES(7)C-terminal amidation
19Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5207PRTArtificial SequenceSynthetic
peptideVARIANT(1)..(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2), (4), (5), (6)Xaa = D-ArgVARIANT(3), (7)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 20Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5217PRTArtificial SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (4),
(7)Xaa = D-ArgVARIANT(5), (6)Xaa = D-AlaMOD_RES(7)C-terminal
amidation 21Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5227PRTArtificial
SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)...(3)Xaa =
D-AlaVARIANT(4)...(7)Xaa = D-ArgMOD_RES(7)C-terminal amidation
22Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5237PRTArtificial SequenceSynthetic
peptideVARIANT(1)..(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2), (4), (5), (7)Xaa = D-ArgVARIANT(3), (6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 23Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5247PRTArtificial SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (5), (6),
(7)Xaa = D-ArgVARIANT(3), (4)Xaa = D-AlaMOD_RES(7)C-terminal
amidation 24Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5257PRTArtificial
SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4), (6)Xaa = D-AlaMOD_RES(7)C-terminal
amidation 25Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5267PRTArtificial
SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (6)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 26Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5277PRTArtificial
SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
disulfide bond to CysVARIANT(2), (6)Xaa = D-AlaVARIANT(3), (4),
(5), (7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 27Xaa Xaa Xaa Xaa
Xaa Xaa Xaa1 5287PRTArtificial SequenceSynthetic
peptideVARIANT(1)..(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationDISULFID(1)..(1)Cys-Cys disulfide bond to CysVARIANT(2),
(3), (5), (7)Xaa = D-ArgVARIANT(4), (6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 28Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5296PRTArtificial SequenceSynthetic peptideVARIANT(1), (5)Xaa =
D-AlaMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (4),
(6)Xaa = D-ArgMOD_RES(7)C-terminal amidation 29Xaa Xaa Xaa Xaa Xaa
Xaa1 5308PRTArtificial SequenceSynthetic peptideVARIANT(1)..(1)Xaa
= bAlaMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-CysVARIANT(3)...(8)Xaa = D-ArgMOD_RES(8)C-terminal amidation
30Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5317PRTArtificial
SequenceSynthetic peptideVARIANT(1)..(1)Xaa = 3-Mercaptopropionic
acidVARIANT(2)...(7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 31Xaa
Xaa Xaa Xaa Xaa Xaa Xaa1 5327PRTArtificial SequenceSynthetic
peptideVARIANT(1)..(1)Xaa = D-HomocysteineMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)...(7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 32Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5337PRTArtificial
SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-penicillamineMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)...(7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 33Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5347PRTArtificial
SequenceSynthetic peptideVARIANT(1)..(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
interchain disulfide bondVARIANT(2), (6)Xaa = D-AlaVARIANT(3), (4),
(5), (7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 34Xaa Xaa Xaa Xaa
Xaa Xaa Xaa1 5357PRTArtificial SequenceSynthetic
peptideMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
disulfide bond to CysVARIANT(2), (6)Xaa = D-AlaVARIANT(3), (4),
(5), (7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 35Cys Xaa Xaa Xaa
Xaa Xaa Xaa1 5367PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationDISULFID(1)..(1)Cys-Cys disulfide bond to CysVARIANT(2),
(6)Xaa = D-AlaVARIANT(4), (5), (7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 36Xaa Xaa Arg Xaa Xaa Xaa Xaa1 5377PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
disulfide bond to CysVARIANT(2), (6)Xaa = D-AlaVARIANT(3), (5),
(7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 37Xaa Xaa Xaa Arg Xaa
Xaa Xaa1 5387PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
disulfide bond to CysVARIANT(2), (6)Xaa = D-AlaVARIANT(3), (4),
(7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 38Xaa Xaa Xaa Xaa Arg
Xaa Xaa1 5397PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
disulfide bond to CysVARIANT(2)Xaa = D-AlaVARIANT(3), (4), (5),
(7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 39Xaa Xaa Xaa Xaa Xaa
Ala Xaa1 5407PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
disulfide bond to CysVARIANT(2)Xaa = D-AlaVARIANT(3), (4), (5),
(6)Xaa = D-ArgMOD_RES(7)C-terminal amidation 40Xaa Xaa Xaa Xaa Xaa
Xaa Arg1 5419PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)...(9)Xaa =
D-ArgMOD_RES(7)C-terminal amidation 41Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa1 5427PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(3), (4), (5),
(7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 42Xaa Gly Xaa Xaa Xaa
Gly Xaa1 5437PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(3), (4), (5),
(7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 43Xaa Ala Xaa Xaa Xaa
Ala Xaa1 5447PRTArtificial SequenceSynthetic
peptideMOD_RES(1)..(1)N-terminal acetylationVARIANT(4)Xaa =
D-ArgVARIANT(2), (6)Xaa = D-AlaMOD_RES(7)C-terminal amidation 44Cys
Xaa Arg Xaa Arg Xaa Arg1 5459PRTArtificial SequenceSynthetic
peptide 45Cys His Asp Ala Pro Ile Gly Tyr Asp1 5469PRTArtificial
SequenceSynthetic peptide 46Cys Pro Asp Tyr His Asp Ala Gly Ile1
54712PRTArtificial SequenceSynthetic
peptideMOD_RES(1)..(1)N-terminal
acetylationMOD_RES(12)..(12)C-terminal amidation 47Cys Tyr Gly Arg
Lys Lys Arg Arg Gln Arg Arg Arg1 5 104811PRTArtificial
SequenceSynthetic peptideMOD_RES(1)..(1)N-terminal
acetylationMOD_RES(11)..(11)C-terminal amidation 48Tyr Gly Arg Lys
Lys Arg Arg Gln Arg Arg Arg1 5 10498PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2), (4), (5)Xaa = D-AlaVARIANT(3), (6), (7),
(8)Xaa = D-ArgMOD_RES(8)C-terminal amidation 49Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa1 55012PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)Xaa = D-TyrVARIANT(3)Xaa = D-GlyVARIANT(4),
(7), (8), (10), (11), (12)Xaa = D-ArgVARIANT(5), (6)Xaa =
D-LysVARIANT(9)Xaa = D-GlnMOD_RES(12)C-terminal amidation 50Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5 10517PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)...(7)Xaa =
D-ArgMOD_RES(7)C-terminal amidation 51Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5527PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (6)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 52Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5537PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
disulfide bonded to GlutathioneVARIANT(2)...(7)Xaa =
D-ArgMOD_RES(7)C-terminal amidation 53Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5547PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysDISULFID(1)..(1)Cys-Cys disulfide bonded to
GlutathioneVARIANT(2)...(7)Xaa = D-Arg 54Xaa Xaa Xaa Xaa Xaa Xaa
Xaa1 5557PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
disulfide bonded to acetylated GlutathioneVARIANT(2), (6)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 55Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5567PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
disulfide bonded to 3-Mercaptopropionic acidVARIANT(2), (6)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 56Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5577PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
disulfide bonded to Polyethylene glycolVARIANT(2), (6)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 57Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5587PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
disulfide bonded to Polyethylene glycolVARIANT(2), (6)Xaa =
D-AlaVARIANT(2)...(7)Xaa = D-ArgMOD_RES(7)C-terminal amidation
58Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5597PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationDISULFID(1)..(1)Cys-Cys disulfide bonded to Polyethylene
glycolVARIANT(2)...(7)Xaa = D-ArgMOD_RES(7)C-terminal amidation
59Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5607PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationDISULFID(1)..(1)Cys-Cys disulfide bonded to
CysVARIANT(2), (6)Xaa = D-AlaVARIANT(3), (4), (5), (7)Xaa =
D-ArgMOD_RES(7)C-terminal amidation 60Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5618PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
bAlaMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-CysDISULFID(2)..(2)Cys-Cys disulfide bonded to CysVARIANT(3),
(7)Xaa = D-AlaVARIANT(4), (5), (6), (8)Xaa =
D-ArgMOD_RES(7)C-terminal amidation 61Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa1 5628PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
bAlaVARIANT(2)Xaa = D-CysDISULFID(2)..(2)Cys-Cys disulfide bonded
to CysVARIANT(3), (7)Xaa = D-AlaVARIANT(4), (5), (6), (8)Xaa =
D-Arg 62Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5637PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(3), (4), (5),
(7)Xaa = D-Arg 63Xaa Gly Xaa Xaa Xaa Gly Xaa1 5647PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(3), (4), (5),
(7)Xaa = D-Arg 64Xaa Ala Xaa Xaa Xaa Ala Xaa1 5657PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (6)Xaa =
D-ValVARIANT(3), (4), (5), (7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 65Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5667PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (6)Xaa =
D-ValVARIANT(3), (4), (5), (7)Xaa = D-Arg 66Xaa Xaa Xaa Xaa Xaa Xaa
Xaa1 5677PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)...(7)Xaa =
D-ArgMOD_RES(7)C-terminal amidation 67Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5687PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-GluMOD_RES(7)C-terminal amidation 68Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5697PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-GluVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 69Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5707PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), 6)Xaa =
D-AlaVARIANT(3), (4), (5)Xaa = D-ArgVARIANT(7)Xaa =
D-LysMOD_RES(7)C-terminal amidation 70Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5717PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-GluVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 71Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5727PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (6)Xaa =
D-AlaVARIANT(3)Xaa = D-LysVARIANT(4), (5), (7)Xaa =
D-ArgMOD_RES(7)C-terminal amidation 72Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5737PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (6)Xaa =
D-AlaVARIANT(4)Xaa = D-LysVARIANT(3), (5), (7)Xaa =
D-ArgMOD_RES(7)C-terminal amidation 73Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5747PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (6)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 74Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5757PRTArtificial
SequenceSynthetic peptideMOD_RES(1)..(1)N-terminal
acetylationMOD_RES(7)C-terminal amidation 75Cys Ala Arg Arg Arg Ala
Arg1 5769PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3)Xaa =
D-AlaVARIANT(4)...(9)Xaa = D-ArgMOD_RES(9)C-terminal amidation
76Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 57710PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (4)Xaa =
D-AlaVARIANT(5)...(10)Xaa = D-ArgMOD_RES(10)C-terminal amidation
77Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5 10789PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (4), (6),
(8)Xaa = D-AlaVARIANT(3), (5), (7), (9)Xaa =
D-ArgMOD_RES(9)C-terminal amidation 78Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa1 5799PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (6), (8)Xaa =
D-AlaVARIANT(3), (4), (5), (7), (9)Xaa = D-ArgMOD_RES(9)C-terminal
amidation 79Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 5807PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa = D-CysVARIANT(2)...(7)Xaa =
D-ArgMOD_RES(7)C-terminal amidation 80Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5817PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
interchain bond with benzoylVARIANT(2)...(7)Xaa =
D-ArgMOD_RES(7)C-terminal amidation 81Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5827PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Cys-Cys
interchain bond with acetylVARIANT(2)...(7)Xaa =
D-ArgMOD_RES(7)C-terminal amidation 82Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5837PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-PheMOD_RES(7)C-terminal amidation 83Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5847PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-IleMOD_RES(7)C-terminal amidation 84Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5857PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-LeuMOD_RES(7)C-terminal amidation 85Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5867PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (6)Xaa =
D-AlaVARIANT(3), (4), (7)Xaa = D-ArgVARIANT(5)Xaa =
D-LysMOD_RES(7)C-terminal amidation 86Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5877PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-ValMOD_RES(7)C-terminal amidation 87Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5887PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-ProMOD_RES(7)C-terminal amidation 88Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5897PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-HisMOD_RES(7)C-terminal amidation 89Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5907PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-GlnMOD_RES(7)C-terminal amidation 90Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5917PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-ThrMOD_RES(7)C-terminal amidation 91Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5927PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-SerMOD_RES(7)C-terminal amidation 92Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5937PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 93Xaa Xaa Xaa Xaa Xaa Gly Xaa1 5947PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-GleVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 94Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
5957PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(3), (4), (5),
(7)Xaa = D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation
95Xaa Gly Xaa Xaa Xaa Xaa Xaa1 5967PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)Xaa = D-IleVARIANT(3), (4), (5), (7)Xaa =
D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation 96Xaa Xaa
Xaa Xaa Xaa Xaa Xaa1 5977PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)Xaa = D-ProVARIANT(3), (4), (5), (7)Xaa =
D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation 97Xaa Xaa
Xaa Xaa Xaa Xaa Xaa1 5987PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)Xaa = D-LeuVARIANT(3), (4), (5), (7)Xaa =
D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation 98Xaa Xaa
Xaa Xaa Xaa Xaa Xaa1 5997PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)Xaa = D-GlnVARIANT(3), (4), (5), (7)Xaa =
D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation 99Xaa Xaa
Xaa Xaa Xaa Xaa Xaa1 51007PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)Xaa = D-ThrVARIANT(3), (4), (5), (7)Xaa =
D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation 100Xaa Xaa
Xaa Xaa Xaa Xaa Xaa1 51017PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)Xaa = D-ValVARIANT(3), (4), (5), (7)Xaa =
D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation 101Xaa Xaa
Xaa Xaa Xaa Xaa Xaa1 51027PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)Xaa = D-SerVARIANT(3), (4), (5), (7)Xaa =
D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation 102Xaa Xaa
Xaa Xaa Xaa Xaa Xaa1 51037PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)Xaa = D-HisVARIANT(3), (4), (5), (7)Xaa =
D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation 103Xaa Xaa
Xaa Xaa Xaa Xaa Xaa1 51047PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)Xaa = D-PheVARIANT(3), (4), (5), (7)Xaa =
D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation 104Xaa Xaa
Xaa Xaa Xaa Xaa Xaa1 51057PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2), (3), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 105Xaa Xaa Xaa Gly Xaa Xaa Xaa1
51067PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-ProVARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 106Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51077PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-GluVARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 107Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51087PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-ThrVARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 108Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51097PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-HisVARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 109Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51107PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-PheVARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 110Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51117PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-SerVARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 111Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51127PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-GlnVARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 112Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51137PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-ValVARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 113Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51147PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-LeuVARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 114Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51157PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-IleVARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 115Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51167PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = N-methylglycine
(sarcosine)VARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation
116Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51177PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
N-methylglycine (sarcosine)MOD_RES(7)C-terminal amidation 117Xaa
Xaa Xaa Xaa Xaa Xaa Xaa1 51187PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2), (6)Xaa = N-methylalanine (Nma)VARIANT(3),
(4), (5), (7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 118Xaa Xaa
Xaa Xaa Xaa Xaa Xaa1 51197PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2), (3), (5), (7)Xaa = D-ArgVARIANT(4)Xaa =
D-AlaVARIANT(6)Xaa = N-methylalanine (Nma)MOD_RES(7)C-terminal
amidation 119Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51207PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (6)Xaa =
2-aminoisobutyric acid (Aib)VARIANT(3), (4), (5), (7)Xaa =
D-ArgMOD_RES(7)C-terminal amidation 120Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51217PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = N-methylalanine (Nma)VARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 121Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51227PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
N-methylalanine (Nma)MOD_RES(7)C-terminal amidation 122Xaa Xaa Xaa
Xaa Xaa Xaa Xaa1 51237PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)Xaa = 2-aminoisobutyric acid (Aib)VARIANT(3),
(4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal
amidation 123Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51247PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
2-aminoisobutyric acid (Aib)MOD_RES(7)C-terminal amidation 124Xaa
Xaa Xaa Xaa Xaa Xaa Xaa1 51257PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2), (6)Xaa = N-methylglycine
(sarcosine)VARIANT(3), (4), (5), (7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 125Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51267PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-AlaVARIANT(6)Xaa = N-methylglycine
(sarcosine)MOD_RES(7)C-terminal amidation 126Xaa Xaa Xaa Xaa Xaa
Xaa Xaa1 51277PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa
= D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
N-methylalanine (Nma)VARIANT(3), (4), (5), (7)Xaa =
D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation 127Xaa Xaa
Xaa Xaa Xaa Xaa Xaa1 51287PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2)Xaa = N-methylglycine (sarcosine)VARIANT(3),
(4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal
amidation 128Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51297PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa = Norleucine
(NLeu)MOD_RES(7)C-terminal amidation 129Xaa Xaa Xaa Xaa Xaa Xaa
Xaa1 51307PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (6)Xaa =
D-Norleucine (dNLeu)VARIANT(3), (4), (5), (7)Xaa =
D-ArgMOD_RES(7)C-terminal amidation 130Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51317PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgVARIANT(6)Xaa =
D-Norvaline (dNval)MOD_RES(7)C-terminal amidation 131Xaa Xaa Xaa
Xaa Xaa Xaa Xaa1 51327PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2), (6)Xaa = D-Norvaline (dNval)VARIANT(3), (4),
(5), (7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 132Xaa Xaa Xaa
Xaa Xaa Xaa Xaa1 51337PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(4)Xaa = D-AlaVARIANT(2), (3), (5), (7)Xaa =
D-ArgVARIANT(6)Xaa = D-Norleucine (dNLeu)MOD_RES(7)C-terminal
amidation 133Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51347PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-Norleucine (dNLeu)VARIANT(3), (4), (5), (7)Xaa =
D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation 134Xaa Xaa
Xaa Xaa Xaa Xaa Xaa1 51357PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-AlaVARIANT(6)Xaa = D-Norvaline
(dNVal)MOD_RES(7)C-terminal amidation 135Xaa Xaa Xaa Xaa Xaa Xaa
Xaa1 51367PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)Xaa =
D-Norvaline (dNVal)VARIANT(3), (4), (5), (7)Xaa =
D-ArgVARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal amidation 136Xaa Xaa
Xaa Xaa Xaa Xaa Xaa1 51377PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2), (3), (5), (7)Xaa = D-ArgVARIANT(4)Xaa =
D-Norvaline (dNVal)VARIANT(6)Xaa = D-AlaMOD_RES(7)C-terminal
amidation 137Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51387PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-Norleucine (dNLeu)VARIANT(6)Xaa =
D-AlaMOD_RES(7)C-terminal amidation 138Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51397PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Bond with
D-homocysteine (dHcy)VARIANT(2), (6)Xaa = D-AlaVARIANT(3), (4),
(5), (7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 139Xaa Xaa Xaa
Xaa Xaa Xaa Xaa1 51407PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationDISULFID(1)..(1)Bond with 3-mercaptopropionic acid
(Mpa)VARIANT(2), (6)Xaa = D-AlaVARIANT(3), (4), (5), (7)Xaa =
D-ArgMOD_RES(7)C-terminal amidation 140Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51417PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Bond with
acetylated L-CysteineVARIANT(2), (6)Xaa = D-AlaVARIANT(3), (4),
(5), (7)Xaa = D-ArgMOD_RES(7)C-terminal amidation 141Xaa Xaa Xaa
Xaa Xaa Xaa Xaa1 51427PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationDISULFID(1)..(1)Bond with D-CysteineVARIANT(2), (6)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 142Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51437PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Bond with
Polyethylene glycolVARIANT(2)...(7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 143Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51447PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationDISULFID(1)..(1)Bond with
Polyethylene glycolVARIANT(2)...(7)Xaa = D-ArgMOD_RES(7)C-terminal
amidation 144Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51457PRTArtificial
SequenceSynthetic peptide 145Cys Glu Glu Glu Glu Glu Glu1
51467PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2)...(5)Xaa =
D-ArgVARIANT(6), (7)Xaa = D-AlaMOD_RES(7)C-terminal amidation
146Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51477PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (6)Xaa =
D-AlaVARIANT(3), (4), (5), (7)Xaa = D-LysMOD_RES(7)C-terminal
amidation 147Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51487PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (4), (6)Xaa =
D-AlaVARIANT(3), (5), (7)Xaa = D-ArgMOD_RES(7)C-terminal amidation
148Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51497PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-AlaMOD_RES(7)C-terminal amidation
149Xaa Xaa Xaa Xaa Xaa Gly Xaa1 51507PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-AlaVARIANT(6)Xaa =
D-GlnMOD_RES(7)C-terminal amidation 150Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51517PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-AlaVARIANT(6)Xaa =
D-HisMOD_RES(7)C-terminal amidation 151Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51527PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (3), (5),
(7)Xaa = D-ArgVARIANT(4)Xaa = D-AlaVARIANT(6)Xaa =
D-IleMOD_RES(7)C-terminal amidation 152Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51536PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysMOD_RES(1)..(1)N-terminal acetylationVARIANT(2), (5)Xaa =
D-AlaDISULFID(2)..(2)Bond with 1,3-diaminopropionic acid
(DAP)VARIANT(3), (4), (6)Xaa = D-ArgMOD_RES(6)C-terminal amidation
153Xaa Xaa Xaa Xaa Xaa Xaa1 51547PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysMOD_RES(1)..(1)N-terminal
acetylationVARIANT(2), (6)Xaa = D-AlaVARIANT(3), (4), (5)Xaa =
D-HomoarginineVARIANT(7)Xaa = D-ArgMOD_RES(7)C-terminal amidation
154Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51557PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa = a thiol-containing amino
acid residueVARIANT(2)Xaa = a non-cationic amino acid
residueVARIANT(3), (4), (7)Xaa = any amino acid
residueVARIANT(5)Xaa = a cationic amino acid residueVARIANT(6)Xaa =
a non-cationic amino acid residue 155Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51567PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysVARIANT(2)Xaa = a non-cationic amino acid residueVARIANT(3),
(4), (7)Xaa = any amino acid residueVARIANT(5)Xaa = D-Arg, L-Arg,
D-Lys or L-LysVARIANT(6)Xaa = a non-cationic amino acid residue
156Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51577PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa = D-CysVARIANT(2), (3),
(4)Xaa = any amino acid residueVARIANT(5), (7)Xaa = any cationic
amino acid residueVARIANT(6)Xaa = a non-cationic amino acid residue
157Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51587PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa = D-CysVARIANT(2), (6)Xaa =
a non-cationic amino acid residueVARIANT(3), (4), (7)Xaa = any
amino acid residueVARIANT(5)Xaa = D-Arg, L-Arg, D-Lys or L-Lys
158Xaa Xaa Xaa Xaa Xaa Xaa Xaa1 51597PRTArtificial
SequenceSynthetic peptideVARIANT(1)Xaa = D-CysVARIANT(2)Xaa =
D-AlaVARIANT(3), (4), (7)Xaa = any cationic amino acid
residueVARIANT(5)Xaa = D-ArgVARIANT(6)Xaa = D-Ala 159Xaa Xaa Xaa
Xaa Xaa Xaa Xaa1 51607PRTArtificial SequenceSynthetic
peptideVARIANT(1)Xaa = D-CysVARIANT(2), (3), (7)Xaa = any cationic
amino acid residueVARIANT(4)Xaa = D-AlaVARIANT(5)Xaa =
D-ArgVARIANT(6)Xaa = D-Ala 160Xaa Xaa Xaa Xaa Xaa Xaa Xaa1
51617PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
D-CysVARIANT(2)Xaa = D-AlaVARIANT(3), (4), (7)Xaa = any amino
acidVARIANT(5)Xaa = D-ArgVARIANT(6)Xaa = D-Ala 161Xaa Xaa Xaa Xaa
Xaa Xaa Xaa1 51628PRTArtificial SequenceSynthetic peptide 162His
Asp Ala Pro Ile Gly Tyr Asp1 51639PRTArtificial SequenceSynthetic
peptide 163Cys His Asp Ala Pro Ile Gly Tyr Asp1 516411PRTArtificial
SequenceSynthetic peptide 164Tyr Gly Arg Lys Lys Arg Arg Gln Arg
Arg Arg1 5 1016512PRTArtificial SequenceSynthetic peptide 165Cys
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg1 5 1016611PRTArtificial
SequenceSynthetic peptide 166Cys Ser Phe Asn Ser Tyr Glu Leu Gly
Ser Leu1 5 101679PRTArtificial SequenceSynthetic peptide 167Cys Pro
Asp Tyr His Asp Ala Gly Ile1 51689PRTArtificial SequenceSynthetic
peptide 168Cys Glu Ala Val Ser Leu Lys Pro Thr1 51698PRTArtificial
SequenceSynthetic peptide 169Glu Ser Val Ser Leu Lys Pro Thr1
517014PRTArtificial SequenceSynthetic peptide 170Cys Arg Phe Ala
Arg Lys Gly Ala Leu Arg Gln Lys Asn Val1 5 101716PRTArtificial
SequenceSynthetic peptide 171Tyr Gly Arg Lys Lys Arg1
51727PRTArtificial SequenceSynthetic peptide 172Cys Tyr Gly Arg Lys
Lys Arg1 517311PRTArtificial SequenceSynthetic peptide 173Tyr Gly
Arg Arg Ala Arg Arg Arg Ala Arg Arg1 5 1017412PRTArtificial
SequenceSynthetic peptide 174Cys Tyr Gly Arg Arg Ala Arg Arg Arg
Ala Arg Arg1 5 101754PRTArtificial SequenceSynthetic peptide 175Cys
Arg Arg Arg11765PRTArtificial SequenceSynthetic peptide 176Cys Arg
Arg Arg Arg1 51778PRTArtificial SequenceSynthetic peptide 177Cys
Arg Arg Arg Arg Arg Arg Arg1 51789PRTArtificial SequenceSynthetic
peptide 178Cys Arg Arg Arg Arg Arg Arg Arg Arg1 517910PRTArtificial
SequenceSynthetic peptide 179Cys Arg Arg Arg Arg Arg Arg Arg Arg
Arg1 5 1018011PRTArtificial SequenceSynthetic peptide 180Cys Arg
Arg Arg Arg Arg Arg Arg Arg Arg Arg1 5 1018112PRTArtificial
SequenceSynthetic peptide 181Cys Arg Arg Arg Arg Arg Arg Arg Arg
Arg Arg Arg1 5 1018213PRTArtificial SequenceSynthetic peptide
182Cys Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg1 5
101837PRTArtificial SequenceSynthetic peptideVARIANT(1)Xaa =
L-CysVARIANT(2), (6)Xaa = a non-cationic amino acid
residueVARIANT(3), (4), (7)Xaa = any amino acid
residueVARIANT(5)Xaa = D-Arg, L-Arg, D-Lys or L-Lys 183Xaa Xaa Xaa
Xaa Xaa Xaa Xaa1 5
* * * * *